SEARCH
Search Details
Souichi Shiratori
| Hokkaido University Hospital Central Clinical Facilities Division of Laboratory and Transfusion Medicine | Assistant Professor |
2004年4月:北海道大学医学部医学科卒業
2007年4月:北海道大学大学院医学研究科医学専攻博士課程入学
2008年4月:北海道大学遺伝子病制御研究所分子生体防御分野 Visiting student
2011年3月:北海道大学大学院医学研究科医学専攻博士課程卒業
2011年4月:北海道大学遺伝子病制御研究所分子生体防御分野 Visiting fellow
2004年4月:北海道大学病院 医員(研修医)
2005年4月:社会医療法人北楡会札幌北楡病院 医員(研修医)
2006年4月:市立函館病院 内科 医員
2007年4月:北海道大学病院 血液内科 医員
2011年4月:エイズ予防財団・リサーチレジデント
2012年4月:北海道大学病院 血液内科 医員
2013年4月:北海道大学病院 血液内科 特任助教
2018年4月:北海道大学病院 血液内科 助教
2025年4月:北海道大学病院 検査・輸血部 助教
Researcher basic information
■ Degree■ URL
researchmap URLホームページURL■ Various IDs
Researcher number
- 00645905
Research Field
Research activity information
■ Papers- Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.
Masahiro Onozawa; Shigeru Kusumoto; Yachiyo Kuwatsuka; Takayoshi Miyazono; Masatsugu Tanaka; Yuho Najima; Kohei Okada; Souichi Shiratori; Takayuki Sato; Junya Kanda; Yuichiro Inagaki; Tohru Murayama; Kaoru Hatano; Koichi Onodera; Masatoshi Sakurai; Shinya Endo; Takahiro Kumode; Hidehiro Itonaga; Yukiyoshi Moriuchi; Nobuhiro Kanemura; Tatsuya Imi; Taro Edahiro; Nobuaki Fukushima; Masahiro Oura; Shunsuke Yui; Mitsumasa Watanabe; Tomomi Toubai; Toshihiko Ando; Daisuke Nakamura; Masaharu Tamaki; Yasutaka Kakinoki; Takahiro Okada; Nobuaki Nakano; Takayoshi Tachibana; Hiroaki Shimizu; Shuichi Ota; Shinsuke Iida; Masaya Sugiyama; Yoshiko Atsuta; Takanori Teshima; Tomoharu Yoshizumi; Masashi Mizokami
Transplantation and cellular therapy, 17 May 2026, [International Magazine]
English, Scientific journal, Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with resolved HBV infection undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Although HBV DNA-guided preemptive nucleos(t)ide analog therapy prevents HBV-related hepatitis, strategies to prevent HBV reactivation itself remain limited. Hepatitis B vaccination after allo-HCT has been suggested as a potential preventive strategy, but prospective randomized evidence is lacking. To evaluate whether hepatitis B (HepB) vaccination reduces HBV reactivation after allo-HCT and to examine the association between vaccination-induced anti-hepatitis B surface antibody (anti-HBs) response and protection against HBV reactivation. In this multicenter randomized controlled trial (UMIN000034113), adults who were hepatitis B surface antigen-negative and anti-hepatitis B core antigen-positive and underwent first allo-HCT were prospectively enrolled. At 140 days post-HCT, patients without HBV reactivation were randomized to receive HepB vaccination or no vaccination. HBV DNA levels and anti-HBs titers were centrally monitored for 2 years after transplantation. The primary endpoint was HBV reactivation, defined as HBV DNA ≥ 1.3 log IU/mL. Vaccine response was defined as anti-HBs response, requiring both an increase in anti-HBs from baseline and a post-vaccination anti-HBs ≥ 10 mIU/mL. Among 109 enrolled patients, 64 were randomized. With a median HBV DNA follow-up of 19.4 months, HBV reactivation occurred in 6 of 33 patients in the vaccination group, including 2 who experienced reactivation before receiving the first vaccine dose, and 9 of 31 patients in the control group. Probabilities of HBV reactivation were 19.8% and 37.9% in the HepB vaccination and control groups, respectively, at 18 months after randomization (P = .205). Baseline anti-HBs <10 mIU/mL was a significant risk factor for HBV reactivation. No HBV-related hepatitis was observed. Vaccine responses were achieved in 9 of 29 patients after the initial series and in 5 of 10 after the additional series. Importantly, HBV reactivation did not occur after patients achieved anti-HBs response, although several reactivation events occurred before vaccination or before anti-HBs response was achieved. No severe vaccine-related adverse events were observed. Although HepB vaccination did not significantly reduce HBV reactivation, it was feasible and induced anti-HBs response in a subset of patients. Achieving vaccine-induced anti-HBs response may provide protective immunity against HBV reactivation after allo-HCT. - Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review.
Shingo Nojima; Toru Miyajima; Reiki Ogasawara; Shota Yoshida; Hiroyuki Kimura; Rintaro Nozu; Fuka Horikita; Takahide Ara; Toshihiro Matsukawa; Souichi Shiratori; Masahiro Onozawa; Masao Nakagawa; Takanori Teshima
Leukemia & lymphoma, 1, 4, 08 Apr. 2026, [International Magazine]
English, Scientific journal - Adenovirus‐Associated Opsoclonus After Allogeneic Hematopoietic Stem Cell Transplantation
Toru Miyajima; Setsuaki Hoshino; Shingo Nojima; Souichi Shiratori; Taishi Iwanami; Takanori Teshima
eJHaem, 7, 2, Wiley, 09 Mar. 2026
Scientific journal - Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study.
Souichi Shiratori; Keito Suto; Yuta Hasegawa; Takahide Ara; Toshihiro Matsukawa; Hideki Goto; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Daisuke Hidaka; Reiki Ogasawara; Kohei Okada; Junichi Sugita; Yasutaka Kakinoki; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
Transplantation and cellular therapy, 06 Nov. 2025, [International Magazine]
English, Scientific journal, Tacrolimus (Tac) and methotrexate (MTX) are standard graft-versus-host disease (GVHD) prophylaxis for umbilical cord blood transplantation (CBT); however, the optimal dose of MTX for CBT remains to be determined. We previously showed the safety and efficacy of reduced-dose MTX (mini-MTX; 5 mg/m2 on days 1, 3, and 6) combined with Tac as GVHD prophylaxis for CBT in a single-center retrospective study. Here we report a multicenter observational study in the North Japan Hematology Study Group (NJHSG; NJHSG-CBT18) conducted to evaluate transplantation outcomes according to GVHD prophylaxis in single-unit CBT, in which patients with hematologic malignancies scheduled for CBT were prospectively registered and followed for 2 years after CBT. A total of 112 patients were registered in NJHSG-CBT18, with a median age of 51 years. Eighty-nine patients received Tac + mini-MTX, 19 patients received Tac + mycophenolate mofetil (MMF), and 4 patients received Tac only as GVHD prophylaxis. Multivariate analysis identified GVHD prophylaxis other than Tac + mini-MTX as a significant risk factor for nonrelapse mortality (NRM) (hazard ratio [HR], 0.160; 95% confidence interval [CI], 0.065 to 0.391; P < .001), overall survival (OS) (HR, 2.971; 95% CI, 1.558 to 5.663; P < .001), progression-free survival (PFS) (HR, 2.383; 95% CI, 1.345 to 4.222; P = .003), and GVHD-free, relapse-free survival (GRFS) (HR, 3.075; 95% CI, 1.799 to 5.256; P < .001). In a comparison of clinical outcomes between the mini-MTX and MMF groups, the cumulative incidences of pre-engraftment immune reaction (5.7% versus 42.1%; P < .001), human herpesvirus 6 encephalitis (2.3% versus 15.8%, P = .011), grade II-IV acute GVHD (14.6% versus 47.4%, P < .001), and NRM (1.1% versus 52.6%, P < .001) were significantly lower and the cumulative incidence of immunosuppressant discontinuation was significantly higher (66.3% versus 18.4%, P = .004) in the mini-MTX group compared to the MMF group, while rates of chronic GVHD and relapse were comparable between the groups. The probabilities of OS (70.6% versus 31.6%, P < .001), PFS (58.1 versus 14.0%, P < .001), and GRFS (44.9% versus 5.1%, P < .001) were significantly higher in the mini-MTX group. Multivariate analysis of risk factors for OS in the mini-MTX group identified high-risk or very high-risk refined Disease Risk Index (rDRI) (HR, 3.896; 95% CI, 1.575 to 9.637; P = .003) and high HCT-CI (HR, 3.338; 95% CI, 1.301 to 8.569; P = .012) as significant risk factors for OS. Our data indicate that a combination of Tac + mini-MTX is safe and effective GVHD prophylaxis in CBT. - A comparative study of GVHD prophylaxis using low dose ATG versus PTCy for PBSCT based on two independent prospective cohorts.
Souichi Shiratori; Junichi Sugita; Jun Ishikawa; Takashi Kuroha; Yasuo Mori; Tetsuya Eto; Senji Kasahara; Kentaro Fukushima; Mine Harada; Takanori Teshima
Scientific reports, 15, 1, 20677, 20677, 01 Jul. 2025, [International Magazine]
English, Scientific journal, Both anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) have shown prophylactic effects on graft-versus-host disease (GVHD) in multiple phase III studies. We conducted a comparative study of for low dose ATG (thymoglobulin) versus PTCy for GVHD prophylaxis in peripheral blood stem cell transplantation (PBSCT). The ATG (n = 67) and PTCy (n = 40) groups included patients enrolled in multicenter phase II studies (JSCT-ATG15 and JSCT-PTCY19, respectively). The probability of GVHD-free and relapse-free survival at 2 years as the primary endpoint was not significantly different between these two groups (57.9% for ATG vs. 67.8% for PTCy, P = 0.49). Both neutrophil and platelet engraftments were both significantly shorter in the ATG group than in the PTCy group (neutrophils: median 13 days vs. 15 days, P = 0.007; platelets: median 20 days vs. 27 days, P = 0.007). The cumulative incidences of acute and chronic GVHD, relapse, non-relapse mortality, and off-immunosuppressant use were similar between these two groups. The probabilities of overall and progression-free survival were 83.4% and 70.0% in the ATG group and 76.5% and 75.2% in the PTCy group, respectively, with no significant differences. These data indicate that low dose ATG and PTCy are equivalent for GVHD prophylaxis for PBSCT. - 本邦の骨髄・末梢血幹細胞移植におけるGVHD予防としてのATG使用件数の年次推移
白鳥 聡一; 大引 真理恵; 土岐 典子; 福田 隆浩; 吉原 哲; 神田 善伸; 西田 徹也; 淺田 騰; 中前 博久; 長谷川 祐太; 熱田 由子; 豊嶋 崇徳
日本輸血細胞治療学会誌, 71, 2, 473, 473, (一社)日本輸血・細胞治療学会, Apr. 2025
Japanese - Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.
Tatsunori Goto; Hiroshi Okamura; Takashi Ikeda; Yasuo Mori; Souichi Shiratori; Shin-Ichiro Fujiwara; Noriko Doki; Ken-Ichi Matsuoka; Yuta Katayama; Yi-Bin Chen; Yngvar Fløisand; Guillermo Rossiter; Johan Jansson; Ryou Nakaya; Takanori Teshima
International journal of hematology, 12 Mar. 2025, [Domestic magazines]
English, Scientific journal, In the randomized, double-blind, phase 3 GRAPHITE study (NCT03657160), anti-α4β7 integrin antibody vedolizumab showed greater efficacy than placebo for prevention of lower-gastrointestinal (GI) acute graft-versus-host disease (aGVHD) after unrelated allogenic hematopoietic stem cell transplantation (allo-HSCT). This post hoc analysis assessed the efficacy and safety of vedolizumab versus placebo for lower-GI aGVHD prevention in Japanese and non-Japanese patients, when added to standard GVHD prophylaxis (calcineurin inhibitor + methotrexate/mycophenolate mofetil + / - anti-thymocyte globulin [ATG]). The analysis included 35 (18 vedolizumab-treated, 17 placebo-treated) Japanese and 298 (150 vedolizumab-treated, 148 placebo-treated) non-Japanese patients. Lower-GI aGVHD-free survival by day + 180 after allo-HSCT (primary endpoint) was 94% in vedolizumab-treated versus 81% in placebo-treated Japanese patients (HR 0.36; 95% CI 0.03-4.01; P = 0.2) and 84% in vedolizumab-treated versus 70% in placebo-treated non-Japanese patients (HR 0.47; 95% CI 0.28-0.78; P = 0.002). The number of events for the 5 key secondary endpoints (lower-GI aGVHD-free and relapse-free survival, Grade C-D aGVHD-free survival, non-relapse mortality, overall survival, and Grade B-D aGVHD-free survival) by day + 180 was lower in vedolizumab- versus placebo-treated Japanese patients. No safety concerns were identified for vedolizumab use as lower-GI aGVHD prophylaxis in Japanese patients. - Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study.
Souichi Shiratori; Kentaro Fukushima; Yasushi Onishi; Noriko Doki; Tatsunori Goto; Masaya Okada; Hirohisa Nakamae; Yoshinobu Maeda; Koji Kato; Takayuki Ishikawa; Tadakazu Kondo; Masako Toyosaki; Takashi Ikeda; Naoyuki Uchida; Akio Maki; Fumika Shimada; Takeshi Tajima; Tommaso Stefanelli; Takanori Teshima
International journal of hematology, 120, 6, 705, 716, Dec. 2024, [Domestic magazines]
English, Scientific journal, Ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, has demonstrated safety and efficacy in patients with graft-versus-host disease (GvHD). This phase 3 randomized trial (REACH3) evaluated the efficacy and the safety of ruxolitinib 10 mg twice daily compared with investigator-selected best available therapy (BAT) in a subgroup of Japanese patients (n = 37) with steroid-refractory or dependent (SR/D) chronic GvHD. At data cut-off, treatment was ongoing in 17 patients and discontinued in 20. The overall response rate (complete or partial) at week 24 was greater with ruxolitinib than BAT (50% vs. 20%; odds ratio, 4.13 [95% CI, 0.90-18.9]). The best overall response rate (complete or partial response at any time point up to week 24) was higher with ruxolitinib than BAT (68.2% vs. 46.7%; odds ratio, 2.69 [95% CI, 0.66-10.9]). Ruxolitinib led to longer median failure-free survival than BAT (18.6 months vs. 3.7 months; hazard ratio, 0.34; [95% CI, 0.14-0.85]). The most common grade ≥ 3 adverse events up to week 24 were anemia (ruxolitinib: 22.7%; BAT: 6.7%) and pneumonia (22.7% and 20.0%, respectively). Ruxolitinib showed a higher response rate and improvement in failure-free survival in Japanese patients with SR/D chronic GvHD, with a safety profile consistent with the overall study population. - HLA半合致移植を施行したShwachman-Diamond症候群(SDS)を背景とした急性骨髄性白血病
塚本 しほり; 中川 雅夫; 小野澤 真弘; 南谷 泰仁; 小島 圭祐; 原田 知弥; 荒 隆英; 松川 敏大; 白鳥 聡一; 遠藤 知之; 豊嶋 崇徳
臨床血液, 65, 10, 1329, 1329, (一社)日本血液学会-東京事務局, Oct. 2024
Japanese - Intracerebral transplantation of MRI-trackable autologous bone marrow stromal cells for patients with subacute ischemic stroke.
Masahito Kawabori; Satoshi Kuroda; Hideo Shichinohe; Kaoru Kahata; Souichi Shiratori; Satoshi Ikeda; Taisuke Harada; Kenji Hirata; Khin Khin Tha; Masato Aragaki; Shunsuke Terasaka; Yoichi M Ito; Naoki Nishimoto; Shunsuke Ohnishi; Ichiro Yabe; Kohsuke Kudo; Kiyohiro Houkin; Miki Fujimura
Med (New York, N.Y.), 18 Mar. 2024, [International Magazine]
English, Scientific journal, BACKGROUND: Ischemic stroke is one of the leading causes of death and neurological disability worldwide, and stem cell therapy is highly expected to reverse the sequelae. This phase 1/2, first-in-human study evaluated the safety, feasibility, and monitoring of an intracerebral-transplanted magnetic resonance imaging (MRI)-trackable autologous bone marrow stromal cell (HUNS001-01) for patients with subacute ischemic stroke. METHODS: The study included adults with severe disability due to ischemic stroke. HUNS001-01 cultured with human platelet lysates and labeled with superparamagnetic iron oxide was stereotactically transplanted into the peri-infarct area 47-64 days after ischemic stroke onset (dose: 2 or 5 × 107 cells). Neurological and radiographic evaluations were performed throughout 1 year after cell transplantation. The trial was registered at UMIN Clinical Trial Registry (number UMIN000026130). FINDINGS: All seven patients who met the inclusion criteria successfully achieved cell expansion, underwent intracerebral transplantation, and completed 1 year of follow-up. No product-related adverse events were observed. The median National Institutes of Health Stroke Scale and modified Rankin scale scores before transplantation were 13 and 4, which showed improvements of 1-8 and 0-2, respectively. Cell tracking proved that the engrafted cells migrated toward the infarction border area 1-6 months after transplantation, and the quantitative susceptibility mapping revealed that cell signals at the migrated area constantly increased throughout the follow-up period up to 34% of that of the initial transplanted site. CONCLUSIONS: Intracerebral transplantation of HUNS001-01 was safe and well tolerated. Cell tracking shed light on the therapeutic mechanisms of intracerebral transplantation. FUNDING: This work was supported by the Japan Agency for Medical Research and Development (AMED; JP17bk0104045 and JP20bk0104011). - Efficacy and Safety of Single-dose Pegfilgrastim for CD34+ Cell Mobilization in Healthy Volunteers: A Phase 2 Study.
Hideki Goto; Junichi Sugita; Yuta Hasegawa; Koji Hayasaka; Kana Sunagoya; Rie Hatase; Mutsumi Nishida; Yuki Ichihashi; Mitsuhiko Odera; Hajime Senjo; Shota Yokoyama; Takahide Ara; Souichi Shiratori; Tomoyuki Endo; Masayuki Hino; Yoshinobu Maeda; Masashi Sawa; Norihiro Sato; Takanori Teshima
Transplantation, 28 Nov. 2023, [International Magazine]
English, Scientific journal, BACKGROUND: Pegfilgrastim, a long-acting form of granulocyte-colony stimulating factor, with a convenient single-injection dosage, is being investigated for peripheral blood stem cell (PBSC) mobilization in healthy volunteers. However, data on the adequate dose of pegfilgrastim for PBSC mobilization are limited. This phase 2, single-arm study evaluated the efficacy and safety of pegfilgrastim for PBSC mobilization in healthy volunteers. METHODS: The study comprised 2 phases: pilot (steps 1-3, dose escalation, a single subcutaneous dose of 3.6, 7.2, and 10.8 mg pegfilgrastim, respectively) and evaluation (step 4, efficacy and safety assessments). The primary endpoint was the proportion of subjects who achieved mobilization of ≥20 × 106/L cluster of differentiation 34 positive (CD34+) cells. RESULTS: Thirty-five subjects (6 each in steps 1 and 2 and 23 in step 4) were included. In the pilot phase, step 3 with a 10.8 mg dose was not conducted due to favorable outcomes in step 2 (desired CD34+ cell count), at 7.2 mg pegfilgrastim, which was identified as the optimal dose for the evaluation phase. In the evaluation phase, successful CD34+ mobilization was achieved in all 23 subjects. The mean peripheral blood CD34+ cells count peaked on day 5. Back pain, thrombocytopenia, transient elevations of alkaline phosphatase, and lactate dehydrogenase were the most common adverse events. All adverse events were mild, and none led to study discontinuation. CONCLUSIONS: A single-dose pegfilgrastim successfully mobilized an optimal number of CD34+ cells and was well tolerated. Pegfilgrastim could be an alternative option for PBSC mobilization in healthy volunteers. The trial was registered at www.clinicaltrials.gov (NCT03993639). - Long-term Use of Ibrutinib in Japanese Patients with Steroid Dependent/Refractory cGVHD: Final Analysis of Multicenter Study.
Masako Toyosaki; Noriko Doki; Souichi Shiratori; Tomoo Osumi; Masaya Okada; Toshiro Kawakita; Masashi Sawa; Takayuki Ishikawa; Yasunori Ueda; Tomoyoshi Hatayama; Nozomi Yoshinari; Ei Fujikawa
Blood cell therapy, 6, 4, 104, 113, 25 Nov. 2023, [Domestic magazines]
English, Scientific journal, BACKGROUND: Chronic graft-versus-host disease (cGVHD) is a serious complication after allogeneic stem cell transplantation. Poor prognosis has been shown in patients with cGVHD after the failure of primary steroid-based treatments. A previous report demonstrated the efficacy and safety of ibrutinib in these patients, leading to the approval of ibrutinib for cGVHD in Japan. Here, we report the extended follow-up of patients in this study. OBJECTIVES: To evaluate the safety and efficacy of ibrutinib in Japanese patients with steroid-dependent or refractory cGVHD. STUDY DESIGN: An open-label, single-arm, multicenter study of ibrutinib in Japanese patients with steroid-dependent or refractory cGVHD (NCT No.: NCT03474679; Clinical Registry No.: CR108443). RESULTS: At the time of the final data cutoff, 7/19 (36.8%) patients completed the study treatment, and 12/19 (63.2%) patients discontinued ibrutinib. After a median follow-up of 31.11 months (range:1.9 to 38.6 months), the best overall response rate was 84.2% (16/19 patients; 95% CI:60.4%, 96.6%) in all treated populations, with a median time to response of 2.81 (range:1.0 to 27.6) months. Of 15 responders with ≥2 organs involved at baseline, seven (46.7%) had responses in multiple organs. An improvement in the organ response rate was observed for the skin, eye, mouth, and esophagus compared with that in a previous report. The rate of sustained response for ≥20 weeks, ≥32 weeks, and ≥44 weeks were 68.8%, 62.5%, and 50.0%, respectively for 16 responders. The median daily corticosteroid dose requirement tended to decrease over time for all treated analysis sets. Twelve of 19 patients (63.2%) reached a corticosteroid dose of <0.15 mg/kg/day for at least one week, and four (21.1%) discontinued corticosteroid treatment for at least 28 days during the study. The failure-free and overall survival rates at 30 months were 62.7% and 62.0%, respectively. The safety findings of this updated analysis were consistent with the safety profile observed at the time of the primary analysis and the known ibrutinib safety profile. Common grade ≥3 treatment-emergent adverse events (TEAEs) were pneumonia (6/19 [31.6%] patients), platelet count decreased, and cellulitis (3/19 [15.8%] patients each). After the primary analysis, no new TEAEs leading to death, treatment discontinuation, or dose reduction were reported, and no new patients reported major hemorrhage. Cardiac arrhythmia (Grade 2 atrial flutter) was reported in 1/19 (5.3%) patients. No new safety signs were observed despite prolonged ibrutinib exposure. CONCLUSIONS: The final results support previous conclusions, demonstrating a clinically meaningful response and acceptable safety profile of ibrutinib in Japanese patients with steroid-dependent or refractory cGVHD. - HokUS-10 scoring system predicts the treatment outcome for sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation.
Souichi Shiratori; Kohei Okada; Junichi Sugita; Mutsumi Nishida; Takahito Iwai; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
Scientific reports, 13, 1, 17374, 17374, 13 Oct. 2023, [International Magazine]
English, Scientific journal, Hepatic sinusoidal obstruction syndrome (SOS) is a severe and life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a multi-center retrospective study to evaluate the utility of our ultrasonographic scoring system for the diagnosis of SOS (HokUS-10) in predicting SOS-related mortality (SOS-RM). We analyzed a total of 42 patients who developed SOS after HSCT. The cumulative incidences of SOS-RM, non-relapse mortality (NRM), and overall survival at day 180 after the diagnosis of SOS were 26.4%, 28.8% and 54.5%, respectively. The area under the receiver operating characteristic curve analysis showed that the optimal cut-off value of HokUS-10 total score to predict SOS-RM was 8 points after the treatment of SOS. In the individual HokUS-10 score, ascites and portal vein flow-related scores (PV mean velocity and PV flow direction) after the treatment of SOS were shown as significant risk factors for SOS-RM. Our study suggested that US findings after the treatment can predict the treatment outcomes for SOS. - Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease.
Preeti Prerna M Vaswani; Masahiro Onozawa; Yuta Hasegawa; Hiroyuki Ohigashi; Takahide Ara; Toshihiro Matsukawa; Atsushi Yasumoto; Souichi Shiratori; Hideki Goto; Masao Nakagawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
Bone marrow transplantation, 05 Sep. 2023, [International Magazine]
English - Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection
Yutaka Tsutsumi; Shinichi Ito; Souichi Shiratori; Takanori Teshima
Cancers, 15, 10, 2852, 2852, MDPI AG, 21 May 2023
Scientific journal, The hepatitis C virus (HCV) is potentially associated with liver cancer, and advances in various drugs have led to progress in the treatment of hepatitis C and attempts to prevent its transition to liver cancer. Furthermore, reactivation of HCV has been observed in the treatment of lymphoma, during which the immortalization and proliferation of lymphocytes occur, which leads to the possibility of further stimulating cytokines and the like and possibly to the development of lymphoid malignancy. There are also cases in which the disappearance of lymphoid malignancy has been observed by treating HCV and suppressing HCV-Ribonucleic acid (RNA), as well as cases of recurrence with an increase in HCV-RNA. While HCV-associated lymphoma has a poor prognosis, improving the prognosis with Direct Acting Antivirals (DAA) has recently been reported. The reduction and eradication of HCV-RNA by means of DAA is thus important for the treatment of lymphoid malignancy associated with HCV infection, and HCV-RNA can presumably play a role as a biomarker. This review provides an overview of what is currently known about HCV-associated lymphoma, its epidemiology, the mechanisms underlying the progression to lymphoma, its treatment, the potential and limits of HCV-RNA as a therapeutic biomarker, and biomarkers that are expected now that DAA therapy has been developed. - Association Between Candidemia and Noninfectious Interstitial Pneumonia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group.
Shun-Ichi Kimura; Yu Akahoshi; Souichi Shiratori; Keiji Okinaka; Kaito Harada; Naoyuki Uchida; Noriko Doki; Kazuhiro Ikegame; Hirohisa Nakamae; Masatsugu Tanaka; Satoru Takada; Toshiro Kawakita; Ken-Ichi Matsuoka; Takahide Ara; Shuichi Ota; Masashi Sawa; Makoto Onizuka; Takahiro Fukuda; Yoshiko Atsuta; Yoshinobu Kanda; Hideki Nakasone
Open forum infectious diseases, 10, 4, ofad163, Apr. 2023, [International Magazine]
English, Scientific journal, BACKGROUND: α-mannan from Candida albicans reportedly induces Th17-mediated pulmonary graft-versus-host disease (GVHD) in mouse models. This study aimed to evaluate the association between candidemia and noninfectious interstitial pneumonia (IP) in allogeneic hematopoietic cell transplantation (HCT) recipients. METHODS: Using a Japanese transplant registry database, we analyzed 9143 pediatric and adult patients with hematological malignancies who underwent their first (n = 7531) or second (n = 1612) allogeneic HCT between 2009 and 2019. RESULTS: Noninfectious IP was observed in 694 patients at a median (range) of 63 (0-1292) days after HCT. Candidemia occurred in 358 patients at a median (range) of 31 (0-903) days after HCT. Candidemia treated as a time-dependent covariate was significantly associated with an increased incidence of noninfectious IP (hazard ratio [HR], 2.51; 95% CI, 1.48-4.25), along with total body irradiation (>8 Gy; HR, 1.57; 95% CI, 1.18-2.10) and malignant lymphoma (vs acute myeloid leukemia; HR, 1.30; 95% CI, 1.004-1.69). On the other hand, prompt platelet recovery (HR, 0.58; 95% CI, 0.45-0.75) and acute lymphoblastic leukemia (vs acute myeloid leukemia; HR, 0.68; 95% CI, 0.49-0.94) were associated with reduced incidence of noninfectious IP. The median survival after the development of noninfectious IP in patients with prior candidemia was significantly shorter than that in those without it (22 days vs 59 days; P < .001). CONCLUSIONS: Candidemia was associated with an increased incidence of noninfectious IP. The prognosis of noninfectious IP after candidemia was extremely poor. - 大腿骨人工骨頭インプラント周囲に発症したALK陰性未分化大細胞型リンパ腫の1例
森 祐斗; 荒 隆英; 中川 雅夫; 吉田 匠汰; 斎藤 祐美花; 横山 翔大; 松川 敏大; 白鳥 聡一; 遠藤 知之; 豊嶋 崇徳
臨床血液, 63, 11, 1592, 1593, (一社)日本血液学会-東京事務局, Nov. 2022
Japanese - Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor.
Takahide Ara; Tomoyuki Endo; Hideki Goto; Kohei Kasahara; Yuta Hasegawa; Shota Yokoyama; Souichi Shiratori; Masao Nakagawa; Ken Kuwahara; Emi Takakuwa; Satoshi Hashino; Takanori Teshima
Antiviral therapy, 27, 5, 13596535221126828, 13596535221126828, Oct. 2022, [International Magazine]
English, Scientific journal, Epstein-Barr virus-associated smooth muscle tumor (EBV-SMT) is a rare mesenchymal tumor which occurs in immunocompromised patients. The immune status is an important factor in the treatment of EBV-SMTs, but the efficacy of antiretroviral therapy (ART) is not elucidated in acquired immune deficiency syndrome (AIDS) related EBV-SMTs. Here, we report the first successful case of a 29-year-old man with hepatic AIDS related EBV-SMT treated with ART solely. Positron emission tomography scan was useful for the evaluation of disease status. Recent advances in ART that enables to restore patient's immune status rapidly may change the treatment strategy in AIDS related EBV-SMT. - Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation.
Yoshiko Atsuta; Junichi Sugita; Hirohisa Nakamae; Yumiko Maruyama; Ken Ishiyama; Souichi Shiratori; Takahiro Fukuda; Mio Kurata; Naoki Shingai; Yukiyasu Ozawa; Masayoshi Masuko; Koji Nagafuji; Satoru Takada; Shinichi Kako; Yoshinobu Kanda; Junya Kanda; Tatsuo Ichinohe; Takanori Teshima
Bone marrow transplantation, 57, 12, 1781, 1787, 12 Sep. 2022, [International Magazine]
English, Scientific journal, We retrospectively compared outcomes of unrelated donor bone marrow transplant (UBMT) and HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) using the Japanese registry data. Recipients of first HCT for acute leukemia and myelodysplastic syndromes between 2012 and 2015 were included. The analyzed subjects comprised UBMT recipients with 8/8 matched HLA alleles (n = 1470), 7/8 matched alleles (n = 859), 6/8 matched alleles (n = 186), and recipients of PTCy-haploPBSCT (n = 133). In multivariate analyses with 8/8 matched UBMT as the reference, PTCy-haploPBSCT showed similar overall mortality, decreased risk of non-relapse mortality (NRM), increased risk of relapse, and decreased risk of grade II-IV acute graft-versus-host disease (GVHD) and chronic GVHD. Adjusted probabilities for 8/8 matched UBMT, PTCy-haploPBSCT, and 7/8 and 6/8 matched UBMT groups at 2 years post-transplant were 61%, 60%, 58%, and 52% for overall survival, 23%, 28%, 21%, and 19% for relapse, and 20%, 7%, 24%, and 33% for NRM. PTCy-haploPBSCT was associated with remarkably low NRM, contributing to survival outcomes that were comparable to 8/8 matched UBMT. The higher relapse rate in the PTCy-haploPBSCT group might be associated with the higher proportion of high-risk patients. PTCy-haploPBSCT may be a viable alternative when HLA-matched related donors are not available. - Serum levels of albumin and creatinine predict the outcome of sinusoidal obstruction syndrome after allogeneic HSCT.
Souichi Shiratori; Kohei Okada; Satomi Matsuoka; Shinichi Ito; Junichi Sugita; Takanori Teshima
Annals of hematology, 101, 9, 2117, 2118, Sep. 2022, [International Magazine]
English - Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation.
Junichi Sugita; Yoshiko Atsuta; Hirohisa Nakamae; Yumiko Maruyama; Ken Ishiyama; Souichi Shiratori; Takahiro Fukuda; Mio Kurata; Naoki Shingai; Yukiyasu Ozawa; Masayoshi Masuko; Koji Nagafuji; Naoyuki Uchida; Masatsugu Tanaka; Makoto Onizuka; Junya Kanda; Takafumi Kimura; Tatsuo Ichinohe; Takanori Teshima
Bone marrow transplantation, 57, 11, 1681, 1688, 20 Aug. 2022, [International Magazine]
English, Scientific journal, HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide (PTCy-haplo) and umbilical cord blood transplantation (UCBT) are alternative to HLA-matched stem cell transplantation. We conducted a matched-pair analysis of PTCy-haplo and UCBT using the Japanese registry data. We identified 136 patients aged between 16 and 69 years who received PTCy-haplo as their first transplantation for acute leukemia or myelodysplastic syndromes. Control group included 408 UCBT recipients selected to match the PTCy-haplo group. Overall and relapse-free survival probabilities at 2 years were comparable between the PTCy-haplo and UCBT groups: 55% vs. 53% for overall survival (p = 0.46), and 47% vs. 48% for relapse-free survival (p = 0.79), respectively. The cumulative incidence of relapse was significantly higher (43% vs. 29%, respectively, p = 0.006), while the cumulative incidence of non-relapse mortality (NRM) was significantly lower (9% vs. 23%, respectively, p < 0.001) in the PTCy-haplo group. The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was lower in the PTCy-haplo group compared to the UCBT group (29% vs. 41%, respectively, p = 0.016), while those of grade III-IV acute GVHD and chronic GVHD were not statistically different between the two groups. Our results suggest that both PTCy-haplo and UCBT are viable alternatives to HLA-matched stem cell transplantation. - Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.
Kotaro Miyao; Yachiyo Kuwatsuka; Makoto Murata; Koji Nagafuji; Takanori Teshima; Yuki Takeuchi; Souichi Shiratori; Yuho Najima; Naoyuki Uchida; Masatsugu Tanaka; Masashi Sawa; Shuichi Ota; Takahiro Fukuda; Yukiyasu Ozawa; Shinichi Kako; Toshiro Kawakita; Takahide Ara; Junji Tanaka; Yoshinobu Kanda; Yoshiko Atsuta; Junya Kanda; Seitaro Terakura
Transplantation and cellular therapy, 28, 3, 153.e1-153.e11, Mar. 2022, [International Magazine]
English, Scientific journal, Previous Japanese studies have shown that bone marrow transplantation (BMT) is associated with better survival compared with peripheral blood stem cell transplantation (PBSCT) from a matched related donor (MRD). PBSCT recipients have shown higher incidences of severe graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) compared with BMT recipients. In recent years, the efficacy and safety of antithymocyte globulin (ATG) for PBSCT recipients has been evaluated worldwide. In the present study, we aimed to compare BMT and PBSCT recipients to identify current improvements and unmet needs among MRD PBSCT recipients. In addition, we evaluated the impact of ATG administration on the outcomes of PBSCT recipients. We retrospectively analyzed patients age ≥16 years with acute leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia who underwent their first BMT or PBSCT from an MRD between 2009 and 2018 in Japan. A total of 3599 transplantations were performed (BMT, n = 1218; PBSCT without ATG [PBSCT-ATG(-)], n = 2288; PBSCT with ATG [PBSCT-ATG(+)], n = 93). The PBSCT-ATG(-) group had a higher NRM (hazard ratio [HR], 1.30; 95% confidence interval [CI], 1.08 to 1.57; P = .005) and lower overall survival (OS) (HR, 1.16; 95% CI, 1.04 to 1.30; P = .011) compared with the BMT group. Furthermore, the PBSCT-ATG(-) group had higher incidences of grade III-IV, stage 2-4 gut, high-risk, and steroid-refractory acute GVHD compared with the BMT group. Acute GVHD had a negative impact on NRM and OS. The PBSCT-ATG(-) group also was associated with an elevated risk of chronic GVHD (HR, 1.89; 95% CI, 1.24 to 2.57; P < .001) and extensive chronic GVHD (HR, 1.44; 95% CI, 1.23 to 1.68; P < .001). The incidences of acute GVHD, chronic GVHD, and NRM and chronic GVHD-free relapse-free survival rates were comparable between the PBSCT-ATG(+) and BMT groups. The OS of patients with acute GVHD was similar in the 3 donor groups. Patients treated with reduced-intensity conditioning in the PBSCT-ATG(+) group had a higher relapse rate and lower OS rate compared with those in the BMT group. In this Japanese cohort, standard calcineurin inhibitor-based GVHD prophylaxis was not sufficient for recipients of MRD PBSCT because of the high incidence of severe acute GVHD. Prophylactic ATG was found to be a promising strategy against GVHD. - 診断に苦慮した陰茎発生顆粒球性肉腫の1例
相澤 翔吾; 大澤 崇宏; 菊地 央; 松本 隆児; 安部 崇重; 白鳥 聡一; 三橋 智子; 篠原 信雄
泌尿器科紀要, 68, 2, 63, 66, 泌尿器科紀要刊行会, Feb. 2022
Japanese, 症例は57歳男性で、陰茎腫瘍を主訴に当科を受診した。初診時MRIでは硬化性リンパ管炎やペロニー病などの良性疾患が考えられたが、2ヵ月後に腫瘤は25×15×8mmから27×15×8mmに増大し、PET-CTで悪性疾患が強く疑われ手術を予定した。既往歴に急性骨髄性白血病(AML)があり、術前検査でAML再燃が疑われたため、陰茎腫瘍生検および骨髄生検を行ったところ、陰茎発生顆粒球性肉腫(GS)が先行したAML再燃の診断に至った。診断後はDNR+AraC療法を行い、陰茎腫瘍の縮小とAMLの寛解が得られた。その後は2回目の同種骨髄幹細胞移植が施行され、現在まで8ヵ月間再発を認めていない。 - Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.
Nobuhiko Imahashi; Seitaro Terakura; Eisei Kondo; Koji Kato; Sung-Won Kim; Akihito Shinohara; Mizuki Watanabe; Takahiro Fukuda; Naoyuki Uchida; Hikaru Kobayashi; Jun Ishikawa; Keisuke Kataoka; Souichi Shiratori; Takashi Ikeda; Ken-Ichi Matsuoka; Shuro Yoshida; Tadakazu Kondo; Takafumi Kimura; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta; Junya Kanda
Bone marrow transplantation, 57, 2, 243, 251, Feb. 2022, [International Magazine]
English, Scientific journal, We retrospectively compared the outcomes of reduced-intensity conditioning (RIC) transplantation from matched related donors (MRD; n = 266), matched unrelated donors (MUD; n = 277), and umbilical cord blood (UCB; n = 513) for mature lymphoid malignancies. The 3-year overall survival rates for the MRD, MUD, and UCB groups were 54%, 59%, and 40%, respectively (P < 0.001). Multivariate analysis showed no differences in survival between the MRD group and the MUD or UCB group. However, survival was significantly affected by the conditioning regimen and graft-versus-host disease (GVHD) prophylaxis in the UCB group, but not in the MRD and MUD groups. Notably, multivariate analysis showed that the risk of overall mortality in the UCB recipients who received the optimal conditioning regimen and GVHD prophylaxis (n = 116) was lower than that in the MRD group (relative risk [RR], 0.69; P = 0.03) and tended to be lower than that in the MUD group (RR, 0.75; P = 0.09). Our results suggest that UCB transplantation performed with the optimal conditioning regimen and GVHD prophylaxis is highly effective. Moreover, UCB is readily available. Thus, UCB transplantation with the optimal conditioning regimen and GVHD prophylaxis is preferable to MUD transplantation when MRD are not available in the setting of RIC transplantation for mature lymphoid malignancies. - [Leukemia Relapse as Granulocytic Sarcoma Beginning with Penile Localization : A Case Report].
Shogo Aizawa; Takahiro Osawa; Hiroshi Kikuchi; Ryuji Matsumoto; Takashige Abe; Souichi Shiratori; Tomoko Mitsuhashi; Nobuo Shinohara
Hinyokika kiyo. Acta urologica Japonica, 68, 2, 63, 66, Feb. 2022, [Domestic magazines]
Japanese, Scientific journal, A 57-year-old man visited the urology department with a painful mass on the dorsal side of the penis. Magnetic resonance imaging sagittal image showed a small nodule. Leukemia recurrence was suspected due to his history of treatment for acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation. No recurrence was identified by bone marrow biopsy ; however, two months later, the recurrence of leukemia was strongly suspected because the tumor grew over time and blasts were found in the peripheral blood. A biopsy of the penile tumor and bone marrow was performed, leading to the diagnosis of granulocytic sarcoma. Patients with a history of leukemia may be preceded by a single recurrence to extramedullary organs, even if blood and bone marrow findings suggest remission. - Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia
Kaito Harada; Shohei Mizuno; Shingo Yano; Akiyoshi Takami; Hiroto Ishii; Kazuhiro Ikegame; Yuho Najima; Shinichi Kako; Takashi Ashida; Souichi Shiratori; Shuichi Ota; Makoto Onizuka; Kentaro Fukushima; Takahiro Fukuda; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Annals of Hematology, 101, 3, 643, 653, Springer Science and Business Media LLC, 06 Jan. 2022, [International Magazine]
English, Scientific journal, Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host disease (GVHD) and the efficacy of haploidentical DLI have not been fully evaluated. We retrospectively analyzed the outcomes after haploidentical DLI for 84 patients with AML using a nationwide database and additional questionnaires. The median number of DLI cycles and infused CD3+ cell dose was 1 and 1.0 × 106/kg, respectively. The infused CD3+ cell count of 5.0 × 105/kg or higher was associated with acute GVHD (grade II-IV, 32.1% vs. 10.5%, p = 0.03; grade III-IV, 21.4% vs. 5.3%, p = 0.10). Patients who developed grade III-IV acute GVHD more frequently succumbed to treatment-related mortality (46.7% vs. 15.8% at 1 year, p = 0.002), although the relapse-related mortality was significantly low (40.0% vs. 72.2% at 1 year, p = 0.025). The overall response to DLI was significantly higher in the preemptive DLI group (47.4%) than in the therapeutic group (13.9%, p = 0.002). In the multivariate analysis, preemptive DLI was the predictive factor for overall response (odds ratio, 5.58; p = 0.003). Our results indicated the substantial risk of acute GVHD after haploidentical DLI with CD3+ cell count of 5.0×105/kg or higher and the favorable outcomes after preemptive DLI. - [Antithymocyte globulin for graft-versus-host disease prophylaxis, past, present and future].
Souichi Shiratori
[Rinsho ketsueki] The Japanese journal of clinical hematology, 63, 5, 412, 422, 2022, [Domestic magazines]
Japanese, Scientific journal, Antithymocyte globulin (ATG) for graft-versus-host disease (GVHD) prophylaxis has been demonstrated for chronic GVHD inhibition by a series of randomized control trials. The optimal dose of ATG remained unestablished; however, the recommended dose of ATG by the European Group for Blood and Marrow Transplantation has recently decreased. While a lower ATG dose has been used in Japan, ATG usage is recommended in peripheral blood stem cell transplantation or human leukocyte antigens (HLA) 1-locus mismatched bone marrow transplantation with myeloablative conditioning from the nation-wide retrospective studies showing that ATG inhibited chronic GVHD and improved GVHD-free, relapse-free survival. The association of absolute lymphocyte counts (ALC) before ATG administration with transplant outcomes has been reported, which suggests a possible strategy to individualize the ATG dose according to ALC before ATG. Recent studies compared the transplant outcomes using ATG and post-transplant cyclophosphamide, which has rapidly spread in haploidentical transplantation; however, further studies are needed to establish those positioning in HLA-matched/mismatched transplantation. - Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.
Shinichi Kobayashi; Yoshinobu Kanda; Takaaki Konuma; Yoshihiro Inamoto; Kimikazu Matsumoto; Naoyuki Uchida; Kazuhiro Ikegame; Toshihiro Miyamoto; Noriko Doki; Hirohisa Nakamae; Yuta Katayama; Satoshi Takahashi; Souichi Shiratori; Shoji Saito; Toshiro Kawakita; Junya Kanda; Takahiro Fukuda; Yoshiko Atsuta; Fumihiko Kimura
Bone marrow transplantation, 57, 1, 43, 50, Jan. 2022, [International Magazine]
English, Scientific journal, Relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with poor prognosis. In a subset of patients, durable remissions can be achieved with a second allo-HSCT (allo-HSCT2). However, many patients experience relapse after allo-HSCT2 and they may be considered for a third allo-HSCT (allo-HSCT3). Nevertheless, the benefit of allo-HSCT3 remains unconfirmed. Thus, herein a retrospective analysis of 253 allo-HSCT3s in patients with relapsed/refractory acute leukemia was carried out. In total, 29 (11.5%) survived at a median follow-up of 794 days (range: 87-4 619). The 3-year leukemia-free survival and overall survival (OS) rates were 9.7% and 10.9%, respectively. Patients who maintained remission for ≥2 years after allo-HSCT2 had a significantly better 3-year OS (35.8%) than those who experienced early relapse (<1 year, 7.8%; 1-2 years, 14.0%; P = 0.004). Complete remission at allo-HSCT3, performance status score of 0-1 at allo-HSCT3, grade I acute graft-versus-host disease after allo-HSCT2, and relapse ≥2 years after allo-HSCT2 were associated with better survival in patients who received allo-HSCT3. The prognosis after allo-HSCT3 in patients with relapsed/refractory acute leukemia is generally unfavorable. However, given the lack of alternative treatment options, allo-HSCT3 may be considered in a group of patients. - An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Noriko Doki; Masako Toyosaki; Souichi Shiratori; Tomoo Osumi; Masaya Okada; Toshiro Kawakita; Masashi Sawa; Takayuki Ishikawa; Yasunori Ueda; Nozomi Yoshinari; Susumu Nakahara
Transplantation and cellular therapy, 27, 10, 867.e1-867.e9, Oct. 2021, [International Magazine]
English, Scientific journal, Chronic graft-versus-host disease (cGVHD) is a serious complication after allogeneic stem cell transplantation. There are no well-established treatment options for cGVHD after primary steroid-based treatment. Ibrutinib showed clinical benefit with an acceptable safety profile in steroid-dependent/refractory cGVHD patients in a Phase 1b/2 study (PCYC-1129-CA, NCT02195869), with which it was approved in the United States for adult cGVHD patients after failure of ≥1 systemic treatments. This open-label, single-arm, multicenter study was conducted to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ibrutinib in Japanese patients ≥12 years of age with steroid-dependent/refractory cGVHD (NCT03474679). Patients were assessed on the basis of the National Institutes of Health (NIH) Consensus Development Project Criteria for Clinical Trials in cGVHD (2014). All patients received ibrutinib at a dose of 420 mg orally once daily, with a dose reduction to 280 mg/d on the concomitant use of voriconazole. Nineteen patients, including 1 adolescent, were enrolled and treated with ibrutinib in the study. At the time of clinical data cutoff (when the last patient completed the efficacy assessment at week 37), 10 of 19 patients (52.6%) remained on treatment whereas 9 of 19 patients (47.4%) had discontinued ibrutinib. The median duration of ibrutinib treatment was 9.63 (range 0.6 to 16.7+) months. The best overall response rate was 73.7%, and the rate of sustained response for ≥20 weeks was 71.4% for the responders (52.6% of all patients). Responses were seen across all the involved organs for cGVHD. Median daily corticosteroid dose requirement decreased by 0.06 mg/kg/d from baseline to week 36, whereas an improvement in the Lee cGVHD Symptom Scale score was observed in 42.1% of patients. The most common treatment-emergent adverse events (TEAEs) were pneumonia and stomatitis (36.8% each), upper respiratory tract infection (31.6%), cellulitis and platelet count decreased (26.3% each), and nausea (21.1%). Furthermore, 11 of 19 patients (57.9%) were reported with ≥1 treatment-emergent serious adverse events; the most common being pneumonia (26.3%) and cellulitis (15.8%). In total, 4 of 19 patients (21.1%) died during the study, of which 3 of 19 patients (15.8%) had TEAEs leading to death whereas 1 patient died of peritonitis, which occurred >30 days after the last dose of ibrutinib. Treatment-emergent adverse events leading to ibrutinib discontinuation were reported in 3 of 19 patients (15.8%). Ibrutinib was rapidly absorbed with a median time to reach maximum plasma concentration (tmax) of ~4.0 hours. Steady-state exposures were ~3.0- and ~1.4-fold higher for the patients receiving fluconazole (n = 8) and voriconazole (n = 4) with ibrutinib, respectively, as compared with patients not receiving CYP3A inhibitors (n = 7). Mean Bruton's tyrosine kinase occupancy was 88.1% at 4 hours after dose on day 1, and occupancy levels were maintained throughout the assessment period, regardless of the ibrutinib daily dose. Ibrutinib showed a clinically meaningful response and an acceptable safety profile in Japanese patients with steroid-dependent/refractory cGVHD; the safety profile was consistent with the known safety profile of ibrutinib in adults and with that seen in cGVHD patients receiving concomitant steroid treatment. Overall, the results were generally consistent with findings observed in the PCYC-1129-CA study. - Improved survival of patients with aggressive ATL by increased use of allo-HCT: A prospective observational study.
Ayumu Ito; Nobuaki Nakano; Takashi Tanaka; Shigeo Fuji; Junya Makiyama; Yoshitaka Inoue; Ilseung Choi; Hirohisa Nakamae; Koji Nagafuji; Ken Takase; Shinichiro Machida; Tsutomu Takahashi; Yasushi Sawayama; Tomohiko Kamimura; Koji Kato; Toshiro Kawakita; Masao Ogata; Rika Sakai; Souichi Shiratori; Kaoru Uchimaru; Yoshihiro Inamoto; Atae Utsunomiya; Takahiro Fukuda
Blood advances, 5, 20, 4156, 4166, 09 Sep. 2021, [International Magazine]
English, Scientific journal, Aggressive adult T-cell leukemia/lymphoma (ATL) is a hematological malignancy that is difficult to treat with chemotherapy alone, and allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy. We conducted a multicenter, prospective, observational study to clarify the treatment outcomes of aggressive ATL in the current era. Between 2015 and 2018, 113 patients aged 70 years or younger with newly diagnosed aggressive ATL were enrolled. The median age at diagnosis was 61 years old. Treatment outcomes were compared with those of 1,792 ATL patients diagnosed between 2000 and 2013 in our previous retrospective study. The inclusion criteria were the same in both studies. The prospective cohort demonstrated better overall survival (OS) than the retrospective cohort (2-year OS, 45% versus 29%, respectively; P<0.001), with a much higher proportion of patients receiving allo-HCT (80% versus 34%, respectively; P<0.001) and a shorter interval from diagnosis to allo-HCT (median, 128 versus 170 days, respectively; P<0.001). Among the 90 patients who received allo-HCT (cord blood, n=30; HLA-haploidentical related donors, n=20; other related donors, n=14; other unrelated donors, n=26), the 2-year probabilities of OS, non-relapse mortality (NRM), and disease progression were 44%, 23%, and 46%, respectively. OS and NRM did not differ statistically according to donor type. Our results suggest that increased application of allo-HCT improved the survival of patients with aggressive ATL. The use of cord blood or HLA-haploidentical donors may be feasible for aggressive ATL when HLA-matched related donors are unavailable. This study was registered with the UMIN Clinical Trials Registry (UMIN 000017672). - Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group.
Shun-Ichi Kimura; Masaharu Tamaki; Keiji Okinaka; Sachiko Seo; Naoyuki Uchida; Aiko Igarashi; Yukiyasu Ozawa; Kazuhiro Ikegame; Tetsuya Eto; Masatsugu Tanaka; Souichi Shiratori; Hirohisa Nakamae; Masashi Sawa; Toshiro Kawakita; Makoto Onizuka; Takahiro Fukuda; Yoshiko Atsuta; Yoshinobu Kanda; Hideki Nakasone
Annals of hematology, 100, 12, 3029, 3038, 07 Sep. 2021, [International Magazine]
English, Scientific journal, There is a matter of debate about the clinical impact of cytomegalovirus (CMV) reactivation on the development of late-onset invasive aspergillosis (IA), which occurs 40 days or later after allogeneic hematopoietic stem cell transplantation (HSCT). Using a Japanese transplant registry database, we analyzed the risk factors for the development of late-onset IA in 21,015 patients who underwent their first allogeneic HSCT between 2006 and 2017. CMV reactivation was defined as the initiation of preemptive anti-CMV antiviral therapy. Overall, there were 582 cases of late-onset IA, which occurred at a median of 95 days after HSCT. The 2-year cumulative incidence was 3.4% (95% confidence interval (CI), 3.0-3.9) in patients with CMV reactivation within 40 days after HSCT and 2.5% (95% CI, 2.3-2.8) in those without it (P < 0.001). In a multivariate analysis, CMV reactivation as a time-dependent covariate was significantly associated with the development of late-onset IA (hazard ratio (HR) 1.40, P < 0.001), as well as grade II-IV acute GVHD, age > 50 and HCT-CI ≥ 3 in the entire cohort. If we focus on the subgroup without grade II-IV acute GVHD, which is generally an indication for systemic corticosteroid therapy (n = 12,622), CMV reactivation was still a significant factor for the development of late-onset IA (HR 1.37, P = 0.045) as well as age > 50 years, HCT-CI ≥ 3, and cord blood transplantation. In conclusion, CMV reactivation was associated with an increased risk of late-onset IA after allogeneic HSCT independently of acute GVHD. Close monitoring for late-onset IA is necessary for patients who develop CMV reactivation even without grade II-IV acute GVHD. - Graft-Versus-Host Disease Prophylaxis Using Low-Dose Antithymocyte Globulin in Peripheral Blood Stem Cell Transplantation-A Matched-Pair Analysis.
Souichi Shiratori; Mio Kurata; Junichi Sugita; Shuichi Ota; Senji Kasahara; Jun Ishikawa; Kazunori Imada; Yasushi Onishi; Ken Ishiyama; Takashi Ashida; Yoshinobu Kanda; Tatsuo Ichinohe; Takahiro Fukuda; Yoshiko Atsuta; Takanori Teshima
Transplantation and cellular therapy, 27, 12, 995.e1-995.e6, 06 Sep. 2021, [International Magazine]
English, Scientific journal, Antithymocyte globulin (ATG) decreases chronic graft-versus-host disease (cGVHD) in peripheral blood stem cell transplantation (PBSCT); however, the optimal ATG dose has not been elucidated. We conducted a matched-pair analysis to evaluate whether low-dose ATG could inhibit cGVHD in HLA-matched PBSCT after myeloablative conditioning. A total of 70 patients who were enrolled in the JSCT-ATG15 study, a multicenter phase II clinical trial of 2 mg/kg of ATG (thymoglobulin) given on days -2 and -1, were compared with 210 patients not receiving ATG, who were matched for age, sex, disease, and calcineurin inhibitor selected from the database in Japan. The primary endpoint, cumulative incidence of extensive cGVHD at 2 years was significantly less in the ATG group than that in the non-ATG group (8.7% [95% CI, 3.5%-16.8%] versus 26.2% [95% CI, 20.3%-32.5%], P = .002). ATG significantly reduced the incidence of overall cGVHD and inhibited multiple organ involvement. The ATG group had favorable outcome compared to the non-ATG group in GVHD-free, and relapse-free survival at 2 years. In conclusion, low-dose ATG effectively inhibits chronic GVHD in PBSCT. - Association between CMV reactivation and late-onset invasive aspergillosis after allogeneic HCT(和訳中)
木村 俊一; 玉置 雅治; 冲中 敬二; 瀬尾 幸子; 内田 直之; 五十嵐 愛子; 小澤 幸泰; 池亀 和博; 衛藤 徹也; 田中 正嗣; 白鳥 聡一; 中前 博久; 澤 正史; 河北 敏郎; 鬼塚 真仁; 福田 隆浩; 熱田 由子; 神田 善伸; 仲宗根 秀樹
日本血液学会学術集会, 83回, OS3, 4, (一社)日本血液学会, Sep. 2021
English - Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors.
Souichi Shiratori; Junichi Sugita; Shigeo Fuji; Jun Aoki; Masashi Sawa; Yukiyasu Ozawa; Daigo Hashimoto; Ken-Ichi Matsuoka; Kazunori Imada; Noriko Doki; Takashi Ashida; Yasunori Ueda; Masatsugu Tanaka; Yasushi Sawayama; Tatsuo Ichinohe; Seitaro Terakura; Satoko Morishima; Yoshiko Atsuta; Takahiro Fukuda; Takanori Teshima
Bone marrow transplantation, 56, 9, 2231, 2240, Sep. 2021, [International Magazine]
English, Scientific journal, Antithymocyte globulin (ATG) has been shown to reduce chronic graft-versus-host disease (GVHD) particularly in allogeneic peripheral blood stem cell transplantation (PBSCT) from unrelated donors; however, anti-GVHD effects of lower doses of ATG remains to be elucidated. We conducted a nationwide retrospective study to compare the outcomes of unrelated PBSCT with or without rabbit ATG (thymoglobulin) in 287 patients. A median ATG dose was 2.0 mg/kg. The primary endpoint, the cumulative incidence of moderate-severe chronic GVHD at 2 years was 22.1% in the ATG group, which was significantly less than that in the non-ATG group (36.3%, P = 0.025). The ATG group had a higher incidence of immunosuppressant discontinuation, GVHD-free, relapse-free survival, and moderate-severe chronic GVHD-free, relapse-free survival at 2 years compared to the non-ATG group. The incidences of grade III-IV aGVHD and moderate-severe chronic GVHD were significantly higher in patients with high absolute lymphocyte count (ALC) before the administration of ATG, whereas relapse rate was significantly higher in patients with low ALC before ATG. In conclusion, low-dose ATG effectively suppresses chronic GVHD in unrelated PBSCT, and ALC before ATG may be a potential predictor for GVHD and relapse. - Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes.
Masamitsu Yanada; Shohei Mizuno; Satoshi Yamasaki; Kaito Harada; Takaaki Konuma; Hiroya Tamaki; Naoki Shingai; Naoyuki Uchida; Yukiyasu Ozawa; Masatsugu Tanaka; Makoto Onizuka; Masashi Sawa; Hirohisa Nakamae; Souichi Shiratori; Ken-Ichi Matsuoka; Tetsuya Eto; Toshiro Kawakita; Yumiko Maruyama; Tatsuo Ichinohe; Yoshinobu Kanda; Yoshiko Atsuta; Jun Aoki; Shingo Yano
Leukemia & lymphoma, 62, 14, 1, 9, 04 Aug. 2021, [International Magazine]
English, Scientific journal, To evaluate whether outcomes following allogeneic hematopoietic cell transplantation differ according to disease type, a three-way comparison for patients with de novo acute myeloid leukemia (AML) (n = 3318), AML evolving from myelodysplastic syndromes (MDS) (n = 208), and MDS with excess blasts (MDS-EB) (n = 994) was performed. The 5-year probabilities of overall survival (OS) for de novo AML, AML evolving from MDS, and MDS-EB were 60%, 42%, and 41% (p < 0.001), respectively. Multivariate analysis revealed that, compared to de novo AML, AML evolving from MDS was associated with a higher risk of NRM (p = 0.030) and MDS-EB with a higher risk of relapse (p < 0.001), both leading to lower OS (p = 0.010 and p < 0.001, respectively). These findings demonstrate inter-disease differences in post-transplant outcomes and highlight the needs to reduce NRM for AML evolving from MDS and to reduce relapse for MDS-EB. - Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality.
Yu Akahoshi; Shun-Ichi Kimura; Yoshihiro Inamoto; Sachiko Seo; Hiroyuki Muranushi; Hiroaki Shimizu; Yukiyasu Ozawa; Masatsugu Tanaka; Naoyuki Uchida; Yoshinobu Kanda; Yuta Katayama; Souichi Shiratori; Shuichi Ota; Ken-Ichi Matsuoka; Makoto Onizuka; Takahiro Fukuda; Yoshiko Atsuta; Makoto Murata; Seitaro Terakura; Hideki Nakasone
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73, 3, e620-e628, 02 Aug. 2021, [International Magazine]
English, Scientific journal, BACKGROUND: Despite a strong association between acute graft-versus-host disease (GVHD) and cytomegalovirus reactivation (CMVR), the joint effect of acute GVHD and CMVR on nonrelapse mortality (NRM) has not been well studied. METHODS: We evaluated the impact of CMVR on NRM stratified according to the development of acute GVHD using a landmark method. This study included 6078 patients who received their first allogeneic hematopoietic cell transplantation (HCT) with a preemptive strategy for CMVR between 2008 and 2017. RESULTS: The cumulative incidences of grade 2-4 acute GVHD (G24GVHD), CMVR by day 100, and CMV disease by day 365 were 37.3%, 52.1%, and 2.9%, respectively. Patients with G24GVHD were associated with the subsequent development of CMVR, and the presence of CMVR also increased the risk of G24GVHD. In a landmark analysis at day 65, the cumulative incidence of NRM at 1 year was 5.4%, 10.0%, 13.9%, and 19.7% in patients with G24GVHD-/CMVR-, G24GVHD-/CMVR+, G24GVHD+/CMVR-, and G24GVHD+/CMVR+, respectively. In a multivariate analysis, CMVR was respectively associated with an increased risk of NRM by day 365 in patients without G24GVHD (hazard ratio [HR], 1.59; 95% confidence interval [CI], 1.24-2.05; P < .001) and with G24GVHD (HR, 1.34; 95% CI, 1.06-1.70; P = .014), but the interaction between G24GVHD and CMVR was not significant (P = .326). Subgroup analyses suggested that the joint effect of acute GVHD and CMVR might vary according to the baseline characteristics. CONCLUSIONS: These data regarding the close relationship between acute GVHD and CMVR should provide important implications for the treatment strategy after HCT. - Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT.
Yu Akahoshi; Yasuyuki Arai; Satoshi Nishiwaki; Takayoshi Tachibana; Akihito Shinohara; Noriko Doki; Naoyuki Uchida; Masatsugu Tanaka; Yoshinobu Kanda; Souichi Shiratori; Yukiyasu Ozawa; Katsuhiro Shono; Yuta Katayama; Junji Tanaka; Takahiro Fukuda; Yoshiko Atsuta; Shinichi Kako
Bone marrow transplantation, 56, 11, 2842, 2848, 30 Jul. 2021, [International Magazine]
English, Scientific journal, White blood cell count (WBC) at diagnosis is the conventional prognostic factor in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Nevertheless, little is known about the impact of WBC at diagnosis considering the minimal residual disease (MRD) status at allogeneic hematopoietic cell transplantation (HCT). We evaluated adult patients with Ph+ ALL who achieved negative-MRD and received HCT in first complete remission between 2006 and 2018. The entire cohort was temporally divided into derivation (n = 258) and validation cohorts (n = 366). Using a threshold of 15,000/μL, which was determined by a receiver operating characteristic curve analysis in the derivation cohort, high WBC was associated with an increased risk of hematological relapse in both the derivation cohort (25.3% vs. 11.6% at 7 years, P = 0.004) and the validation cohort (16.2% vs. 8.5% at 3 years, P = 0.025). In multivariate analyses, high WBC was a strong predictor of hematological relapse in the derivation cohort (HR, 2.52, 95%CI 1.32-4.80, P = 0.005) and in the validation cohort (HR, 2.32, 95%CI, 1.18-4.55; P = 0.015). In conclusion, WBC at diagnosis with a new threshold of 15,000/μL should contribute to better risk stratification in patients with negative-MRD at HCT. - Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.
Takaaki Konuma; Tadakazu Kondo; Masayoshi Masuko; Hiroaki Shimizu; Souichi Shiratori; Takahiro Fukuda; Jun Kato; Masashi Sawa; Yukiyasu Ozawa; Shuichi Ota; Naoyuki Uchida; Yoshinobu Kanda; Shinichi Kako; Shin Fujisawa; Kentaro Fukushima; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Bone marrow transplantation, 56, 11, 2779, 2787, 16 Jul. 2021, [International Magazine]
English, Scientific journal, Pretransplant measurable residual disease (MRD) has been shown to be associated with relapse incidence following allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). However, it remains less clear whether pretransplant MRD status affects transplant outcomes in core binding factor AML (CBF-AML). We retrospectively evaluated the effect of pretransplant MRD, which was measured by a polymerase chain reaction of RUNX1-RUNX1T1 or CBFB-MYH11 fusion transcripts, on transplant outcomes for a cohort of 959 adult patients with t(8;21) or inv(16) AML treated by allogeneic HCT during complete remission (CR), between 2000 and 2018. Multivariate analysis showed the absence of pretransplant MRD was significantly associated with lower relapse (hazard ratio [HR], 0.46; P < 0.001), treatment failure (HR, 0.66; P = 0.004), and overall mortality (HR, 0.72; P = 0.037) among patients with t(8;21). However, pretransplant MRD negativity was not associated with relapse (HR, 0.73; P = 0.420), treatment failure (HR, 0.64; P = 0.063), or overall mortality (HR, 0.69; P = 0.149) among patients with inv(16). In subgroup analysis, pretransplant MRD status significantly affected relapse and LFS only in patients with t(8;21) undergoing allogeneic HCT during CR2. In conclusion, our data demonstrate the different prognostic values of pretransplant MRD for CBF-AML, highlighting the need to develop effective therapeutic strategies for such MRD-positive patients. - Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.
Momoko Nakamura; Yasuyuki Arai; Shigeki Hirabayashi; Tadakazu Kondo; Noriko Doki; Naoyuki Uchida; Takahiro Fukuda; Yukiyasu Ozawa; Masatsugu Tanaka; Masashi Sawa; Yuta Katayama; Yoshinobu Kanda; Souichi Shiratori; Hirohisa Nakamae; Satoshi Yoshioka; Makoto Onizuka; Tatsuo Ichinohe; Yoshiko Atsuta; Shinichi Kako
British journal of haematology, 194, 2, 403, 413, Jul. 2021, [International Magazine]
English, Scientific journal, Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is one of the curative treatment options for acute lymphoblastic leukaemia (ALL). However, the outcomes in patients transplanted without complete remission (non-CR) have not yet been fully reported, and detailed analyses are required to identify subgroups in which optimal prognosis is expected and to optimize pre-transplant therapeutic strategies. Hence, we performed a multicentred retrospective cohort study including a total of 663 adult ALL patients transplanted at non-CR status; the median bone marrow (BM) blast counts at HSCT was 13·2%, and 203 patients (30·6%) were treated at primary induction failure status. The overall survival (OS) was 31·1% at two years, and the multivariate analyses identified five prognostic risk factors, including older age (≥50 years), increased BM blasts (≥10%), poor performance status, high haematopoietic cell transplantation (HCT)-comorbidity index, and relapsed disease status, among which BM blast was the most significantly related. A predictive scoring system composed of these risk factors clearly stratified OS (15·6-59·5% at two years). In conclusion, this is the first large-scale study to analyze the correlation of patient characteristics with post-transplant prognosis in ALL transplanted at non-CR status. The importance of blast control before HSCT should be focused on for better patient prognosis. - Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation.
Masatoshi Sakurai; Takehiko Mori; Koji Kato; Minoru Kanaya; Shohei Mizuno; Souichi Shiratori; Toshio Wakayama; Naoyuki Uchida; Hikaru Kobayashi; Kohmei Kubo; Itsuto Amano; Takanori Ohta; Yasuhiko Miyazaki; Junya Kanda; Takahiro Fukuda; Yoshiko Atsuta; Eisei Kondo
Bone marrow transplantation, 56, 6, 1462, 1466, Jun. 2021, [International Magazine]
English - High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease.
Souichi Shiratori; Hiroyuki Ohigashi; Takahide Ara; Atsushi Yasumoto; Hideki Goto; Masao Nakagawa; Junichi Sugita; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
Annals of hematology, 100, 5, 1321, 1328, May 2021, [International Magazine]
English, Scientific journal, Antithymocyte globulin (ATG) reduces severe acute and chronic graft-versus-host disease (GVHD) in allogeneic peripheral blood stem cell transplantation (PBSCT). However, risk factors for severe acute GVHD in PBSCT using ATG remain to be determined. We conducted a single-center, retrospective study to analyze the association of acute GVHD requiring systemic corticosteroid (SC-aGVHD) with absolute lymphocyte counts (ALC) before the administration of ATG or conditioning in 53 patients with HLA-matched PBSCT using low-dose thymoglobulin (2 mg/kg) after myeloablative conditioning. The cumulative incidence of SC-aGVHD was 17.0% and ALC before ATG were significantly higher in patients with SC-aGVHD compared to that in patients without it (median, 0.15 × 109/L vs 0.06 × 109/L, P = 0.047). The cumulative incidence of SC-aGVHD was significantly higher in patients with high ALC before ATG (≥ 0.15 × 109/L) than in those with low ALC (38.5% vs 10.0%, P = 0.016). Non-relapse mortality (NRM) was also significantly higher in the high ALC before ATG group than the low ALC before ATG group (2-year NRM: 23.9% vs 6.0%, P = 0.048), leading to worse survival (2-year overall survival: 69.2% vs 83.5%, P = 0.039). Our study suggested that high ALC before ATG is a risk factor for SC-aGVHD. - Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma.
Ayumi Fujimoto; Tatsuhiko Anzai; Takahiro Fukuda; Naoyuki Uchida; Takanori Ohta; Takehiko Mori; Masashi Sawa; Satoshi Yoshioka; Toshihiro Miyamoto; Hitoji Uchiyama; Yuta Katayama; Ken-Ichi Matsuoka; Souichi Shiratori; Hideyuki Nakazawa; Junya Kanda; Tatsuo Ichinohe; Yoshiko Atsuta; Naoto Fujita; Eisei Kondo; Ritsuro Suzuki
Blood advances, 5, 5, 1412, 1424, 09 Mar. 2021, [International Magazine]
English, Scientific journal, We evaluated the impact of event-free survival (EFS) status at 24 months (EFS24) and 60 months (EFS60) after hematopoietic stem cell transplantation (HSCT) using registry data. Patients who underwent their first autologous HSCT (auto-HSCT) or allogeneic HSCT (allo-HSCT) for lymphoma between 1981 and 2018 were included. Overall survival was compared with that of the age-, sex, and calendar period-matched general population. A total of 14 977 patients, including 10 964 and 4013 who underwent auto-HSCT and allo-HSCT, respectively, were analyzed. Although patients who achieved EFS24 and EFS60 had favorable outcomes, most had significantly poorer survival rates than the general population. The standardized mortality ratios (SMRs) of patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) were significantly higher than that of the general population even after achieving EFS24 or EFS60. The SMRs of those after auto-HSCT were 2.5 to 3.5 and 2.7 to 3.7, respectively. The SMR was consistently highest in Hodgkin lymphoma (HL) patients after HSCT. By contrast, subsequent survival of patients with primary mediastinal large B-cell lymphoma, intravascular large B-cell lymphoma, or peripheral T-cell lymphoma, not otherwise specified, who achieved EFS60 after auto-HSCT, and those with extranodal natural killer/T-cell lymphoma who achieved EFS60 after allo-HSCT did not significantly differ from that of the general population, with SMRs of 1.6, 1.2, 1.8, and 1.3, respectively. Our results suggest that EFS24 and EFS60 were clinically useful end points after HSCT for lymphoma patients. Furthermore, patients with certain lymphoma subtypes who achieved EFS had a comparable prognosis with that of the general population and were potentially cured after HSCT. - Prognostic Impact of the Fractionation of Total Body Irradiation for Patients with Acute Myeloid Leukemia Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Norihiro Ueda; Takaaki Konuma; Jun Aoki; Satoshi Takahashi; Yukiyasu Ozawa; Takehiko Mori; Shuichi Ota; Tetsuya Eto; Satoru Takada; Satoshi Yoshioka; Souichi Shiratori; Shinichi Kako; Makoto Onizuka; Takahiro Fukuda; Yoshinobu Kanda; Yoshiko Atsuta; Masamitsu Yanada
Transplantation and cellular therapy, 27, 2, 185.e1-185.e6, Feb. 2021, [International Magazine]
English, Scientific journal, Fractionated total body irradiation (TBI) at a total dose of 12 Gy is widely used for patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (HCT); however, there is limited information regarding the optimal number of fractions. To address this issue, Japanese nationwide transplantation registry data were analyzed. Because it was found that TBI was delivered almost exclusively in 4 (n = 1215, 30%) or 6 fractions (n = 2697, 67%), we focused on comparing 4- versus 6-fraction TBI. Compared to 6-fraction TBI, the 4-fraction version was associated with reduced risk of overall mortality (P = .002) and relapse (P = .018), while there was no difference in the risk of nonrelapse mortality (P = .422). The 4-fraction version did not aggravate acute graft-versus-host disease (GVHD), interstitial pneumonia, or sinusoidal obstruction syndrome of the liver. Chronic GVHD developed more frequently with the use of 4-fraction TBI, although the incidence of extensive chronic GVHD was similar. Subgroup analyses revealed that the 4-fraction version provided benefits for patients in non-complete remission (non-CR) but not for those in CR at transplantation. These findings suggest the advantage of 4-fraction over 6-fraction TBI for patients with AML undergoing allogeneic HCT in non-CR. - Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.
Satoshi Nishiwaki; Yu Akahoshi; Shuichi Mizuta; Akihito Shinohara; Shigeki Hirabayashi; Yuma Noguchi; Takahiro Fukuda; Naoyuki Uchida; Masatsugu Tanaka; Makoto Onizuka; Yukiyasu Ozawa; Shuichi Ota; Souichi Shiratori; Yasushi Onishi; Yoshinobu Kanda; Masashi Sawa; Junji Tanaka; Yoshiko Atsuta; Shinichi Kako
Blood advances, 5, 2, 584, 592, 26 Jan. 2021, [International Magazine]
English, Scientific journal, Although measurable residual disease (MRD) at the time of allogeneic hematopoietic cell transplantation (allo-HCT) has been reported to be an important prognostic factor for Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) during first complete remission (CR1), the prognostic impact of MRD is unclear during second CR (CR2). To clarify the impact of MRD for both CR1 and CR2, we analyzed data from a registry database including 1625 adult patients with Ph+ ALL who underwent first allo-HCT during either CR1 or CR2 between 2002 and 2017. Adjusted overall and leukemia-free survival rates at 4 years were 71% and 64%, respectively, for patients undergoing allo-HCT during CR1 with MRD-, 55% and 43% during CR1 with MRD+, 51% and 49% during CR2 with MRD-, and 38% and 29% during CR2 with MRD+. Although survival rates were significantly better among patients with CR1 MRD- than among patients with CR2 MRD-, no significant difference was observed in survival rate between patients with CR1 MRD+ and CR2 MRD-. Relapse rates after 4 years were 16% in patients with CR1 MRD-, 29% in CR1 MRD+, 21% in patients with CR2 MRD-, and 46% in patients with CR2 MRD+. No significant difference was identified in relapse rate between patients with CR1 MRD- and CR2 MRD-. CR2 MRD- was not a significant risk factor for relapse in multivariate analysis (hazard ratio, 1.26; 95% confidence interval, 0.69-2.29; P = .45 vs CR1 MRD-). MRD at time of allo-HCT was an important risk factor in patients with Ph+ ALL during both CR1 and CR2. - [Antithymocyte globulin for GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation].
Souichi Shiratori
[Rinsho ketsueki] The Japanese journal of clinical hematology, 62, 8, 1265, 1274, 2021, [Domestic magazines]
Japanese, Scientific journal, Graft versus host disease (GVHD) prophylaxis using antithymocyte globulin (ATG) has been shown for chronic GVHD inhibition effect by a series of randomized control trials in unrelated hematopoietic or peripheral blood stem cell transplantation (PBSCT). Lower doses of ATG have been used in recent studies, although the optimal dose of ATG remains undefined. Consequently, a multicenter phase II study of low-dose ATG (2 mg/kg Thymoglobulin®) was conducted in patients undergoing human leukocyte antigen-matched PBSCT, showing the safety and efficacy for the prevention of both acute and chronic GVHD. In a nationwide retrospective study for ATG in unrelated PBSCT, the ATG group had a significantly lower incidence of chronic GVHD and a higher probability of GVHD- and relapse-free survival compared with the non-ATG group, although the dose of ATG used was low (1.0-3.0 mg/kg of Thymoglobulin®). Regarding absolute lymphocyte count (ALC) before the administration of ATG, the incidences of grades III-IV acute GVHD and moderate-to-severe chronic GVHD were significantly higher in patients with high ALC before ATG. Conversely, the relapse rate was significantly higher in patients with low ALC before ATG, suggesting a strategy to individualize ATG dosing by modulating ATG doses according to ALC before ATG. - Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation.
Souichi Shiratori; Junichi Sugita; Shuichi Ota; Senji Kasahara; Jun Ishikawa; Takayoshi Tachibana; Yoshiki Hayashi; Goichi Yoshimoto; Tetsuya Eto; Hiromi Iwasaki; Mine Harada; Keitaro Matsuo; Takanori Teshima
Bone marrow transplantation, 56, 1, 129, 136, Jan. 2021, [Peer-reviewed], [International Magazine]
English, Scientific journal, Allogeneic peripheral blood stem cell transplantation (PBSCT) is associated with an increased risk of severe acute and chronic graft-versus-host disease (GVHD) compared to bone marrow transplantation. Anti-thymocyte globulin (ATG) can reduce severe acute and chronic GVHD in PBSCT; however, an optimal dose of ATG remains undefined. We conducted a multicenter phase II study to investigate safety and efficacy of low-dose ATG (a total of 2 mg/kg Thymoglobulin) in patients undergoing HLA-matched PBSCT after myeloablative conditioning. The primary endpoint was grades III-IV GVHD at 100 days. Seventy-seven patients were enrolled and 72 patients with a median age of 46.5 years were eligible for analysis. The primary endpoint, cumulative incidence of grades III-IV acute GVHD at 100 days was 1.4% (95% CI, 0.1-6.7%), which was greatly less than our pre-defined statistical threshold value (18.0%). The incidence of chronic GVHD at 1 year was also low (all-grade; 15.3%, moderate to severe; 5.6%). Non-relapse mortality, relapse, overall survival, disease-free survival, and GVHD-free, relapse-free survival at 1 year were 4.2%, 20.8%, 84.7%, 75.0%, and 69.4%, respectively. Low dose thymoglobulin is promising to reduce severe acute and chronic GVHD in HLA-matched PBSCT following myeloablative conditioning. - Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial.
Shun-Ichi Kimura; Yoshinobu Kanda; Masaki Iino; Takahiro Fukuda; Emiko Sakaida; Tatsuo Oyake; Hiroki Yamaguchi; Shin-Ichiro Fujiwara; Yumi Jo; Akinao Okamoto; Hiroyuki Fujita; Yasushi Takamatsu; Yoshio Saburi; Itaru Matsumura; Jun Yamanouchi; Souichi Shiratori; Moritaka Gotoh; Shingen Nakamura; Kazuo Tamura
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 100, 292, 297, Nov. 2020, [International Magazine]
English, Scientific journal, OBJECTIVES: The D-index is defined as the area over the neutrophil curve during neutropenia. The CEDMIC trial confirmed the noninferiority of D-index-guided early antifungal therapy (DET) using micafungin to empirical antifungal therapy (EAT). In this study, we evaluated the efficacy and safety of micafungin in these settings. METHODS: From the CEDMIC trial, we extracted 67 and 113 patients who received micafungin in the DET and EAT groups, respectively. Treatment success was defined as the fulfilment of all components of a five-part composite end point. Fever resolution was evaluated at seven days after the completion of therapy. RESULTS: The proportion of high-risk treatments including induction chemotherapy for acute leukemia and allogeneic hematopoietic stem cell transplantation was significantly higher in the DET group than in the EAT group (82.1% vs. 52.2%). The efficacy of micafungin was 68.7% (95%CI: 56.2-79.4) and 79.6% (71.0-86.6) in the DET and EAT groups, respectively. When we focused on high-risk treatments, the efficacy was 69.1% (55.2-80.9%) and 78.0% (65.3-87.7%), respectively (P = 0.30). There was no significant difference in any of the 5 components between the two groups. CONCLUSIONS: The efficacy of micafungin in patients undergoing high-risk treatment was not strongly impaired in DET compared to that in EAT. - Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan.
Takuya Yamashita; Akiyoshi Takami; Naoyuki Uchida; Takahiro Fukuda; Tetsuya Eto; Souichi Shiratori; Shuichi Ota; Takashi Akasaka; Shigesaburo Miyakoshi; Tadakazu Kondo; Michihiro Hidaka; Junya Kanda; Yoshiko Atsuta; Shingo Yano
Bone marrow transplantation, 55, 10, 1955, 1965, Oct. 2020, [International Magazine]
English, Scientific journal, Reduced-intensity conditioning (RIC) has been facilitating allogeneic hematopoietic cell transplantation (allo-HCT) for patients originally considered ineligible for HCT with myeloablative conditioning. Fludarabine (Flu) with reduced doses of busulfan (Bu) (Flu + Bu) and Flu with reduced doses of melphalan (Mel) (Flu + Mel) are widely used RIC regimens for acute myeloid leukemia (AML). A nationwide retrospective study comparing clinical outcomes of adult patients with AML receiving first allo-HCT after RIC between 2001 and 2010 was performed. Cumulative incidences of relapse were not significantly different among the Flu + ivBu-based (FBiv), Flu + poBu-based (FBpo), and Flu + Mel-based (FM) groups (p = 0.29). Non-relapse mortality (NRM) was significantly lower in patients receiving FBiv compared with FBpo (p = 0.003) and FM (p < 0.001). On multivariate analysis, there was no significant difference in overall survival, but FM was associated with a significantly lower risk of relapse (hazard ratio (HR) = 0.65, 95% confidence interval (CI): 0.50-0.85, p = 0.002), higher NRM (HR = 1.60, 95% CI: 1.10-2.33, p = 0.013) and better leukemia-free survival (HR = 0.77, 95% CI: 0.63-0.95, p = 0.015) compared with FBiv. These results suggest that Flu + Mel has a more intense disease control potential and Flu + ivBu is less toxic than the other. Both RIC regimens provide similar survival outcomes and are effective and useful regimens for patients with AML who received allo-HCT. - Feasibility and efficacy of low-dose pegfilgrastim for CD34+ cell mobilization in lymphoma.
Hideki Goto; Daisuke Hidaka; Satoshi Yamamoto; Koji Hayasaka; Rie Michimata; Ikuko Kagawa; Kana Sunagoya; Hiroaki Iijima; Eiko Hayase; Souichi Shiratori; Kohei Okada; Junichi Sugita; Masahiro Onozawa; Daigo Hashimoto; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Chikara Shimizu; Takanori Teshima
Journal of clinical apheresis, 35, 5, 413, 419, Sep. 2020, [International Magazine]
English, Scientific journal, BACKGROUND: Pegfilgrastim has equivalent efficacy to daily granulocyte colony-stimulating factor (G-CSF) in enhancing neutrophil recovery after chemotherapy, but data on its use for peripheral blood stem cell (PBSC) mobilization are limited. We evaluated the safety and efficacy of CD34+ PBSC mobilization by low-dose (3.6 mg) pegfilgrastim after chemotherapy in patients with malignant lymphoma. STUDY DESIGN AND METHODS: Twenty patients with malignant lymphoma were enrolled in this study. Cytotoxic chemotherapy was started on day 1, and 3.6 mg of pegfilgrastim was subcutaneously administered on day 7. CD34+ cells were counted in the peripheral blood daily from days 11 to 14 using a flow cytometric analysis. RESULTS: In 19 of the 20 patients (95%), the CD34+ cell counts in the peripheral blood exceeded 10 × 106/L, with a mean value of 20.3 on day 11, 38.0 on day 12, 40.3 on day 13, and 40.1 on day 14. Older age was associated with lower maximum CD34+ cell mobilization. The most frequent adverse events associated with pegfilgrastim were back pain, nausea, appetite loss, and lactate dehydrogenase elevation. CONCLUSION: Our data indicated that a single dose of 3.6 mg pegfilgrastim on day 7 after chemotherapy safely and effectively mobilized CD34+ cells. - Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome.
Takehiko Mori; Souichi Shiratori; Junji Suzumiya; Mineo Kurokawa; Motohiro Shindo; Uchida Naoyuki; Takenaka Katsuto; Toshihiro Miyamoto; Satoshi Morishige; Makoto Hirokawa; Takahiro Fukuda; Yoshiko Atsuta; Ritsuro Suzuki
Hematological oncology, 38, 3, 266, 271, Aug. 2020, [International Magazine]
English, Scientific journal, Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome. - Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.
Yu Akahoshi; Satoshi Nishiwaki; Yasuyuki Arai; Kaito Harada; Yuho Najima; Yoshinobu Kanda; Katsuhiro Shono; Shuichi Ota; Takahiro Fukuda; Naoyuki Uchida; Souichi Shiratori; Masatsugu Tanaka; Junji Tanaka; Yoshiko Atsuta; Shinichi Kako
Bone marrow transplantation, 55, 7, 1317, 1325, Jul. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, Reduced-intensity conditioning (RIC) regimens have been widely used for allogeneic hematopoietic cell transplantation (HCT) in elderly patients. After the emergence of tyrosine kinase inhibitor (TKI), most patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) now achieve negative results for minimal residual disease (MRD) at HCT. In this study, we evaluated patients aged 50 years or more with Ph-positive ALL who received TKI before HCT, achieved negative-MRD at HCT, and underwent their first allogeneic HCT between 2008 and 2017. In total, 90 and 136 patients who received myeloablative conditioning (MAC) and a RIC regimen, respectively, were included. The median age of patients with MAC and RIC was 54 and 60 years, respectively. Even in multivariate analyses, RIC was not significantly associated with overall mortality (hazard ratio [HR], 1.09; P = 0.724), hematological relapse (HR, 1.97; P = 0.170), or non-relapse mortality (HR, 0.84; P = 0.540). Subgroup analyses suggested that RIC resulted in superior overall survival due to a lower incidence of non-relapse mortality in patients with a poor performance status or a high HCT comorbidity index. In conclusion, RIC is a reasonable option for elderly patients with negative-MRD at HCT. - Post-transplant indolent T cell lymphoproliferative disorder in living donor liver transplantation: a case report.
Ryoichi Goto; Norio Kawamura; Masaaki Watanabe; Yasuyuki Koshizuka; Souichi Shiratori; Momoko Ara; Shohei Honda; Tomoko Mitsuhashi; Yoshihiro Matsuno; Tsuyoshi Shimamura; Akinobu Taketomi
Surgical case reports, 6, 1, 147, 147, 26 Jun. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) of T cell type has been rarely reported. Accurate diagnosis of this life-threatening rare form of PTLD is important for the treatment strategy. CASE PRESENTATION: A 7-year-old boy had severe diarrhea and weight loss progressively at 7 years post-living donor liver transplantation (LDLT) for biliary atresia. Endoscopy in the gastrointestinal (GI) tract revealed multiple erosions and ulcer lesions with prominent intraepithelial lymphocytosis in the duodenum and terminal ileum. Immunohistochemical examination demonstrated that these accumulated lymphocytes mainly comprised small- to medium-sized T cells expressing CD3, CD4, CD5, CD7, and CD103, but lacking CD8, CD56, and Epstein-Barr virus-encoded small RNAs. In addition, T cell receptor β gene rearrangement was detected by polymerase chain reaction analysis. Comprehensively, the lesions were best interpreted as post-transplant indolent T cell lymphoproliferative disorder (LPD) of the intestine. Clinical remission was achieved by reducing the immunosuppressant. CONCLUSION: A rarely reported indolent type of T cell LPD in post-LDLT was diagnosed by direct inspection and histological investigation. Although the histological classification and therapeutic strategy for post-transplant indolent T cell LPD have not been established, reducing immunosuppression allowed complete remission in our case. To prevent the incidence of PTLD and de novo malignancy, developing a methodology to set a proper dose of immunosuppressant is required. - Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation.
Shigeo Fuji; Kumi Oshima; Kazuteru Ohashi; Masashi Sawa; Takeshi Saito; Tetsuya Eto; Masatsugu Tanaka; Makoto Onizuka; Hirohisa Nakamae; Souichi Shiratori; Yukiyasu Ozawa; Michihiro Hidaka; Tokiko Nagamura-Inoue; Hidenori Tanaka; Takahiro Fukuda; Tatsuo Ichinohe; Yoshiko Atsuta; Masao Ogata
Bone marrow transplantation, 55, 4, 722, 728, Apr. 2020, [International Magazine]
English, Scientific journal, Graft failure (GF) remains a major complication of cord blood transplantation (CBT). Although the presence of pretransplant, donor-specific anti-HLA antibodies (DSA) was reported to be associated with an increased risk of GF after CBT, data are still limited. Thus, we conducted a retrospective analysis of recipients of single-unit CBT with pretransplant anti-HLA antibodies using the database of Japan Society for Hematopoietic Cell Transplantation (JSHCT). Data for recipients of single-unit CBT with pretransplant anti-HLA antibodies from 2010 to 2014 were obtained. In total, 343 patients who received CBT and who had detailed information about anti-HLA antibodies were included. The median age was 51 years (range, 0-71). Regarding DSA, 25 patients had a mean fluorescence intensity (MFI) ≥ 1000 (DSA-positive group) and 318 patients had a MFI <1000 (DSA-negative group). The cumulative incidence of neutrophil engraftment at 60 days after CBT was 75.7% (95% CI, 70.6-80.1) in the DSA-negative group and 56.0% (95% CI, 34.1-73.1) in the DSA-positive group (P = 0.03). In conclusion, pretransplant DSA with a MFI ≥ 1000 was associated with an increased risk of GF in single-unit CBT. - Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.
Ayumi Fujimoto; Nobuhiro Hiramoto; Satoshi Yamasaki; Yoshihiro Inamoto; Masao Ogata; Yasuhiro Sugio; Takahiro Fukuda; Naoyuki Uchida; Kazuhiro Ikegame; Ken-Ichi Matsuoka; Souichi Shiratori; Tadakazu Kondo; Toshihiro Miyamoto; Tetsuya Eto; Tatsuo Ichinohe; Yoshinobu Kanda; Yoshiko Atsuta; Ritsuro Suzuki
Hematological oncology, 38, 2, 146, 152, Apr. 2020, [International Magazine]
English, Scientific journal, Posttransplant lymphoproliferative disorder (PTLD) is a serious complication after hematopoietic stem cell transplantation (HSCT). Several studies of risk factors for PTLD have been reported; however, the probability of, and risk factors for, PTLD in patients with lymphoma is unknown. Japanese nationwide transplant registry data from 5270 patients with lymphoma after allogeneic HSCT were analyzed. Mature B-cell, T/NK-cell, and T-cell lymphoblastic subtypes accounted for 49%, 26%, and 9.6% of lymphoma cases, respectively. Rituximab was used in 1678 lymphoma patients, most of whom (89%) received HSCT for mature B-cell lymphoma. Thirty-one patients with lymphoma developed PTLD, representing a probability of 0.77% at 2 years post-HSCT, which did not differ significantly from that in patients with other diseases (P = .98). Year of HSCT after 2010 (hazard ratio [HR] = 5.6, 95% confidence interval [CI], 1.48-21.3), antithymocyte globulin (ATG) use in the conditioning regimen (HR = 4.5, 95% CI, 1.61-12.5), and no rituximab use before HSCT (HR = 3.2, 95% CI, 1.26-7.90) were identified as risk factors for PTLD. Probabilities of PTLD at 1 year post-HSCT according to rituximab and ATG use were 0.23% (rituximab+, ATG-), 0.75% (rituximab-, ATG-), 1.25% (rituximab+, ATG+), and 3.53% (rituximab-, ATG+). Regarding lymphoma subtypes, patients with mature B-cell lymphoma had the lowest incidence of PTLD (0.35% at 2 years). Among high-risk patients receiving ATG, the mortality rate due to infection was elevated in those previously treated with rituximab (22%) relative to those without (14%); however, the difference was not significant (P = .10). Rituximab use before HSCT significantly reduces the risk of PTLD. Adding rituximab to the conditioning regimen is potentially a good strategy to prevent the development of PTLD in high-risk patients. - D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial.
Yoshinobu Kanda; Shun-Ichi Kimura; Masaki Iino; Takahiro Fukuda; Emiko Sakaida; Tatsuo Oyake; Hiroki Yamaguchi; Shin-Ichiro Fujiwara; Yumi Jo; Akinao Okamoto; Hiroyuki Fujita; Yasushi Takamatsu; Yoshio Saburi; Itaru Matsumura; Jun Yamanouchi; Souichi Shiratori; Moritaka Gotoh; Shingen Nakamura; Kazuo Tamura
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38, 8, 815, 822, 10 Mar. 2020, [International Magazine]
English, Scientific journal, PURPOSE: Empiric antifungal therapy (EAT) is recommended for persistent febrile neutropenia (FN), but in most patients, it is associated with overtreatment. The D-index, calculated as the area surrounded by the neutrophil curve and the horizontal line at a neutrophil count of 500/μL, reflects both the duration and depth of neutropenia and enables real-time monitoring of the risk of invasive fungal infection in individual patients at no cost. We investigated a novel approach for patients with persistent FN called D-index-guided early antifungal therapy (DET), in which antifungal treatment is postponed until a D-index reaches 5,500 or the detection of positive serum or imaging tests, and compared it with EAT in this multicenter open-label noninferiority randomized controlled trial. PATIENTS AND METHODS: We randomly assigned 423 patients who underwent chemotherapy or hematopoietic stem-cell transplantation for hematologic malignancies to the EAT or DET group. The prophylactic use of antifungal agents other than polyenes, echinocandins, or voriconazole was allowed. Micafungin at 150 mg per day was administered as EAT or DET. RESULTS: In an intent-to-treat analysis of 413 patients, the incidence of probable/proven invasive fungal infection was 2.5% in the EAT group and 0.5% in the DET group, which fulfilled the predetermined criterion of noninferiority of the DET group (-2.0%; 90% CI, -4.0% to 0.1%). The survival rate was 98.0% versus 98.6% at day 42 and 96.4% versus 96.2% at day 84. The use of micafungin was significantly reduced in the DET group (60.2% v 32.5%; P < .001). CONCLUSION: A novel strategy, DET, decreased the use and cost of antifungal agents without increasing invasive fungal infections and can be a reasonable alternative to empiric or preemptive antifungal therapy. - A consideration for efficient unrelated hematopoietic stem cell source acquisition-from an experience of Japan.
Satoshi Nishiwaki; Koichi Miyamura; Yoshinobu Kanda; Minoko Takanashi; Naoyuki Uchida; Takahiro Fukuda; Kazuhiro Ikegame; Kazuteru Ohashi; Tetsuya Eto; Yukiyasu Ozawa; Souichi Shiratori; Koji Iwato; Ken-Ichi Matsuoka; Michihiro Hidaka; Tatsuo Ichinohe; Yoshiko Atsuta; Yoshihisa Kodera; Shinichiro Okamoto
Bone marrow transplantation, 55, 3, 657, 660, Mar. 2020, [International Magazine]
English - Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation.
Souichi Shiratori; Hiroyuki Ohigashi; Shuichiro Takahashi; Takahide Ara; Hideki Goto; Masao Nakagawa; Junichi Sugita; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
Annals of hematology, 99, 3, 591, 598, Mar. 2020, [Peer-reviewed], [International Magazine]
English, Scientific journal, Although a combination of calcineurin inhibitor and methotrexate (MTX) is used for graft-versus-host disease (GVHD) prophylaxis in umbilical cord blood transplantation (CBT), optimal dose of MTX for CBT remains to be determined.We conducted a retrospective study to evaluate the safety and efficacy of standard-dose MTX (St-MTX, 15 mg/m2 on day 1 and 10 mg/m2 on days 3 and 6) and mini-dose MTX (Mini-MTX, 5 mg/m2 on days 1, 3 and 6) for GVHD prophylaxis in patients who underwent single unit CBT against hematological malignancies.Thirty-two and 26 patients received St-MTX and Mini-MTX, respectively. Cumulative incidence of neutrophil engraftment was significantly higher in the Mini-MTX group than in the St-MTX group (88.5% vs 65.6%, P = 0.00448). Cumulative incidences of grade II to IV and grade III to IV of acute graft-versus-host disease (GVHD) were 34.4% and 6.2% in the St-MTX group, and 34.6% and 7.7% in the Mini-MTX group with no statistical significance. One-year non-relapse mortality (NRM) was significantly lower in the Mini-MTX group compared to the St-MTX group (31.2% vs 3.8%, P = 0.00938), whereas relapse rate was not different between the groups. Multivariate analysis also indicated that Mini-MTX significantly improved engraftment (HR, 0.5359; 95% CI, 0.3082 to 0.9318; P = 0.0270) and reduced NRM (HR, 0.117; 95% CI, 0.0151 to 0.9067; P = 0.040).Our study suggests that GVHD prophylaxis using Mini-MTX in CBT is feasible and associated with improvement of engraftment and reduction in NRM. - Late mortality and causes of death among long-term survivors after autologous hematopoietic stem cell transplantation.
Minako Iida; Hideki Nakasone; Takuya Yamashita; Masami Inoue; Yasushi Ishida; Hitoji Uchiyama; Yuta Katayama; Toshihiro Miyamoto; Satoshi Yoshioka; Souichi Shiratori; Takehiko Mori; Masashi Sawa; Yasuhiro Sugio; Takahiro Fukuda; Tatsuo Ichinohe; Yoshiko Atsuta; Yoshihiro Inamoto
Blood cell therapy, 3, 1, 11, 17, 25 Feb. 2020, [Domestic magazines]
English, Scientific journal, By evaluating risks of late mortality and causes of death among long-term survivors after autologous hematopoietic stem cell transplantation (HSCT) in Japan, we clarified what we should focus on during follow-up to reduce them. The study cohort included 6,780 patients who had survived for ≥2 years after the first autologous HSCT performed from 1974 to 2012 for hematological diseases. With a median follow-up of 6.0 years among survivors, overall survival probabilities at 5 and 10 years after HSCT were 92% and 83%, respectively. Eight hundred thirty deaths occurred: 451, recurrent primary diseases; 87, subsequent solid cancers; 57, subsequent hematological malignancies; 55, infections; 41, respiratory diseases; 19, cardiovascular diseases; 15, liver diseases; 10, neurological diseases; and 7, kidney/genitourinary diseases (Except small numbers of other causes and missing). According to the log-rank test, the risk of overall mortality was remarkably increased among HSCT recipients compared with the that in the general Japanese population (observed/expected ratio [O/E]=5.4; 95% confidence interval [CI], 5.0-5.8). The risks of cause-specific mortality increased with infection (O/E=6.8; 95% CI, 5.1-8.8), subsequent solid cancers (O/E=1.4; 95% CI, 1.1-1.7), subsequent hematological malignancies (O/E=14.3; 95% CI, 10.8-18.5), kidney/genitourinary diseases (O/E=3.4; 95% CI, 1.4-7.1), respiratory disease (O/E=9.0; 95% CI, 6.5-1.2), and liver diseases (O/E=2.6; 95% CI, 1.4-4.2). Long-term survivors after autologous HSCT are at an increased risk of death due to secondary cancers, infections, and any organ diseases as well as recurrence compared to the general population. When monitoring these patients in the outpatient clinic, it is important for physicians to predict a change in the patient's condition and to start treatment earlier. - Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation.
Takakazu Kawase; Hidenori Tanaka; Hiroto Kojima; Naoyuki Uchida; Kazuteru Ohashi; Takahiro Fukuda; Yukiyasu Ozawa; Kazuhiro Ikegame; Tetsuya Eto; Takehiko Mori; Toshihiro Miyamoto; Michihiro Hidaka; Souichi Shiratori; Minoko Takanashi; Yoshiko Atsuta; Tatsuo Ichinohe; Yoshinobu Kanda; Junya Kanda
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25, 12, 2482, 2489, Dec. 2019, [International Magazine]
English, Scientific journal, Some studies support the hypothesis that HLA genes and haplotypes evolved by natural selection through their protective abilities against specific infectious pathogens. However, very little is known regarding the impact of high-frequency HLA haplotypes on the risk of relevant infectious diseases among a given ethnic group. We evaluated the impact of high-frequency HLA haplotypes on cytomegalovirus (CMV) reactivation and infection in allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a Japanese population as a model of infectious disease that has coexisted with humans. A total of 21,127 donor-patient pairs were analyzed. HLA-A-B-DRB1 haplotypes were estimated using the maximum probability algorithm. Seven haplotypes with >1% frequency were defined as high-frequency haplotypes (HfHPs). Homozygotes of HfHP and heterozygotes had significantly lower risk of CMV reactivation and infection (hazard ratio [HR] = 0.88, P = .009 and HR = 0.93, P = .003, respectively) than homozygotes of low-frequency HLA haplotypes (LfHPs). In subgroup analyses of a different donor source, these associations were statistically significant in unrelated donor transplants. Finally, CMV risk for homozygotes and heterozygotes of each HfHP was compared with that of homozygotes of LfHPs. The 2 most predominant HfHP groups (A*24:02-B*52:01-DRB1*15:02 group and A*24:02-B*07:02-DRB1*01:01 group) had a significantly lower risk of CMV reactivation and infection (HR = 0.86, P < .001 and HR = 0.91, P = .033, respectively). Our findings suggest that HfHPs may be protective against CMV reactivation and infection and that increased care regarding CMV reactivation and infection may be necessary for patients with LfHP after allo-HSCT. - 妊娠後期に診断された発作性夜間ヘモグロビン尿症に対してeculizumabを導入した1例
小島 圭祐; 荒 隆英; 遠藤 知之; 高橋 承吾; 米田 和樹; 横山 翔大; 笠原 耕平; 白鳥 聡一; 後藤 秀樹; 中川 雅夫; 森川 守; 山本 準也; 豊嶋 崇徳
臨床血液, 60, 11, 1583, 1583, (一社)日本血液学会-東京事務局, Nov. 2019
Japanese - Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yu Akahoshi; Satoshi Nishiwaki; Shuichi Mizuta; Kazuteru Ohashi; Naoyuki Uchida; Masatsugu Tanaka; Takahiro Fukuda; Yukiyasu Ozawa; Satoshi Takahashi; Makoto Onizuka; Souichi Shiratori; Hirohisa Nakamae; Yoshinobu Kanda; Tatsuo Ichinohe; Yoshiko Atsuta; Shinichi Kako
Cancer science, 110, 10, 3255, 3266, Oct. 2019, [International Magazine]
English, Scientific journal, Tyrosine kinase inhibitor (TKI) administration after allogeneic hematopoietic stem cell transplantation (HSCT) may carry a survival benefit in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Therefore, we investigated whether TKI prophylaxis for negative-minimal residual disease (MRD) after HSCT would improve patient outcomes in this nationwide retrospective cohort study. We included patients with Ph+ ALL who underwent their first allogeneic HSCT between 2001 and 2016, received TKI before HSCT, and achieved negative-MRD status within 180 days after HSCT. Of 850 patients for inclusion, 50 patients received TKI prophylaxis, mostly imatinib or dasatinib (median dose: 400 mg with imatinib and 40 mg with dasatinib). In a multivariate analysis, disease status at HSCT was the sole risk factor for relapse (hazard ratio, 3.58; P < .001 for positive-MRD with complete remission [CR] and hazard ratio, 6.13; P < .001 for active disease). TKI prophylaxis was not associated with a decreased risk of relapse or superior overall survival in either the whole cohort or in the analysis limited to negative-MRD or positive-MRD with CR1 at HSCT. Meanwhile, TKI prophylaxis limited to dasatinib might be associated with a decreased risk of relapse (hazard ratio, 0.34; P = .140), unlike imatinib. Alternative strategies using new-generation TKI for high-risk patients are warranted to improve the outcomes after allogeneic HSCT. - Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation
Hisayuki Yokoyama; Junya Kanda; Shunichi Kato; Eisei Kondo; Yoshinobu Maeda; Hiroo Saji; Satoshi Takahashi; Makoto Onizuka; Yasushi Onishi; Yukiyasu Ozawa; Heiwa Kanamori; Jun Ishikawa; Yuju Ohno; Tatsuo Ichinohe; Minoko Takanashi; Koji Kato; Yoshiko Atsuta; Yoshinobu Kanda; Kazuhiro Ikegame; Atae Utsunomiya; Takakazu Kawase; Sung-Won Kim; Yachiyo Kuwatsuka; Takeshi Kobayashi; Yoshifusa Takatsuka; Yoshiyuki Takahashi; Junji Tanaka; Hiroya Tamaki; Masanori Tsuji; Tetsuya Nishida; Masayoshi Masuko; Ryosuke Matsuno; Makoto Murata; Satoko Morishima; Yasuo Morishima; Hisayuki Yokoyama; Atsushi Wake; Nobuhiro Watanabe; T. Ashida; Takumi Hoshino; Toshio Yabe; Kana Sakamoto; Shigeo Fuji; Koichi Miyamura; Nobuyoshi Arima; Eisei Kondo; Makoto Yoshimitsu; Koji Kawamura; Takahito Kawata; Kenji Kishimoto; Raine Tatara; Takeshi Hagino; Shin-Ichiro Fujiwara; Yoshimitsu Shimomura; Hirotoshi Sakaguchi; Shigeki Hirabayashi; Hiroto Ishii; Yoshiyuki Onda; Itaru Kato; Akihisa Kawajiri; Takero Shindo; Masahito Tokunaga; Atsushi Nonami; Hiroyuki Muranushi; Noriyoshi Yoshinaga; Naomi Kawashima; Souichi Shiratori; Yuma Tada; Sus-Umu Tanoue; Masahiro Hirayama; Keiko Fukunaga; Marie Ohbiki
BONE MARROW TRANSPLANTATION, 54, 7, 1004, 1012, Jul. 2019
English, Scientific journal - Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.
Ayumi Fujimoto; Nobuhiro Hiramoto; Satoshi Yamasaki; Yoshihiro Inamoto; Naoyuki Uchida; Tetsuo Maeda; Takehiko Mori; Yoshinobu Kanda; Tadakazu Kondo; Souichi Shiratori; Shigesaburo Miyakoshi; Ken Ishiyama; Kazuhiro Ikegame; Yoshiko Matsuhashi; Junji Tanaka; Tatsuo Ichinohe; Yoshiko Atsuta; Masao Ogata; Ritsuro Suzuki
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25, 7, 1441, 1449, ELSEVIER SCIENCE INC, Jul. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, We analyzed data from 64,539 consecutive patients in the Japanese national transplant registry, including 40,195 after allogeneic hematopoietic stem cell transplantation (HSCT), 24,215 after autologous HSCT and 129 after syngeneic HSCT, of whom 299 developed Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (PTLD). The probability of developing PTLD at 2 years post-HSCT was .79% after allogeneic transplantation, .78% after syngeneic transplantation, and .11% after autologous transplantation. The following variables were identified as risk factors after allogeneic HSCT in multivariate analysis: antithymocyte globulin (ATG) use in a conditioning regimen, ATG use for acute graft-versus-host disease (GVHD) treatment, donor other than an HLA-matched related donor, aplastic anemia, second or subsequent allogeneic HSCT, the most recent year of transplantation, and acute GVHD. The probability at 2 years increased particularly after 2009 (1.24%) than before 2009 (.45%). To stratify the risk of PTLD before allogeneic HSCT, we developed a novel 5-point scoring system based on 3 pretransplant risk factors: ATG use in a conditioning regimen (high dose, 2 points; low dose, - 初回治療から18年後に生じた多臓器進展を伴うホジキンリンパ腫の一剖検例
五味川 龍; 杉野 弘和; 白鳥 聡一; 石田 雄介; 王 磊; 畑中 佳奈子; 松野 吉宏; 豊嶋 崇徳; 田中 伸哉
日本病理学会会誌, 108, 1, 453, 453, (一社)日本病理学会, Apr. 2019
Japanese - Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades.
Masamitsu Yanada; Masayoshi Masuko; Jinichi Mori; Jun Aoki; Shohei Mizuno; Takahiro Fukuda; Kazuhiko Kakihana; Yukiyasu Ozawa; Shuichi Ota; Heiwa Kanamori; Takehiko Mori; Hirohisa Nakamae; Tetsuya Eto; Souichi Shiratori; Tetsuo Maeda; Koji Iwato; Tatsuo Ichinohe; Yoshinobu Kanda; Junji Tanaka; Yoshiko Atsuta; Shingo Yano
Bone marrow transplantation, 54, 4, 578, 586, NATURE PUBLISHING GROUP, Apr. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, It remains unclear how specific innovations in allogeneic hematopoietic cell transplantation (HCT) attained over the past decades have contributed to improvement in transplantation outcomes. To address this question, we conducted a registry-based study of adults with acute myeloid leukemia in first or second complete remission who underwent allogeneic HCT between 1994 and 2013 from a sibling (N = 1600) or unrelated (N = 2113) donor matched at the antigen level for HLA-A, -B, and -DR. Preliminary analysis led us to focus on comparisons between the 1994-2006 and 2007-2013 periods. Significant improvement in survival was observed in the later cohort compared to the earlier cohort for unrelated HCT (P = 0.004), but not for related HCT (P = 0.767). The improvement in unrelated HCT was solely due to diminished non-relapse mortality (P = 0.001), while incidence of relapse did not change over time (P = 0.934). The percentage of patients receiving transplants from 8/8-matched unrelated donors was significantly higher in the later cohort (P < 0.001), and their survival was significantly better than that of those undergoing mismatched unrelated HCT (P = 0.022). These findings suggest that adv - UTILITY OF LISS AS AN AUTOANTIBODY ADSORPTION METHOD FOR DETECTION OF COEXISTING ALLOANTIBODIES IN PATIENTS WITH AUTOANTIBODIES
Takayo Uwatoko; Chiaki Watanabe; Makoto Ito; Ryo Uozumi; Yasuhiro Hayashi; Shuichiro Takahashi; Naohiro Miyashita; Souichi Shiratori; Daigo Hashimoto; Junichi Sugita; Eiko Hayase; Koji Akizawa; Takanori Teshima
Japanese Journal of Transfusion and Cell Therapy, 65, 1, 98, 102, Japan Society of Transfusion Medicine and Cell Therapy, 28 Feb. 2019
Scientific journal - 自己抗体保有患者の同種抗体検出におけるLISSを用いた自己抗体吸着法の有用性の検討
上床 貴代; 渡邊 千秋; 伊藤 誠; 魚住 諒; 林 泰弘; 高橋 秀一郎; 宮下 直洋; 白鳥 聡一; 橋本 大吾; 杉田 純一; 早瀬 英子; 秋沢 宏次; 豊嶋 崇徳
日本輸血細胞治療学会誌, 65, 1, 98, 102, (一社)日本輸血・細胞治療学会, Feb. 2019
Japanese - Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.
Takaaki Konuma; Yoshimitsu Shimomura; Yukiyasu Ozawa; Yasunori Ueda; Naoyuki Uchida; Makoto Onizuka; Megumi Akiyama; Takehiko Mori; Hirohisa Nakamae; Yuju Ohno; Souichi Shiratori; Yasushi Onishi; Yoshinobu Kanda; Takahiro Fukuda; Yoshiko Atsuta; Ken Ishiyama
Hematological oncology, 37, 1, 85, 95, Wiley, Feb. 2019, [Peer-reviewed], [International Magazine]
English, Scientific journal, To reduce post-transplant relapse, acute myeloid leukemia (AML) type remission induction chemotherapy has been attempted to reduce disease burden before allogeneic hematopoietic cell transplantation (HCT) in patients with advanced myelodysplastic syndrome (MDS). However, the efficacy of induction chemotherapy before HCT is unclear. We retrospectively analyzed the Japanese registration data of 605 adult patients, who had received allogeneic HCT for advanced MDS between 2001 and 2016, to compare the post-transplant relapse between patients who received induction chemotherapy followed by allogeneic HCT and those who received upfront HCT. Propensity score matching identified 230 patients from each cohort. There were no significant differences in overall survival and non-relapse mortality between the two groups. The cumulative incidence of relapse was significantly higher in patients who received induction chemotherapy than those who received upfront HCT. In the subgroup analyses, upfront HCT had a significantly reduced relapse incidence among patients with poor cytogenetics, those with higher international prognostic scoring system at diagnosis, and those who received reduced-intensity conditioning. Our results suggested that AML type remission induction chemotherapy before HCT did not improve post-transplant relapse and survival for adult patients with advanced MDS. Upfront HCT is preferable for patients with a poor karyotype. - Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
Daisuke Hidaka; Masahiro Onozawa; Junichi Hashiguchi; Naohiro Miyashita; Kohei Kasahara; Shinichi Fujisawa; Eiko Hayase; Kohei Okada; Souichi Shiratori; Hideki Goto; Junichi Sugita; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Tomoyuki Endo; Satoshi Yamamoto; Yutaka Tsutsumi; Yoshihito Haseyama; Takahiro Nagashima; Akio Mori; Shuichi Ota; Hajime Sakai; Toshimichi Ishihara; Kiyotoshi Imai; Takuto Miyagishima; Yasutaka Kakinoki; Mitsutoshi Kurosawa; Hajime Kobayashi; Hiroshi Iwasaki; Chikara Shimizu; Takeshi Kondo; Takanori Teshima
Clinical lymphoma, myeloma & leukemia, 18, 11, e469-e479, e479, Nov. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of acute myelogenous leukemia (AML) has been controversial. The aim of the present study was to determine the correlations of WT1 expression at the diagnosis of AML with established prognostic alterations. PATIENTS AND METHODS: We analyzed diagnostic bone marrow samples from 252 patients. WT1 expression, single nucleotide polymorphism (SNP) in the WT1 gene (rs16754), and Fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation were analyzed for all patients. The nucleophosmin 1 (NPM1) mutation and CCAAT/enhancer-binding protein-α (CEBPA) double mutation were analyzed for cytogenetically normal (CN)-AML. The KIT mutation was analyzed for core-binding factor AML. RESULTS: Within the cytogenetically favorable prognosis group, WT1 expression in AML with inv(16) or t(15;17) was significantly greater than that in AML with t(8;21). In cases with CN-AML, FLT3-ITD and NPM1 mutations both correlated with greater expression of WT1, and the CEBPA double mutation was related to lower WT1 expression. The existence of both FLT3-ITD and NPM1 mutations showed synergistically greater expression of WT1 in CN-AML. SNP in the WT1 gene (rs16754) was significantly associated with lower expression of WT1. The WT1 levels were not prognostic factors in the total cohort or any cytogenetic group or stratified by SNP status. CONCLUSION: Because WT1 expression has correlated with known prognostic factors, the prognostic effect of WT1 levels could be misunderstood depending on the distribution of the collaborative mutations in each cohort. We have concluded that the prognostic significance of WT1 at the diagnosis of AML is weak compared with the other established prognostic factors. - Hematogones Predict Better Outcome in Allogeneic Hematopoietic Stem Cell Transplantation Irrespective of Graft Sources.
Takashi Ishio; Junichi Sugita; Takahiro Tateno; Daisuke Hidaka; Eiko Hayase; Souichi Shiratori; Kohei Okada; Hideki Goto; Masahiro Onozawa; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Takanori Teshima
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 24, 10, 1990, 1996, Oct. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, Benign precursors of B lymphocytes, termed hematogones, are observed in the regenerative state of hematopoiesis following chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have demonstrated that expansion of hematogones correlates with better clinical outcomes after allo-HSCT. We retrospectively analyzed the association between hematogones and clinical outcomes in 309 consecutive patients who underwent allo-HSCT, which is the largest population-based cohort reported so far. The incidence of hematogones was significantly higher in complete remission (CR) patients at the time of transplantation than in non-CR patients, after myeloablative conditioning than after reduced-intensity conditioning, with tacrolimus-based graft-versus-host disease (GVHD) prophylaxis than with cyclosporine-based prophylaxis, and with disease other than malignant lymphoma (all P < .05). Patients with hematogones developed less acute GVHD and infections than did those without them (P < .05). Emergence of hematogones was associated with superior GVHD-free relapse-free survival and lower nonrelapse mortality, and was an independent prognostic factor for overall survival, irrespective of donor sources. - 成人急性リンパ性白血病におけるIKZF1欠失およびCRLF2発現の解析(Analysis of IKZF1 deletion and CRLF2 expression in adult patients with acute lymphoblastic leukemia)
橋口 淳一; 小野澤 真弘; 藤澤 真一; 高橋 秀一郎; 宮下 直洋; 早瀬 英子; 白鳥 聡一; 後藤 秀樹; 杉田 純一; 中川 雅夫; 橋本 大吾; 加畑 馨; 遠藤 知之; 山本 聡; 堤 豊; 長谷山 美仁; 永嶋 貴博; 盛 暁生; 太田 秀一; 宮城島 拓人; 柿木 康孝; 黒澤 光俊; 岩崎 博; 近藤 健; 豊嶋 崇徳
臨床血液, 59, 9, 1648, 1648, (一社)日本血液学会-東京事務局, Sep. 2018
English - The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation.
Daisuke Hidaka; Eiko Hayase; Souichi Shiratori; Yuta Hasegawa; Takashi Ishio; Takahiro Tateno; Kohei Okada; Hideki Goto; Junichi Sugita; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
Clinical transplantation, 32, 9, e13361, Sep. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, Intestinal microbiota plays an important role in the regulation of allogeneic immune reaction after allogeneic hematopoietic stem cell transplantation (allo-SCT). Intestinal graft-vs-host disease (GVHD) is one of the major causes of mortality after allo-SCT and often complicated with intestinal dysbiosis. Recent studies suggest that antibiotic-induced dysbiosis is a risk factor for intestinal GVHD. We retrospectively evaluated the impacts of antibiotic use on the incidence of intestinal GVHD occurring before day 100 after allo-SCT. Among 213 patients who underwent allo-SCT, 200 patients achieving engraftment were analyzed. Antibiotics were classified into carbapenem, quinolone, penicillin, cephem, and glycopeptide. Among 128 patients who developed acute GVHD, intestinal GVHD developed in 36 patients. Patients with intestinal GVHD received significantly longer administration of carbapenem and glycopeptide compared to those without it in periengraftment period. In multivariate analysis, use of carbapenem for greater than 7 days was associated with an increased risk of intestinal GVHD. However, use of antibiotics for greater than 7 days was not associated with poor overall survival and high nonrelapse mortality. Long use of carbapenem in periengraftment period may be a risk for intestinal GVHD. Prospective studies are required to validate our findings. - Remission of Cutaneous Involvement in Splenic Marginal Zone Lymphoma after Splenectomy.
Shoko Mai; Ken Natsuga; Souichi Shiratori; Yoshimasa Takahashi; Hiroshi Shimizu
Acta dermato-venereologica, 98, 8, 801, 802, 29 Aug. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal - AMLにおけるWT1発現量と染色体・遺伝子異常の関連
日高 大輔; 小野澤 真弘; 橋口 淳一; 宮下 直洋; 笠原 耕平; 藤澤 真一; 早瀬 英子; 岡田 耕平; 白鳥 聡一; 後藤 秀樹; 杉田 純一; 中川 雅夫; 加畑 馨; 橋本 大吾; 遠藤 知之; 山本 聡; 堤 豊; 長谷山 美仁; 永嶋 貴博; 盛 暁生; 太田 秀一; 酒井 基; 石原 敏道; 今井 陽俊; 宮城島 拓人; 柿木 康孝; 黒澤 光俊; 小林 一; 岩崎 博; 清水 力; 近藤 健; 豊嶋 崇徳
臨床血液, 59, 7, 964, 964, (一社)日本血液学会-東京事務局, Jul. 2018
Japanese - Hepatobiliary and Pancreatic: Pancreatic cancer with elevated serum IgG4 level due to multiple myeloma mimicking localized autoimmune pancreatitis.
Kato S; Kuwatani M; Kawakubo K; Sugiura R; Hirata K; Tanikawa S; Mitsuhashi T; Shiratori S; Sakamoto N
Journal of gastroenterology and hepatology, 33, 7, 1310, 1310, Wiley, Jul. 2018, [Peer-reviewed]
Scientific journal - Re-infection of Toxoplasma gondii after HSCT presenting lymphadenopathy resembling recurrence of lymphoma.
Junichi Hashiguchi; Masahiro Onozawa; Tomoaki Naka; Kanako C Hatanaka; Souichi Shiratori; Junichi Sugita; Katsuya Fujimoto; Yoshihiro Matsuno; Takanori Teshima
Transplant infectious disease : an official journal of the Transplantation Society, 20, 3, e12892, Jun. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal, Toxoplasma gondii (T. gondii) reactivation is one of the fatal complications after hematopoietic stem cell transplantation (HSCT); however, re-infection has not been reported. Here, we report a case of mycosis fungoides in which cervical lymphadenopathy developed after HSCT. Initially, recurrent lymphoma was suspected. However, biopsy of the lymph node showed typical histology of toxoplasmosis and serology showed re-infection of T. gondii. Toxoplasmosis needs to be differentiated for cases with lymphoadenopthy after HSCT. - 担癌患者の精査加療中、偶発的に病理組織診断された慢性リンパ性白血病/リンパ球性リンパ腫の3例
岡田 宏美; 清水 亜衣; 桑原 健; 大塚 拓也; 高桑 恵美; 岡田 耕平; 白鳥 聡一; 遠藤 知之; 豊嶋 崇徳; 三橋 智子; 松野 吉宏
日本リンパ網内系学会会誌, 58, 111, 111, (一社)日本リンパ網内系学会, May 2018
Japanese - T-cell depletion effects of low-dose antithymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation.
Souichi Shiratori; Mizuha Kosugi-Kanaya; Eiko Hayase; Kohei Okada; Hideki Goto; Junichi Sugita; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Daigo Hashimoto; Tomoyuki Endo; Takeshi Kondo; Takanori Teshima
Transplant immunology, 46, 21, 22, Feb. 2018, [Peer-reviewed], [International Magazine]
English, Scientific journal - Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
Yutaka Tsutsumi; Chie Nakayama; Koki Kamada; Ryo Kikuchi; Daiki Kudo; Shinichi Ito; Satomi Matsuoka; Souichi Shiratori; Yoshiya Yamamoto; Hirohito Naruse; Takanori Teshima
Annals of hematology, 96, 12, 2057, 2061, Dec. 2017, [Peer-reviewed], [International Magazine]
English, Scientific journal - Disseminated toxoplasmosis after hematopoietic stem cell transplantation showing unusual magnetic resonance images.
Takahiro Tateno; Masahiro Onozawa; Junichi Hashiguchi; Takashi Ishio; Sayaka Yuzawa; Satomi Matsuoka; Mizuha Kosugi-Kanaya; Kohei Okada; Souichi Shiratori; Hideki Goto; Taichi Kimura; Junichi Sugita; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Shinya Tanaka; Satoshi Hashino; Takanori Teshima
Transplant infectious disease : an official journal of the Transplantation Society, 19, 4, e12720, Aug. 2017, [Peer-reviewed], [International Magazine]
English, Scientific journal - Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
Souichi Shiratori; Hiroyuki Ohhigashi; Shinichi Ito; Kazuhiro Kudo; Maki Adachi; Toshiyuki Minamimoto; Junji Kato; Yasue Osai; Yutaka Tsutsumi; Takanori Teshima
Hematological oncology, 35, 1, 138, 140, Mar. 2017, [Peer-reviewed], [International Magazine]
English - Successful T-cell Replete Hematopoietic Stem Cell Boost Without Conditioning for Late Graft Failure
Tsutsumi Y; Tateno T; Ito S; Shiratori S; Teshima T
Transplant Proc, 48, 9, 3225, 3226, Nov. 2016, [Peer-reviewed]
English, Scientific journal - Evaluation of Short-Term Ruxolitinib Tapering Strategy Before Allogeneic Stem Cell Transplantation for Primary Myelofibrosis Through the Transition of Serum Cytokines and Growth Factors.
Souichi Shiratori; Takahiro Tateno; Shinichi Ito; Yutaka Tsutsumi; Takanori Teshima
Transplantation direct, 2, 8, e95, Aug. 2016, [Peer-reviewed], [International Magazine]
English, Scientific journal - Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome.
Souichi Shiratori; Katsuya Fujimoto; Machiko Nishimura; Kanako C Hatanaka; Mizuha Kosugi-Kanaya; Kohei Okada; Junichi Sugita; Akio Shigematsu; Daigo Hashimoto; Tomoyuki Endo; Takeshi Kondo; Riichiro Abe; Satoshi Hashino; Yoshihiro Matsuno; Hiroshi Shimizu; Takanori Teshima
Hematological oncology, 34, 1, 9, 16, Mar. 2016, [Peer-reviewed], [International Magazine]
English, Scientific journal - 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report.
Yutaka Tsutsumi; Hiroyuki Ohigashi; Shinichi Ito; Souichi Shiratori; Takanori Teshima
Journal of medical case reports, 10, 1, 27, 27, 02 Feb. 2016, [Peer-reviewed], [International Magazine]
English, Scientific journal, BACKGROUND: The loss of CD20 protein expression after a rituximab-containing regimen is one of the resistance mechanisms in non-Hodgkin's lymphoma. Recently, it was reported that 5-azacitidine administration upregulates the expression of CD20 in CD20-negative B-cell acute lymphoblastic leukemia. Here we report a similar upregulation in a patient with follicular lymphoma who was treated with 5-azacitidine against secondary myelodysplastic syndrome. CASE PRESENTATION: A 69-year-old Japanese woman with follicular lymphoma with treatment-related myelodysplastic syndrome was negative for the CD20 antibody at the time of her relapse. After treatment of 5-azacytidine for her myelodysplastic syndrome, CD20 expression was upregulated in the follicular lymphoma cells in her peripheral blood. We also observed follicular lymphoma cell stimulation in her peripheral blood due to 5-azacytidine. CONCLUSIONS: Although partial, CD20 expression was upregulated after treatment with 5-azacitidine. However, CD20 expression was not re-upregulated after a second administration of 5-azacitidine and we also observed the risk of lymphoma cell stimulation due to 5-azacitidine. - Determination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution.
Shinichi Ito; Yutaka Tsutsumi; Hiroyuki Ohigashi; Souichi Shiratori; Takanori Teshima
Molecular and clinical oncology, 4, 1, 51, 57, Jan. 2016, [Peer-reviewed], [International Magazine]
English, Scientific journal, Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocytosis (ET) and primary myelofibrosis (PMF), are clonal hematopoietic diseases. A single-institution retrospective analysis was performed, including 71 MPN patients diagnosed at the Hakodate Municipal Hospital between April, 2001 and April, 2014, and certain clinical characteristics were identified as effective prognostic factors. The patients were categorized by risk factor scoring based on age, number of abnormal blood cell lineages and splenomegaly at diagnosis, and the association between this categorization and prognosis was analyzed using a statistical procedure. The effect of Janus kinase 2 (JAK2) V617F mutation on prognosis was also investigated. The MPN patients were consolidated into three risk groups based on the margin of intergroup survival differences: i) Score 1-2 (n=23), ii) score 3 (n=24) and iii) score 4-5 (n=24). MPN patients with scores of 4 or 5 exhibited poorer overall survival (OS) compared with those with lower scores (P<0.001). In addition, there were significant differences in event-free survival (EFS) among scoring groups (P=0.0059). PV and ET had a better prognosis compared with PMF, although this analysis suggested that PV and ET patients with scores of 4 or 5 may have a poorer prognosis in terms of OS (P=0.0052) and EFS (P=0.022) and should be closely followed up. We observed no significant prognostic effect of the JAK2V167F mutation for OS (P=0.28) or EFS (P=0.17). Our results suggested that a simple scoring system based on age, blood cell counts and presence of splenomegaly at diagnosis may be used for the long-term prognosis of MPN patients. - Unplanned discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia.
Yutaka Tsutsumi; Shinichi Ito; Hiroyuki Ohigashi; Souichi Shiratori; Takanori Teshima
Molecular and clinical oncology, 4, 1, 89, 92, Jan. 2016, [Peer-reviewed], [International Magazine]
English, Scientific journal, This study was conducted to investigate the outcomes of patients with chronic myeloid leukemia (CML) who discontinued tyrosine kinase inhibitor (TKI) treatment. A single-center retrospective analysis was performed, including 46 chronic-phase (CP) CML patients who achieved complete molecular response (CMR) with TKIs. TKI treatment was discontinued in 13 patients based on their requests. The BCR-ABL transcript levels were monitored in the peripheral blood by quantitative polymerase chain reaction analysis following treatment discontinuation. Of the 13 patients who discontinued TKI treatment, 7 remained in CMR, with a median follow-up of 26 months (range, 10-60 months). The remaining 6 patients lost CMR following TKI discontinuation; 2 of these patients achieved a second CMR following re-administration of TKIs, 2 patients spontaneously achieved CMR and 2 remained in complete hematological response (CHR) without TKI treatment with a median follow-up of 29.5 months (range, 10-52 months). In conclusion, the survival of patients who lost CMR following TKI discontinuation may not be affected, even without re-administration of TKIs. Vigilant observation is recommended for such patients. The limitations of this study included the small patient sample, retrospective design and patient heterogeneity. Therefore, the results must be interpreted with caution. - Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma.
Tsutsumi Yutaka; Shinichi Ito; Hiroyuki Ohigashi; Miyashita Naohiro; Joji Shimono; Shiratori Souichi; Takanori Teshima
Leukemia & lymphoma, 56, 11, 3216, 8, Mar. 2015, [Peer-reviewed], [International Magazine]
English - Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma.
Souichi Shiratori; Mizuha Kosugi-Kanaya; Akio Shigematsu; Hajime Kobayashi; Satoshi Yamamoto; Naoki Kobayashi; Hiroshi Iwasaki; Akio Mori; Yasuyuki Kunieda; Tsutsumi Yutaka; Mitsutoshi Kurosawa; Yasutaka Kakinoki; Tomoyuki Endo; Takeshi Kondo; Satoshi Hashino; Takanori Teshima
Leukemia & lymphoma, 56, 9, 2592, 7, 2015, [Peer-reviewed], [International Magazine]
English, Scientific journal - [Case Report; Primary central nervous system lymphoma mimicking progressive multifocal leukoencephalopathy in a patient with acquired immune deficiency syndrome].
Tomohiro Yamakawa; Katsuya Fujimoto; Ko Ebata; Junko Iwasaki; Shojiro Takahashi; Souichi Shiratori; Junichi Sugita; Takeshi Kondo; Mitsufumi Nishio; Takanori Teshima
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 103, 10, 2578, 80, 10 Oct. 2014, [Peer-reviewed], [Domestic magazines]
Japanese, Scientific journal - チゲサイクリンとコリスチンの併用が奏功した多剤耐性アシネトバクター・バウマニによるカテーテル関連血流感染症の1例
山田武宏; 白鳥聡一; 杉田純一; 藤本勝也; 豊嶋崇徳; 福元達也; 岩崎澄央; 秋沢宏治
日本化学療法学会雑誌, 62, 4, 501, 505, (公社)日本化学療法学会, Jul. 2014, [Peer-reviewed]
Japanese - Stenotrophomonas maltophilia infection during allogeneic hematopoietic stem cell transplantation: a single-center experience.
Souichi Shiratori; Kentaro Wakasa; Kohei Okada; Junichi Sugita; Koji Akizawa; Akio Shigematsu; Daigo Hashimoto; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Chikara Shimizu; Satoshi Hashino; Takanori Teshima
Clinical transplantation, 28, 6, 656, 61, Jun. 2014, [Peer-reviewed], [International Magazine]
English, Scientific journal - Bone marrow graft-versus-host disease: evaluation of its clinical impact on disrupted hematopoiesis after allogeneic hematopoietic stem cell transplantation.
Yusuke Shono; Souichi Shiratori; Mizuha Kosugi-Kanaya; Satoshi Ueha; Junichi Sugita; Akio Shigematsu; Takeshi Kondo; Daigo Hashimoto; Katsuya Fujimoto; Tomoyuki Endo; Mitsufumi Nishio; Satoshi Hashino; Yoshihiro Matsuno; Kouji Matsushima; Junji Tanaka; Masahiro Imamura; Takanori Teshima
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 20, 4, 495, 500, Apr. 2014, [Peer-reviewed], [International Magazine]
English, Scientific journal - ビンクリスチンによる麻痺性イレウスに引き続きposterior reversible encephalopathy syndromeを発症したT細胞性リンパ芽球性リンパ腫
早瀬 英子; 杉田 純一; 藤本 勝也; 江端 浩; 山川 知宏; 吉田 美穂; 竹村 龍; 岩崎 純子; 高橋 正二郎; 白鳥 聡一; 近藤 健; 田中 淳司; 豊嶋 崇徳
臨床血液, 55, 2, 249, 253, (一社)日本血液学会-東京事務局, Feb. 2014
Japanese - [Posterior reversible encephalopathy syndrome following paralytic ileus caused by vincristine in a patient with T cell lymphoblastic lymphoma].
Eiko Hayase; Junichi Sugita; Katsuya Fujimoto; Ko Ebata; Tomohiro Yamakawa; Miho Yoshida; Ryo Takemura; Junko Iwasaki; Shojiro Takahashi; Souichi Shiratori; Takeshi Kondo; Junji Tanaka; Takanori Teshima
[Rinsho ketsueki] The Japanese journal of clinical hematology, 55, 2, 249, 53, 2, Feb. 2014, [Peer-reviewed], [Domestic magazines]
Japanese, Scientific journal, A 22-year-old woman presented with high fever, chest tightness and cough in January 20XX. Since CT scans revealed an anterior mediastinal mass, percutaneous needle biopsies of the mass were performed and she was diagnosed with T-cell lymphoblastic lymphoma (T-LBL). After the immunophenotype of lymphocytes in her pleural effusion had been identified, she received CHOP therapy because her dyspnea worsened, and induction therapy for acute lymphoblastic leukemia was subsequently performed after confirmation of her diagnosis as T-LBL. During this induction therapy, she developed paralytic ileus. One week thereafter, she suddenly exhibited visual disturbance, headache and nausea. Her cerebrospinal fluid was normal. Magnetic resonance imaging showed symmetrical high signal intensities on T2-weighted and fluid-attenuated inversion recovery images, and low signal intensities on T1-weighted images in the cortical and subcortical white matter of the posterior parietal and occipital lobes. Based on these findings, she was diagnosed as having posterior reversible encephalopathy syndrome (PRES). During chemotherapy for hematologic malignancies, some patients with PRES reportedly develop paralytic ileus or tumor lysis syndrome. PRES should be considered in patients with neurological abnormalities following such complications during chemotherapy. - Epstein-barr virus-associated smooth muscle tumors after bone marrow transplantation.
Eiko Hayase; Katsuya Fujimoto; Tomoko Mitsuhashi; Yutaka Hatanaka; Miho Yoshida; Ryo Takemura; Junko Iwasaki; Souichi Shiratori; Junichi Sugita; Takeshi Kondo; Junji Tanaka; Masahiro Imamura; Yoshihiro Matsuno; Takanori Teshima
Transplantation, 97, 1, e1-3, 3, 15 Jan. 2014, [Peer-reviewed], [International Magazine]
English, [症例報告] - Effect of combination therapy of tigecycline and colistin against a case of catheter-related bloodstream infection by multidrug-resistant Acinetobacter baumannii
Takehiro Yamada; Souichi Shiratori; Junichi Sugita; Katsuya Fujimoto; Takanori Teshima; Tatsuya Fukumoto; Sumio Iwasaki; Koji Akizawa; Katsuya Narumi; Nobuhisa Ishiguro; Ken Iseki
Japanese Journal of Chemotherapy, 62, 4, 501, 505, Japan Society of Chemotherapy, 2014
Japanese, Scientific journal - Analysis of the influence of dabigatran on coagulation factors and inhibitors
Tsutsumi Y; Shimono J; Ohhigashi H; Ito S; Shiratori S; Teshima T
Int J Lab Hematol, 2014, [Peer-reviewed]
2014 Jun 25. [Epub ahead of print] - Successful engraftment in HLA-mismatched bone marrow transplantation despite the persistence of high-level donor-specific anti-HLA-DR antibody.
Souichi Shiratori; Makoto Ito; Maki Yoneoka; Koji Hayasaka; Eiko Hayase; Junko Iwasaki; Junichi Sugita; Akio Shigematsu; Katsuya Fujimoto; Takeshi Kondo; Chikara Shimizu; Takanori Teshima
Transplantation, 96, 5, e34-44, e35, 15 Sep. 2013, [Peer-reviewed], [International Magazine]
English - 顔面の腫脹から診断に至った皮下脂肪織炎様T細胞性リンパ腫(subcutaneous panniculitis-like T-cell lymphoma:SPTCL)の1例
中里 信一; 藤田 靖幸; 古口 華子; 長谷部 育恵; 西江 渉; 清水 宏; 白鳥 聡一; 近藤 健
日本皮膚科学会雑誌, 123, 8, 1539, 1539, (公社)日本皮膚科学会, Jul. 2013
Japanese - 顔面の腫脹から診断に至った皮下脂肪織炎様T細胞性リンパ腫(SPTCL)の1例
中里 信一; 藤田 靖幸; 古口 華子; 長谷部 育恵; 西江 渉; 清水 宏; 白鳥 聡一; 近藤 健
日本皮膚科学会雑誌, 123, 6, 1098, 1098, (公社)日本皮膚科学会, May 2013
Japanese - 左副腎原発メトトレキサート関連悪性リンパ腫の一例
亀田啓; 中垣整; 永井聡; 近藤琢磨; 三橋智子; 松野吉宏; 安部崇重; 篠原信雄; 野々村克也; 白鳥聡一; 豊嶋崇徳; 三好秀明; 清水力; 清水力; 渥美達也
日本内分泌学会雑誌, 88, 3, 1034, 20 Dec. 2012
Japanese - Dasatinib enhances the expansion of CD56+CD3- NK cells from cord blood.
Junji Tanaka; Junichi Sugita; Souichi Shiratori; Akio Shigematsu; Masahiro Imamura
Blood, 119, 25, 6175, 6, 25, 21 Jun. 2012, [Peer-reviewed], [International Magazine]
English - Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD
J. Sugita; T. Matsushita; H. Kashiwazaki; M. Kosugi; S. Takahashi; K. Wakasa; S. Shiratori; M. Ibata; Y. Shono; A. Shigematsu; M. Obara; K. Fujimoto; T. Endo; M. Nishio; T. Kondo; S. Hashino; J. Tanaka; M. Asaka; M. Imamura
BONE MARROW TRANSPLANTATION, 47, 2, 258, 264, Feb. 2012, [Peer-reviewed]
English, Scientific journal - Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia.
Kotaro Arita; Takeshi Kondo; Junichi Sugita; Akio Shigematsu; Souichi Shiratori; Kentaro Wakasa; Atsushi Yasumoto; Makoto Ibata; Yusuke Shono; Misato Kikuchi; Hideki Goto; Yukari Takeda; Mutsumi Takahata; Naoko Kato; Mitsufumi Nishio; Shuichi Ota; Junji Tanaka; Masahiro Imamura
International journal of hematology, 94, 3, 291, 295, 3, Sep. 2011, [Peer-reviewed], [Domestic magazines]
English, Scientific journal, The prognosis of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for refractory acute lymphoblastic leukemia (ALL) is very poor. To improve survival rates, we attempted to intensify the conditioning regimen with daunorubicin, vincristine, prednisolone, medium-dose etoposide, cyclophosphamide, and total body irradiation (DNR/VCR/PSL plus medium-dose VP/CY/TBI). Four patients in relapse or induction failure of B-precursor ALL without other complications underwent allogeneic HSCT. Initially, chemotherapy comprising DNR 60 mg/m(2) for 3 days, VCR 1.4 mg/m(2) for 1 day, and PSL 60 mg/m(2) for 3 days was administered, which was followed by medium-dose VP/CY/TBI; some modifications were made for individual patients. All patients achieved engraftment and complete remission after HSCT. Regimen-related toxicities were tolerable and no patient died within 100 days. Two patients were alive without disease on days 563 and 1,055. The third patient relapsed on day 951, while the fourth died on day 179 without disease. Our results indicate that intensified myeloablative HSCT should be considered for patients with refractory ALL. - Expansion of CD4(+)CD25 (+) regulatory T cells from cord blood CD4(+) cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin.
Shinsuke Asanuma; Junji Tanaka; Junichi Sugita; Mizuha Kosugi; Souichi Shiratori; Kentarou Wakasa; Yusuke Shono; Akio Shigematsu; Takeshi Kondo; Takahiko Kobayashi; Masahiro Asaka; Masahiro Imamura
Annals of hematology, 90, 6, 617, 24, 6, Jun. 2011, [Peer-reviewed], [International Magazine]
English, Scientific journal, Rapamycin has important roles in the modulation of regulatory T cells. We tried to expand CD4(+)CD25(+) regulatory T cells (Treg cells) from umbilical cord blood (CB) CD4-positive cells using interleukin (IL)-15 or IL-2 with transforming growth factor (TGF)-β and rapamycin. We were able to obtain more than 500-fold expansion of CD4(+)CD25(+) cells from CB CD4(+) cells using IL-15 and TGF-β with rapamycin. These expanded CD4(+)CD25(+) cells expressed forkhead box P3 (FoxP3) mRNA at a level about 100-fold higher and could suppress allogeneic mixed lymphocyte culture (MLC) by more than 50%. Early after rapamycin stimulation, CB CD4(+) cells showed increased expression of FoxP3 and a serine/threonine kinase Pim2 and sustained expression of negative phosphoinositide 3-kinase regulator phosphatase and tensin homolog deleted on chromosome 10 (PTEN). On the other hand, CD4(+)CD25(+) cells expanded with rapamycin for 8 days showed much higher levels of FoxP3 mRNA expression and decreased expression of PTEN. A comparison of IL-15 stimulation and IL-2 stimulation showed slightly higher efficiency of IL-15 for expansion of CD4(+)CD25(+) cells, and for FoxP3 expression, IL-15 also showed significantly higher efficacy for inhibition of MLC. The combination of the common γ-chain cytokine IL-15, TGF-β, and rapamycin may be a useful means for expanding Treg cells. Pim2 expression early after stimulation with rapamycin may be important for conferring rapamycin resistance for growth of Treg cells. IL-15 is not less useful than IL-2 for expansion of Treg cells. - Donor cell leukemia after umbilical cord blood transplantation: recurrent or de novo? The importance of diagnosis for therapeutic decision making.
Yusuke Shono; Mizuha Kosugi-Kanaya; Souichi Shiratori; Junichi Sugita; Katsuya Fujimoto; Takeshi Kondo; Mitsufumi Nishio; Junji Tanaka; Masahiro Imamura
International journal of hematology, 93, 4, 563, 565, 4, Apr. 2011, [Peer-reviewed], [Domestic magazines]
English - c-myc rearrangement in B-cell lymphoblastic lymphoma with the involvement of multiple extranodal lesions.
Souichi Shiratori; Takeshi Kondo; Shinichi Fujisawa; Kanako Kubota; Mizuha Kosugi; Yusuke Shono; Junichi Sugita; Katsuya Fujimoto; Mitsufumi Nishio; Junji Tanaka; Takao Koike; Yoshihiro Matsuno; Kazuhiko Matsuno; Masahiro Asaka; Masahiro Imamura
Leukemia & lymphoma, 52, 4, 716, 8, Apr. 2011, [Peer-reviewed], [International Magazine]
English - ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses.
Sumio Hayakawa; Souichi Shiratori; Hiroaki Yamato; Takeshi Kameyama; Chihiro Kitatsuji; Fumi Kashigi; Showhey Goto; Shoichiro Kameoka; Daisuke Fujikura; Taisho Yamada; Tatsuaki Mizutani; Mika Kazumata; Maiko Sato; Junji Tanaka; Masahiro Asaka; Yusuke Ohba; Tadaaki Miyazaki; Masahiro Imamura; Akinori Takaoka
Nature immunology, 12, 1, 37, 44, Jan. 2011, [Peer-reviewed], [International Magazine]
English, Scientific journal - 抗ウイルス応答のためのRIG-1を介するシグナルを強く刺激する分子の同定(Identification of a potent stimulator of RIG-I mediated signaling for antiviral response)
北辻 千展; 早川 清雄; 白鳥 聡一; 大和 弘明; 亀山 武志; 樫木 芙美; 後藤 翔平; 亀岡 章一郎; 大場 雄介; 宮崎 忠昭; 高岡 晃教
日本生化学会大会・日本分子生物学会年会合同大会講演要旨集, 83回・33回, 2T11, 11, (公社)日本生化学会, Dec. 2010
English - Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen.
Shigematsu A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Yamaguchi K; Wakasa K; Takahata M; Goto H; Ito S; Takemura R; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Transplant infectious disease : an official journal of the Transplantation Society, 12, 5, 412, 420, Oct. 2010, [Peer-reviewed], [International Magazine]
English, Scientific journal, Although bacterial infection is a major cause of death even after reduced-intensity conditioning (RIC) for allogeneic stem cell transplantation (SCT), little is known about the epidemiology and risk factors. The incidence of bacterial infection in 43 patients who received allogeneic bone marrow transplantation (BMT) using a RIC regimen was compared with that in 68 patients who received BMT using a myeloablative conditioning regimen, and risk factors for bacterial infection were identified. Before engraftment, incidences of febrile neutropenia (FN) and documented infections (DI) were significantly decreased in RIC patients (FN: 59.5% vs. 89.6%, P<0.01, DI: 4.8% vs. 17.9%, P<0.01). However, incidence of bacterial infection was significantly increased in RIC patients in the post-engraftment phase (53.8% vs. 11.1%, log-rank, P<0.01). Blood stream was the most frequent focus of infection in both groups. In multivariate analysis, RIC and acute graft-versus-host disease were revealed to be significant risk factors for bacterial infection in this phase. In summary, risk of bacterial infection after engraftment was significantly higher in RIC patients, although infection was decreased before engraftment, and we need to develop a RIC-specific strategy against bacterial infection after RIC SCT. - Differential effects of interleukin-12 and interleukin-15 on expansion of NK cell receptor-expressing CD8+ T cells.
Junichi Sugita; Junji Tanaka; Atsushi Yasumoto; Souichi Shiratori; Kentaro Wakasa; Misato Kikuchi; Akio Shigematsu; Takeshi Kondo; Masahiro Asaka; Masahiro Imamura
Annals of hematology, 89, 2, 115, 20, 2, Feb. 2010, [Peer-reviewed], [International Magazine]
English, Scientific journal, The cytolytic activity of cells expressing natural killer cell receptors (NKRs) depends on the balance between stimulatory and inhibitory signals. We investigated both inhibitory NK receptor (CD94/NKG2A) expression and stimulatory NKR (NKG2D) expression on T cells after stimulation with cytokines (IL-12 or IL-15). Cytolytic NKR-expressing CD8(+) T cells were expanded from normal adult peripheral blood mononuclear cells using anti-CD3 monoclonal antibody and cytokines (IL-12 or IL-15). The proportion and absolute number of CD94/NKG2A-expressing T cells expanded by IL-12 were significantly larger than those of the cells expanded by IL-15. On the other hand, the proportion and absolute number of NKG2D-expressing T cells expanded by IL-15 were significantly larger than those of the cells expanded by IL-12. The proportions of NKG2D and intracellular granzyme A expression in CD94-expressing cells were much more increased in PBMCs cultured with IL-15 than those of cells cultured with IL-12. A real-time polymerase chain reaction assay showed that there was a 1.68-fold increase in NKG2D mRNA expression level and a 1.37-fold increase in DAP10 mRNA expression level in CD94-expressing cells expanded by IL-15 compared with those of the cells expanded by IL-12. The cytolytic activity levels of purified CD94-expressing cells from 8-day culture with IL-15 tested against (51)Cr-labeled K562 cells by standard 4-h (51)Cr release assays without prior sensitization were much higher than those of cells from 8-day culture with IL-12. IL-15 appears to be able to enhance the cytolytic activity of CD94/NKG2A-expressing cells through induction of NKG2D and intracellular granzyme expression much more efficiently than does IL-12. - Increased number of CD16(+)CD56(dim) NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation.
Junji Tanaka; Junichi Sugita; Shinsuke Asanuma; Kotaro Arita; Yusuke Shono; Misato Kikutchi; Souichi Shiratori; Kentaro Wakasa; Atsushi Yasumoto; Akio Shigematu; Takeshi Kondo; Takahiko Kobayashi; Masahiro Asaka; Masahiro Imamura
Human immunology, 70, 9, 701, 5, 9, Sep. 2009, [Peer-reviewed], [International Magazine]
English, Scientific journal, In the present study, we investigated subpopulations of natural killer (NK) cells and the expression of stimulatory and inhibitory NK receptors after adult blood and bone marrow transplantation (BBMT) and cord blood transplantation (CBT). There were significant increases in CD16(+)CD56(dim) cell proportion and in absolute number in peripheral blood mononuclear cells (PBMC) during a period of 4-9 months after CBT compared with these in normal PBMC, cord blood (CB), and in PBMC after BBMT. Also, increased numbers of CD16(+)CD56(dim) NK cells were sustained in some patients until 4 years after CBT. This CD16(+)CD56(dim) cell subset after CBT exhibited decreased expression of NKG2A compared with that in CB and increased expression of NKG2C. Purified CD16(+)CD56(dim) cells from patients 8-9 months after CBT exhibited significantly higher levels of cytolytic activity against K562 than did purified CD16(+)CD56(bright) cells and also whole PBMC. The CD16(+)CD56(dim) cell subset with a high level of cytolytic activity significantly increased after CBT, and these cells may be responsible for NK cell-mediated immunity after CBT. - Influence of conditioning regimens and stem cell sources on donor-type chimerism early after stem cell transplantation.
Junichi Sugita; Junji Tanaka; Aya Hashimoto; Souichi Shiratori; Atsushi Yasumoto; Kentaro Wakasa; Misato Kikuchi; Akio Shigematsu; Yoko Miura; Yutaka Tsutsumi; Takeshi Kondo; Masahiro Asaka; Masahiro Imamura
Annals of hematology, 87, 12, 1003, 8, 12, Dec. 2008, [Peer-reviewed], [International Magazine]
English, Scientific journal, We retrospectively analyzed very early chimerism before and ongoing neutrophil engraftment (days 7, 14, 21, 28) and investigated the influence of conditioning regimens and stem cell sources on donor-type chimerism in 59 Japanese patients who had received allogeneic hematopoietic stem cell transplantation. The percentage of donor-type chimerism increased before engraftment in all patients who achieved engraftment. The average percentage of donor-type chimerism in patients who had received reduced-intensity stem cell transplantation (RIST) with total body irradiation (TBI) was significantly higher than that in patients who had received RIST without TBI (98.8% vs 87.5% on day 21, P<0.01; 99.3% vs 84.3% on day 28, P<0.01). The average percentage of donor-type chimerism after peripheral blood stem cell transplantation was significantly higher than that after bone marrow transplantation on day 7 (81.5% vs 43.1%, P<0.01), and the average percentage of donor-type chimerism after cord blood transplantation was significantly lower on day 14 (55.8% vs 84.8%, P<0.05). Compared with the average percentage of donor-type chimerism in patients who achieved engraftment with each stem cell source, a notable decrease in donor-type chimerism was observed in patients who failed to achieve engraftment. This study suggests that differences in conditioning regimens and stem cell sources should be taken into account when considering donor-type chimerism. - T cell receptor excision circle levels in CD94-expressing CD8 T Cells during graft-versus-host disease.
Junichi Sugita; Noriaki Iwao; Junji Tanaka; Naoko Kato; Souichi Shiratori; Kentarou Wakasa; Akio Shigematsu; Tomomi Toubai; Mutsumi Takahata; Takeshi Kondo; Masahiro Asaka; Masahiro Imamura
Leukemia & lymphoma, 49, 7, 1306, 10, 7, Jul. 2008, [Peer-reviewed], [International Magazine]
English, Scientific journal, T cell receptor excision circles (TRECs) have been suggested to be useful markers of recent thymic output and graft-versus-host disease (GVHD) was thought to have an adverse effect on thymic output. On the other hand, TREC concentrations are diluted with T cell expansion. The C-type lectin superfamily inhibitory receptor CD94 expression on T cells might be a consequence of CD8 T cell expansion. Therefore, this study was designed to analyse TREC DNA level in CD4 and CD8 T cell subset expressing CD94 during GVHD. We investigated TREC DNA copy numbers (TREC levels) of CD4+, CD94+/CD8+ and CD94-/CD8+ T cells in 24 patients who had undergone allogeneic stem cell transplantation and also of in vitro activated and expanded CD94-expressing cells by immobilised anti-CD3 mAb and IL-15. TREC level of CD94+/CD8+ T cells in patients with chronic GVHD was lower than that in patients with no GVHD and with remission status of GVHD. In vitro activated and expanded CD94-expressing cells had a significantly lower TREC level than that in untreated CD8 cells. Therefore, the low TREC level of CD94+/CD8+ T cells is related to chronic GVHD and may reflect T cell expansion during chronic GVHD. - A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.
Souichi Shiratori; Atsushi Yasumoto; Junji Tanaka; Akio Shigematsu; Satoshi Yamamoto; Mitsufumi Nishio; Satoshi Hashino; Rena Morita; Mutsumi Takahata; Masahiro Onozawa; Kaoru Kahata; Takeshi Kondo; Shuichi Ota; Kentaro Wakasa; Junichi Sugita; Takao Koike; Masahiro Asaka; Masaharu Kasai; Masahiro Imamura
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14, 7, 817, 23, Jul. 2008, [Peer-reviewed], [International Magazine]
English, Scientific journal - Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 14, 5, 568, 575, 5, May 2008, [Peer-reviewed] - HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution.
Souichi Shiratori; Yutaka Tsutsumi; Takahito Kawamura; Kazuhiro Kudo; Norihiko Shimoyama; Nobuo Masauzi; Junji Tanaka; Masahiro Asaka; Masahiro Imamura
International journal of hematology, 87, 3, 298, 302, Apr. 2008, [Peer-reviewed], [Domestic magazines]
English, Scientific journal
- Belumosudil in steroid-dependent/resistant chronic graft-versus-host disease: Long-term outcomes
松岡賢市; 松岡賢市; 加藤光次; 河北敏郎; 大西康; 白鳥聡一; 池亀和博; 平本展大; 豊崎誠子; 片山雄太; 古賀友紀; 古賀友紀; 村山竣; 笹川裕次; 畠清彦; 畠清彦; 前田嘉信; 豊嶋祟徳; 稲本賢弘; 稲本賢弘, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47th, 2025 - Comparative study of GVHD prophylaxis using low-dose ATG or PTCy in PBSCT
白鳥聡一; 杉田純一; 石川淳; 黒羽高志; 森康雄; 衛藤徹也; 笠原千嗣; 福島健太郎; 原田実根; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47th, 2025 - ステロイド依存性/抵抗性慢性GVHDに対するベルモスジル:製造販売後臨床試験パートを含む最終成績
白鳥聡一; 加藤光次; 河北敏郎; 大西康; 松岡賢市; 松岡賢市; 池亀和博; 平本展大; 豊崎誠子; 片山雄太; 古賀友紀; 古賀友紀; 村山竣; 笹川裕次; 進藤麻未; 畠清彦; 畠清彦; 前田嘉信; 豊嶋崇徳; 稲本賢弘; 稲本賢弘, 日本血液学会学術集会抄録(Web), 87th, 2025 - Zanubrutinibが奏効したBing-Neel症候群の1例
野島慎悟; 野津麟太郎; 堀北風花; 宮島徹; 吉田匠汰; 木村弘幸; 荒隆英; 小笠原励起; 松川敏大; 白鳥聡一; 中川雅夫; 豊嶋崇徳, 臨床血液, 66, 11, 2025 - 低用量ST合剤による同種造血幹細胞移植後ニューモシスチス肺炎の予防効果についての検討
荒隆英; 遠藤知之; 長谷川祐太; 大東寛幸; 白鳥聡一; 橋本大吾; 豊嶋崇徳, 日本内科学会雑誌, 113, 2024 - Belumosudil for steroid-dependent/resistant chronic graft versus host disease: Phase3 Japanese study
河北敏郎; 稲本賢弘; 加藤光次; 大西康; 松岡賢市; 白鳥聡一; 池亀和博; 平本展大; 豊崎誠子; 片山雄太; 村山竣; 笹川裕次; 前田嘉信; 畠清彦; 畠清彦; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024 - Impact of duration of response of prior therapy on therapeutic efficacy of CAR-T therapy in DLBCL
後藤秀樹; 荒隆英; 大東寛幸; 長谷川祐太; 千葉雅尋; 千丈創; 松川敏大; 安本篤史; 白鳥聡一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024 - Low-molecular-weight heparin and the incidence of SOS/VOD during HSCT
白鳥聡一; 長谷川祐太; 大東寛幸; 荒隆英; 松川敏大; 安本篤史; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024 - HLA不適合造血幹細胞移植における高感度HLA交差適合試験法の有用性の検討
櫻澤貴代; 伊藤誠; 南昭子; 白鳥聡一; 杉田純一; 渡邊千秋; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 日本輸血細胞治療学会誌, 69, 2, 2023 - 中枢病変を有した成人T細胞性白血病/リンパ腫(ATLL)の1例
塚本しほり; 清水亜衣; 森祐斗; 横山翔大; 荒隆英; 松川敏大; 白鳥聡一; 中川雅夫; 遠藤知之; 高桑恵美; 加留部謙之輔; 松野吉宏; 豊嶋崇徳, 臨床血液, 64, 7, 2023 - The incidence of Pneumocystis pneumonia after allogeneic hematopoietic stem cell transplantation
荒隆英; 長谷川祐太; 大東寛幸; 安本篤史; 白鳥聡一; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022 - Multicenter study of Defibrotide for sinusoidal obstruction syndrome after allogeneic HSCT
白鳥聡一; 岡田耕平; 松岡里湖; 伊東慎市; 豊嶋崇徳; 豊嶋崇徳; 杉田純一, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022 - HokUS-10 scoring system predicts the treatment response for SOS: NJHSG-Transplantation WG
白鳥聡一; 岡田耕平; 杉田純一; 西田睦; 岩井孝仁; 太田秀一; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022 - Retrospective analysis of allo-SCT for adult T cell leukemia/lymphoma in single institution
荒隆英; 横山翔大; 長谷川祐太; 大東寛幸; 松川敏大; 安本篤史; 白鳥聡一; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022 - Bacillus species bacteremia in patients who underwent hematopoietic stem cell transplant
森祐斗; 荒隆英; 横山翔大; 松川敏大; 白鳥聡一; 中川雅夫; 遠藤知之; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022 - CRP is a predictive marker of the antifebrile effect of tocilizumab on CRS during CAR-T cell therapy
横山翔大; 後藤秀樹; 荒隆英; 森祐斗; 長谷川祐太; 大東寛幸; 松川敏大; 安本篤史; 白鳥聡一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022 - Association between candidemia and non-infectious interstitial pneumonia after allogeneic HCT
木村俊一; 赤星佑; 赤星佑; 白鳥聡一; 冲中敬二; 冲中敬二; 原田介斗; 内田直之; 土岐典子; 池亀和博; 中前博久; 田中正嗣; 高田覚; 河北敏郎; 松岡賢市; 荒隆英; 太田秀一; 澤正史; 鬼塚真仁; 福田隆浩; 熱田由子; 熱田由子; 神田善伸; 神田善伸; 仲宗根秀樹, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022 - ATG could potentially overcome an adverse effect of acute GVHD in matched-related PBSCT
宮尾康太郎; 鍬塚八千代; 村田誠; 長藤宏司; 豊嶋崇徳; 竹内裕貴; 白鳥聡一; 名島悠峰; 内田直之; 田中正嗣; 澤正史; 太田秀一; 福田隆浩; 小澤幸泰; 賀古真一; 河北敏弘; 荒隆英; 田中淳司; 神田善伸; 熱田由子; 諫田淳也; 寺倉精太郎, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022 - GVHD prophylaxis using low-dose antithymocyte globulin in PBSCT-A matched-pair analysis-
白鳥聡一; 倉田美穂; 杉田純一; 太田秀一; 笠原千嗣; 石川淳; 今田和典; 大西康; 石山謙; 芦田隆司; 神田善伸; 一戸辰夫; 福田隆浩; 熱田由子; 熱田由子; 豊嶋崇徳; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022 - Letermovir Is Effective for Prevention of Cytomegalovirus Reactivation in HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Takahide Ara; Yuta Hasegawa; Hiroyuki Ohigashi; Souichi Shiratori; Atsushi Yasumoto; Hideki Goto; Junichi Sugita; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Daigo Hashimoto; Takanori Teshima, BLOOD, 138, Nov. 2021
English, Summary international conference - Safety and efficacy of Defibrotide for sinusoidal obstruction syndrome
木村弘幸; 白鳥聡一; 大東寛幸; 荒隆英; 安本篤史; 後藤秀樹; 中川雅夫; 杉田純一; 小野澤真弘; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021 - Anti-thymocyte globulin in patients undergoing unrelated PBSCT
白鳥聡一; 杉田純一; 藤重夫; 青木淳; 澤正史; 小澤幸泰; 橋本大吾; 橋本大吾; 松岡賢市; 今田和典; 土岐典子; 芦田隆司; 上田恭典; 一戸辰夫; 寺倉精太郎; 森島聡子; 熱田由子; 福田隆浩; 豊嶋崇徳; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021 - Loeffler心内膜炎による左室内血栓および壁運動異常を併発したPDGFRA遺伝子再構成を伴う慢性好酸球性白血病の1例
吉田匠汰; 荒隆英; 塚本しほり; 齋藤祐美花; 伊藤謙一; 白鳥聡一; 後藤秀樹; 中川雅夫; 遠藤知之; 豊嶋崇徳, 臨床血液, 62, 12, 2021 - Impact of low-dose ATG for quality of life after peripheral blood stem cell transplantation
白鳥聡一; 杉田純一; 熱田由子; 原田実根; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 83rd, 2021 - Ruxolitinib vs best available therapy in steroid-refractory cGvHD: REACH3 in Japanese patients
福島健太郎; 白鳥聡一; 大西康; 土岐典子; 後藤辰徳; 岡田昌也; 中前博久; 前田嘉信; 加藤光次; 石川隆之; 近藤忠一; 豊崎誠子; 池田宇次; 谷口修一; 岩本章子; 島田文香; STEFANELLI Tommaso; HOLLAENDER Norbert; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 83rd, 2021 - Fluid retention after allogeneic hematopoietic stem cell transplantation has a poor prognosis
宮下直樹; 須藤啓斗; 日高大輔; 大東寛幸; 荒隆英; 白鳥聡一; 安本篤史; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021 - Prognostic impact of fractionation of TBI in myeloablative allogeneic HSCT for patient with AML
上田格弘; 小沼貴晶; 青木淳; 高橋聡; 小澤幸泰; 森毅彦; 太田秀一; 衛藤徹也; 高田覚; 吉岡聡; 白鳥聡一; 賀古真一; 福田隆浩; 鬼塚真仁; 神田善伸; 熱田由子; 熱田由子; 柳田正光, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021 - The impact of WBC at diagnosis for Ph-positive ALL in patients with negative-MRD at HCT
赤星佑; 新井康之; 西脇聡史; 立花崇孝; 篠原明仁; 土岐典子; 内田直之; 田中正嗣; 神田善伸; 神田善伸; 白鳥聡一; 小澤幸泰; 鐘野勝洋; 片山雄太; 田中淳司; 福田隆浩; 熱田由子; 熱田由子; 賀古真一, 日本血液学会学術集会抄録(Web), 83rd, 2021 - 少量ATGを用いたPBSCTの移植成績-R-PBSCTとUR-PBSCTの比較検討-
白鳥聡一; 大東寛幸; 高橋秀一郎; 荒隆英; 横山絵美; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本輸血細胞治療学会誌, 66, 2, 2020 - A phase II study of anti-thymocyte globulin in patients undergoing HLA-matched PBSCT-JSCT-ATG15-
白鳥聡一; 杉田純一; 太田秀一; 笠原千嗣; 石川淳; 金森平和; 林良樹; 吉本五一; 衛藤徹也; 岩崎浩己; 松尾恵太郎; 原田実根; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020 - Efficacy of low-dose and short term cidofovir treatment for adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients
大東寛幸; 後藤秀樹; 藤本勝也; 荒隆英; 白鳥聡一; 杉田純一; 小野澤真弘; 森康雄; 吉本五一; 橋本大吾; 遠藤知之; 加藤光次; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020 - 同種造血幹細胞移植後早期のプロカルシトニン測定の有用性についての検討
大東寛幸; 杉田純一; 荒隆英; 白鳥聡一; 後藤秀樹; 小野澤真弘; 中川雅夫; 橋本大吾; 遠藤知之; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020 - 再発難治性DLBCLへのtisagenlecleucelの安全性
後藤秀樹; 杉田純一; 杉田純一; 大東寛幸; 荒隆英; 高橋秀一郎; 高橋秀一郎; 横山絵美; 白鳥聡一; 小野澤真弘; 中川雅夫; 加畑馨; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020 - 同種造血幹細胞移植後肺合併症の診断における気管支肺胞洗浄液CD4+/CD8+比の有用性
千丈創; 杉田純一; 岡田耕平; 鈴木雅; 千葉雅尋; 大東寛幸; 高橋秀一郎; 荒隆英; 横山絵美; 白鳥聡一; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020 - 各種移植片対宿主病予防法におけるレテルモビル予防内服時の至適タクロリムス初回投与量に関する検討
荒隆英; 大東寛幸; 高橋秀一郎; 白鳥聡一; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020 - 少量ATGはHLA適合PBSCTにおいて重症の急性,慢性GVHDの発症を抑制する
白鳥聡一; 杉田純一; 太田秀一; 笠原千嗣; 石川淳; 立花崇孝; 林良樹; 吉本五一; 衛藤徹也; 岩崎浩己; 松尾恵太郎; 原田実根; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020 - VWF含有第VIII因子製剤および第IX因子製剤を併用して関節手術を施行したVWD合併血友病B保因者
遠藤知之; 岡敏明; 小野寺智洋; 遠藤香織; 高橋承吾; 米田和樹; 荒隆英; 白鳥聡一; 後藤秀樹; 中川雅夫; 豊嶋崇徳, 日本血栓止血学会誌, 31, 2, 2020 - 10年という長期寛解後に全身再発を来した節外性NK/T cell lymphoma(鼻型)の1例
土田直央; 荒隆英; 遠藤知之; 横山翔大; 笠原耕平; 白鳥聡一; 後藤秀樹; 中川雅夫; 豊嶋崇徳; 福井秀章; 松野吉宏, 臨床血液, 60, 7, 2019 - タクロリムスと減量メソトレキセートを用いた臍帯血移植におけるGVHD予防法
白鳥聡一; 高橋秀一郎; 宮下直洋; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 杉田純一; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 41st, 2019 - 当院における60歳以上の高齢者に対する同種造血幹細胞移植の後方視的解析
横山翔大; 白鳥聡一; 荒隆英; 笠原耕平; 高橋秀一郎; 宮下直洋; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 杉田純一; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 41st, 2019 - 進行期骨髄異形成症候群に対する移植前寛解導入化学療法の意義:傾向スコアマッチング解析
小沼貴晶; 小沼貴晶; 下村良充; 下村良充; 小澤幸泰; 小澤幸泰; 上田恭典; 上田恭典; 内田直之; 内田直之; 鬼塚真仁; 鬼塚真仁; 秋山めぐみ; 秋山めぐみ; 森毅彦; 森毅彦; 中前博久; 中前博久; 大野裕樹; 大野裕樹; 白鳥聡一; 白鳥聡一; 大西康; 大西康; 神田善伸; 神田善伸; 福田隆浩; 福田隆浩; 熱田由子; 熱田由子; 石山謙; 石山謙, 日本造血細胞移植学会総会プログラム・抄録集, 41st, 2019 - Comparable Survival Outcomes of Haploidentical Stem Cell Transplantation and Unrelated Bone Marrow Transplantation
Junichi Sugita; Yoshiko Atsuta; Mio Kurata; Hirohisa Nakamae; Naoki Kurita; Ken Ishiyama; Souichi Shiratori; Takahiro Fukuda; Kazuteru Ohashi; Yukiyasu Ozawa; Junya Kanda; Tatsuo Ichinohe; Takanori Teshima, BLOOD, 132, Nov. 2018
English, Summary international conference - AMLにおけるWT1発現量と染色体・遺伝子異常の関連
日高 大輔; 小野澤 真弘; 橋口 淳一; 宮下 直洋; 笠原 耕平; 藤澤 真一; 早瀬 英子; 岡田 耕平; 白鳥 聡一; 後藤 秀樹; 杉田 純一; 中川 雅夫; 加畑 馨; 橋本 大吾; 遠藤 知之; 山本 聡; 堤 豊; 長谷山 美仁; 永嶋 貴博; 盛 暁生; 太田 秀一; 酒井 基; 石原 敏道; 今井 陽俊; 宮城島 拓人; 柿木 康孝; 黒澤 光俊; 小林 一; 岩崎 博; 清水 力; 近藤 健; 豊嶋 崇徳, 臨床血液, 59, 7, 964, 964, Jul. 2018
(一社)日本血液学会-東京事務局, Japanese - ステロイド抵抗性急性移植片対宿主病に対するヒト間葉系幹細胞療法の後方視的解析
白鳥 聡一; 早瀬 英子; 岡田 耕平; 後藤 秀樹; 杉田 純一; 小野澤 真弘; 中川 雅夫; 加畑 馨; 橋本 大吾; 遠藤 知之; 近藤 健; 豊嶋 崇徳, 日本輸血細胞治療学会誌, 64, 2, 452, 452, Apr. 2018
(一社)日本輸血・細胞治療学会, Japanese - 脾摘後に自然消退した続発性皮膚B細胞リンパ腫の1例
眞井 翔子; 夏賀 健; 清水 宏; 白鳥 聡一; 高橋 祥公, 日本皮膚科学会雑誌, 128, 4, 608, 608, Apr. 2018
(公社)日本皮膚科学会, Japanese - 同種造血幹細胞移植後にT細胞由来の異型リンパ球増加を伴い伝染性単核球症様症状を呈した再生不良性貧血
江端浩; 郎朗; 長谷川祐太; 早瀬英子; 白鳥聡一; 後藤秀樹; 中川雅夫; 遠藤知之; 豊嶋崇徳, 臨床血液, 59, 7, 2018 - FUNCTIONAL COMPARISON BETWEEN Spectra Optia® MNC AND CMNC MODES FOR PERIPHERAL BLOOD STEM CELL COLLECTION
Ito Makoto; Takahashi Syuichiro; Miyashita Naohiro; Goto Hideki; Onozawa Masahiro; Shiratori Souichi; Sugita Junichi; Hashimoto Daigo; Akizawa Koji; Sato Norihiro; Teshima Takanori; Hayase Eiko; Watanabe Chiaki; Uwatoko Takayo; Uozumi Ryo; Hayashi Yasuhiro; Hayasaka Koji; Mogi Yuko; Kahata Kaoru, Japanese Journal of Transfusion and Cell Therapy, 64, 6, 742, 751, 2018
<p><b>Background: </b>Spectra Optia<sup>®</sup> is an apheresis system that enables peripheral blood stem cell collection (PBSCC) to be easily conducted due to its unique automated interface management system. We retrospectively analyzed the number for CD34-positive cells in collected products and the collection efficiency for CD34-positive cells between the Spectra Optia<sup>®</sup> MNC mode (MNC group) and CMNC mode (CMNC group) for PBSCC.</p><p><b>Methods: </b>We retrospectively analyzed 233 cases of PBSCC (autologous PBSCC: 103 cases, allogeneic PBSCC: 130 cases), which were performed in our institution between August 2013 and February 2018.</p><p><b>Results: </b>In autologous PBSCC, there was no significant difference in the number of CD34-positive cells in collected products or the collection efficiency for CD34-positive cells between the two groups. In allogeneic PBSCC, the number of CD34-positive cells in collected products and the collection efficiency for CD34-positive cells in the CMNC group were significantly higher than those in the MNC group. Peripheral blood platelet count and hemoglobin concentration were identified as the factors influencing the collection efficiency for CD34-positive cells.</p><p><b>Conclusion: </b>In autologous PBSCC, the number and collection efficiency for CD34-positive cells were not significantly different between the two modes, whereas in allogeneic PBSCC, the CMNC mode was more efficient for PBSCC than the MNC mode.</p>, The Japan Society of Transfusion Medicine and Cell Therapy, Japanese - 造血幹細胞移植後に発症したトキソプラズマ症の2症例
立野 貴大; 石尾 崇; 橋口 淳一; 小杉 瑞葉; 白鳥 聡一; 杉田 純一; 小野澤 真弘; 中川 雅夫; 藤本 勝也; 豊嶋 崇徳, 臨床血液, 58, 11, 2302, 2302, Nov. 2017
(一社)日本血液学会-東京事務局, Japanese - 中枢神経血管内リンパ腫の5例
工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 加納 崇裕; 矢部 一郎; 白鳥 聡一; 後藤 秀樹; 加畑 馨; 近藤 健; 佐々木 秀直, 神経治療学, 34, 6, S223, S223, Nov. 2017
(一社)日本神経治療学会, Japanese - 中枢神経血管内リンパ腫の5例
工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 加納 崇裕; 矢部 一郎; 白鳥 聡一; 後藤 秀樹; 加畑 馨; 近藤 健; 佐々木 秀直, 神経治療学, 34, 6, S223, S223, Nov. 2017
日本神経治療学会, Japanese - 当院においてドナーリンパ球輸注を施行した34症例の検討
石尾 崇; 立野 貴大; 笠原 耕平; 小杉 瑞葉; 白鳥 聡一; 岡田 耕平; 後藤 秀樹; 杉田 純一; 小野澤 真弘; 橋本 大吾; 加畑 馨; 藤本 勝也; 遠藤 知之; 近藤 健; 豊嶋 崇徳, 日本輸血細胞治療学会誌, 63, 2, 148, 149, Apr. 2017
(一社)日本輸血・細胞治療学会, Japanese - 菌状息肉症/Sezary症候群に対する同種移植後における早期再発予防としてのVorinostat療法:北日本血液研究会(NJHSG)
白鳥聡一; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 藤本勝也; 橋本大吾; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 39th, 210, 15 Feb. 2017
Japanese - 同種造血幹細胞移植後のHematogonesと予後に関する検討
石尾崇; 立野貴大; 日高大輔; 早瀬英子; 白鳥聡一; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 39th, 2017 - 体外式超音波検査による造血幹細胞移植後の遅発性類洞閉塞症候群の非侵襲的診断
西田睦; 西田睦; 加畑馨; 早瀬英子; 早瀬英子; 佐藤恵美; 佐藤恵美; 工藤悠輔; 工藤悠輔; 表原里美; 表原里美; 岩井孝仁; 岩井孝仁; 高杉莉佳; 樋岡拓馬; 樋岡拓馬; 坂野稜典; 坂野稜典; 秋沢宏次; 澁谷斉; 岡田耕平; 白鳥聡一; 後藤秀樹; 杉田純一; 小野沢真弘; 中川雅夫; 橋本大吾; 遠藤知之; 近藤健; 清水力; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017 - 当院における骨髄異形成症候群に対する同種造血幹細胞移植の成績
郎朗; 白鳥聡一; 早瀬英子; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 橋本大吾; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017 - 悪性リンパ腫患者における化学療法併用pegfilgrastim投与によるCD34陽性細胞数の末梢血中の推移
後藤秀樹; 日高大輔; 山本聡; 早坂光司; 道又理恵; 香川郁子; 砂後谷加奈; 飯島弘章; 早瀬英子; 白鳥聡一; 岡田耕平; 杉田純一; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 清水力; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017 - 当院における急性骨髄性白血病に対する同種造血幹細胞移植の後方視的解析
長谷川祐太; 白鳥聡一; 早瀬英子; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 橋本大吾; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017 - セフェピム脳症を来した末梢性T細胞リンパ腫の1例
長谷川祐太; 工藤彰彦; 郎朗; 江端浩; 早瀬英子; 白鳥聡一; 後藤秀樹; 中川雅夫; 加納崇裕; 遠藤知之; 豊嶋崇徳, 臨床血液, 58, 12, 2017 - 半夏瀉心湯による移植関連口腔粘膜炎の予防効果に関する検討
岡田耕平; 重松明男; 中澤誠多朗; 松下貴惠; 山崎裕; 杉田純一; 笠師久美子; 池田陽子; 早瀬英子; 白鳥聡一; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 橋本大吾; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017 - HIV感染症合併血友病患者に対するMRIによる脳スクリーニングの意義
遠藤知之; 遠藤知之; 宮下直洋; 宮下直洋; 笠原耕平; 笠原耕平; 小杉瑞葉; 岡田耕平; 白鳥聡一; 後藤秀樹; 杉田純一; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 藤本勝也; 近藤健; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 18, 4, 439, 439, 20 Nov. 2016
(一社)日本エイズ学会, Japanese - HIV感染症合併血友病患者に対するMRIによる脳スクリーニングの意義
遠藤 知之; 宮下 直洋; 笠原 耕平; 小杉 瑞葉; 岡田 耕平; 白鳥 聡一; 後藤 秀樹; 杉田 純一; 小野澤 真弘; 橋本 大吾; 加畑 馨; 藤本 勝也; 近藤 健; 橋野 聡; 豊嶋 崇徳, 日本エイズ学会誌, 18, 4, 439, 439, Nov. 2016
日本エイズ学会, Japanese - 少量ATGを用いたHLA一致末梢血幹細胞移植におけるGVHD予防法
白鳥聡一; 小杉瑞葉; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 加畑馨; 藤本勝也; 橋本大吾; 遠藤智之; 近藤健; 豊嶋崇徳, MHC (Web), 23, 2 Suppl, 94, 15 Oct. 2016
Japanese - 少量ATGを用いたHLA一致末梢血幹細胞移植におけるGVHD予防法
白鳥 聡一; 小杉 瑞葉; 岡田 耕平; 後藤 秀樹; 杉田 純一; 小野澤 真弘; 加畑 馨; 藤本 勝也; 橋本 大悟; 遠藤 智之; 近藤 健; 豊嶋 崇徳, MHC: Major Histocompatibility Complex, 23, 2Suppl., 94, 94, Oct. 2016
日本組織適合性学会, Japanese - Evaluation of short term ruxolitinib tapering strategy prior to allogeneic stem cell transplantation for primary myelofibrosis through the transition of serum cytokines and growth factors; North Japan Hematology Study Group
S. Shiratori; T. Tateno; S. Ito; Y. Tsutsumi; T. Teshima, BONE MARROW TRANSPLANTATION, 51, S589, S590, Mar. 2016
English, Summary international conference - 重症VOD/SOSに対するデンバーシャントの姑息的治療を超えた可能性―2症例の解析―
白鳥聡一; 立野貴大; 伊東慎市; 堤豊, 日本造血細胞移植学会総会プログラム・抄録集, 38th, 303, 10 Feb. 2016
Japanese - Hepatitis B virus reactivation with a rituximab-containing regimen.
Yutaka Tsutsumi; Yoshiya Yamamoto; Shinichi Ito; Hiroyuki Ohigashi; Souichi Shiratori; Hirohito Naruse; Takanori Teshima, World journal of hepatology, 7, 21, 2344, 51, 28 Sep. 2015, [International Magazine]
Baishideng Publishing Group Co, English - 後天性免疫不全症の患者に発症し,進行性多巣性白質脳症との鑑別に苦慮した中枢神経原発悪性リンパ腫の1例
山川知宏; 藤本勝也; 江端浩; 岩崎純子; 高橋正二郎; 白鳥聡一; 杉田純一; 近藤健; 西尾充史; 豊嶋崇徳, 日本内科学会雑誌, 103, 10, 2578, 2580, 10 Oct. 2014
Japanese - 菌状息肉症に対する同種造血幹細胞移植の後方視的解析―更なる移植成績の向上に向けて―
白鳥聡一; 山川知宏; 江端浩; 小笠原励起; 佐賀智之; 高橋正二郎; 岩崎純子; 岡田耕平; 井端淳; 杉田純一; 高畑むつみ; 重松明男; 橋本大吾; 藤本勝也; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 246, 14 Feb. 2014
Japanese - Blastic Plasmacytoid Dendritic Cell Neoplasm(BPCDN)に対する造血幹細胞移植(SCT)
西尾充史; 西尾充史; 藤本勝也; 遠藤知之; 白鳥聡一; 杉田純一; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014 - 成人同種造血幹細胞移植後の出血性膀胱炎~単施設での後方視的解析結果~
藤本勝也; 江端浩; 小笠原励起; 佐賀智之; 山川知宏; 岩崎純子; 高橋正二郎; 岡田耕平; 白鳥聡一; 井端淳; 杉田純一; 重松明男; 高畑むつみ; 橋本大吾; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014 - Gemtuzumab ozogamicinを併用した強化前処置にて血縁者間末梢血幹細胞移植を施行した非寛解MLL-AF9陽性急性骨髄性白血病
狩野皓平; 江端浩; 山川知宏; 早瀬英子; 高橋正二郎; 岩崎純子; 白鳥聡一; 杉田純一; 藤本勝也; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014 - 空腸原発CD30陽性末梢性T細胞リンパ腫非特定型(PTCL,NOS)の1例
高橋正二郎; 江端浩; 山川知宏; 岩崎純子; 白鳥聡一; 杉田純一; 藤本勝也; 近藤健; 豊嶋崇徳; 畑中佳奈子; 松野吉宏, 臨床血液, 55, 7, 2014 - 同種造血細胞移植後のCMV網膜炎~臨床像と治療~
高畑むつみ; 小笠原励起; 佐賀智之; 山川知宏; 江端浩; 岩崎純子; 高橋正二郎; 岡田耕平; 白鳥聡一; 井端淳; 杉田純一; 重松明男; 藤本勝也; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014 - Gemtuzumab ozogamicinを使用した造血幹細胞移植症例の検討
江端浩; 小笠原励起; 佐賀智之; 山川知宏; 高橋正二郎; 岩崎純子; 岡田耕平; 白鳥聡一; 井端淳; 杉田純一; 重松明男; 高畑むつみ; 藤本勝也; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014 - 造血幹細胞移植後VOD/SOSに対して遺伝子組換えトロンボモジュリンα製剤を使用した同種移植14症例の肝腺維化マーカーの検討
安本篤史; 安本篤史; 杉田純一; 白鳥聡一; 重松明男; 橋本大吾; 藤本勝也; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014 - 当科における造血幹細胞移植後心不全の検討
岩崎純子; 榊原守; 江端浩; 小笠原励起; 佐賀智之; 山川知宏; 高橋正二郎; 岡田耕平; 白鳥聡一; 井端淳; 杉田純一; 重松明男; 高畑むつみ; 橋本大吾; 藤本勝也; 遠藤知之; 近藤健; 筒井裕之; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014 - 顔面の腫脹から診断に至った皮下脂肪織炎様T細胞性リンパ腫の1例
中里 信一; 藤田 靖幸; 古口 華子; 長谷部 育恵; 近藤 健; 白鳥 聡一; 西江 渉; 清水 宏, 皮膚科の臨床, 55, 9, 1204, 1205, Sep. 2013
19歳男性。左頬部の腫脹を主訴に複数の医療機関を受診するも原因は特定できず、発熱も加わったため著者らの口腔外科へ受診となった。白血球減少や肝機能障害ほか、MRIにてWeber-Christian病が疑われ、皮膚科へ紹介となったが、所見では左頬〜下顎にかけて熱感を伴うびまん性の腫脹がみられ、同部位の皮下には1〜2cm大の硬結が複数触知された。また、MRIでは両頬部と後頸部の皮下脂肪層内に索状病変が確認され、PET-CTでは頸部、胸部、腹部、上腕の皮下組織にFDG集積が多発していた。以上、これらの所見を踏まえ、あわせて皮膚病理所見から本症例は皮下脂肪織炎様T細胞性リンパ腫の診断され、CHOP療法を6コース施行した結果、現在のところmetabolic CRを保っている。, 金原出版(株), Japanese - 高レベルのドナーHLA特異抗体存在下でのHLA不一致非血縁者間骨髄移植における生着不全の予防
白鳥聡一; 早瀬英子; 岩崎純子; 杉田純一; 伊藤誠; 重松明男; 藤本勝也; 近藤健; 清水力; 田中淳司; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 257, 08 Feb. 2013
Japanese - 同種骨髄移植後の慢性GVHDに対する免疫抑制療法中に合併したEBV-associated smooth muscle tumorの1成人例
早瀬英子; 吉田美穂; 竹村龍; 岩崎純子; 白鳥聡一; 杉田純一; 藤本勝也; 近藤健; 田中淳司; 豊嶋崇徳; 今村雅寛; 三橋智子, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013 - 当院における同種末梢血幹細胞採取の経験
杉田純一; 早瀬英子; 岩崎純子; 岡田耕平; 白鳥聡一; 安本篤史; 井端淳; 重松明男; 藤本勝也; 遠藤知之; 近藤健; 橋野聡; 田中淳司; 佐藤典宏; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013 - Maraviroc追加投与を行ったimmunological non-responder症例におけるTリンパ球の免疫学的変化の検討
藤本勝也; 吉田美穂; 竹村龍; 白鳥聡一; 杉田純一; 重松明男; 橋本大吾; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本エイズ学会誌, 15, 4, 2013 - Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD
杉田 純一; 松下 貴恵; 柏崎 晴彦; 高橋 正二郎; 白鳥 聡一; 井端 淳; 重松 明男; 藤本 勝也; 遠藤 知之; 近藤 健; 橋野 聡; 田中 淳司; 豊嶋 崇徳, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 87, 6, 272, 272, 01 Nov. 2012
Japanese - FDG PET/CTによって病変範囲と治療効果を画像化できた皮下脂肪織炎様T細胞リンパ腫の一例
渡邊 史郎; 真鍋 治; 石尾 崇; 小林 健太郎; 平田 健司; 服部 直也; 玉木 長良; 白鳥 聡一; 藤本 勝也; 田中 淳司, 核医学, 49, 4, 414, 414, Nov. 2012
(一社)日本核医学会, Japanese - 抗ウイルス応答において活性化されるRIG-Iの強力な調節因子ZAPSの同定
白鳥 聡一; 早川 清雄; 大和 弘明; 亀山 武志; 北辻 千展; 樫木 芙美; 後藤 翔平; 亀岡 章一郎; 藤倉 大輔; 山田 大翔; 水谷 龍明; 数馬田 美香; 佐藤 麻衣子; 田中 淳司; 浅香 正博; 大場 雄介; 宮崎 忠昭; 今村 雅寛; 高岡 晃教, 北海道醫學雜誌 = Acta medica Hokkaidonensia, 87, 4, 194, 194, 01 Aug. 2012
Japanese - t(14;19)を含む複雑な染色体異常を持ち,自然消退を繰り返したB細胞性リンパ腫と考えられる一例
西尾充史; 西尾充史; 松野吉宏; 武田紫; 高桑康成; 近藤健; 藤本勝也; 杉田純一; 白鳥聡一; 竹村龍; 吉田美穂; 佐藤昌明; 田中淳司; 久保田佳奈子, 日本リンパ網内系学会会誌, 52, 116, 19 May 2012
Japanese - Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells
J. Tanaka; J. Sugita; S. Shiratori; A. Shigematu; S. Asanuma; K. Fujimoto; M. Nishio; T. Kondo; M. Imamura, LEUKEMIA, 26, 5, 1149, 1152, May 2012
English, Report scientific journal - 複数回に渡る低用量DLIにより移植後後期に低下したdonor造血の改善を認めた再生不良性貧血の一例
竹村龍; 吉田美穂; 小杉瑞葉; 白鳥聡一; 庄野雄介; 杉田純一; 武田紫; 藤本勝也; 西尾充史; 近藤健; 田中淳司; 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 278, 01 Feb. 2012
Japanese - HIV感染者における梅毒血清反応と抗カルジオリピン抗体に関する検討
遠藤知之; 藤本勝也; 後藤秀樹; 白鳥聡一; 杉田純一; 重松明男; 西尾充史; 近藤健; 田中淳司; 橋野聡; 今村雅寛; 佐藤典宏, 日本エイズ学会誌, 13, 4, 363, 363, 20 Nov. 2011
(一社)日本エイズ学会, Japanese - 移植後再発ALLに対する臍帯血移植後に,臍帯血由来のALLを発症した一例
吉田美穂; 竹村龍; 小杉瑞葉; 白鳥聡一; 庄野雄介; 武田紫; 杉田純一; 藤本勝也; 西尾充史; 近藤健; 田中淳司; 今村雅寛, 臨床血液, 52, 9, 1241, 30 Sep. 2011
Japanese - Management of oral mucositis after allogeneic stem cell transplantation
SUGITA JUNICHI; MATSUSHITA TAKAE; KASHIWAZAKI HARUHIKO; KOSUGI MIZUHA; TAKAHASHI SHOJIRO; WAKASA KENTARO; SHIRATORI SOUICHI; IBATA MAKOTO; SHONO YUSUKE; SHIGEMATSU AKIO; OBARA MASATO; FUJIMOTO KATSUYA; ENDO TOMOYUKI; NISHIO MITSUFUMI; KONDO TAKESHI; HASHINO SATOSHI; TANAKA JUNJI; ASAKA MASAHIRO; IMAMURA MASAHIRO, Journal of germfree life and gnotobiology, 41, 1, 48, 53, 01 Sep. 2011
日本無菌生物ノートバイオロジー学会, Japanese - THE COMPARATIVE STUDY FOR EXPANSION OF CD4(+)CD25(+)FOXP3(+) REGULATORY T CELLS FROM CORD BLOOD CD4(+) CELLS USING IL-15 OR IL-2 WITH RAPAMYCIN
J. Tanaka; J. Sugita; S. Asanuma; S. Shiratori; A. Shigematu; K. Fujimoto; M. Nishio; T. Kondo; M. Imamura, EXPERIMENTAL HEMATOLOGY, 39, 8, S58, S59, Aug. 2011
English, Summary international conference - ZAPSトランスジェニックマウスを用いた自然免疫応答の解析
早川清雄; 大和弘明; 白鳥聡一; 白鳥聡一; 山田大翔; 亀山武志; 数馬田美香; 大場雄介; 宮崎忠明; 高岡晃教, 日本ウイルス学会北海道支部夏季シンポジウム講演抄録, 45th, 2011 - リンパ芽球性リンパ腫に対し臍帯血移植を施行後,PET‐CTを契機に亜急性甲状腺炎の診断に至った1例
小杉瑞葉; 小杉瑞葉; 白鳥聡一; 白鳥聡一; 庄野雄介; 庄野雄介; 杉田純一; 杉田純一; 藤本勝也; 藤本勝也; 西尾充史; 西尾充史; 近藤健; 近藤健; 田中淳司; 田中淳司; 小池隆夫; 浅香正博; 今村雅寛; 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 324, 2011
Japanese - 当院におけるvalGCVの使用経験
高橋正二郎; 高橋正二郎; 小杉瑞葉; 小杉瑞葉; 白鳥聡一; 白鳥聡一; 若狭健太郎; 若狭健太郎; 杉田純一; 杉田純一; 重松明男; 重松明男; 小原雅人; 小原雅人; 西尾充史; 西尾充史; 藤本勝也; 藤本勝也; 遠藤知之; 遠藤知之; 近藤健; 近藤健; 橋野聡; 橋野聡; 今村雅寛; 今村雅寛; 浅香正博; 浅香正博, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 321, 2011
Japanese - 同種造血幹細胞移植におけるStenotrophomonas maltophilia感染症~顆粒球輸注の有用性について~
白鳥聡一; 若狭健太郎; 小杉瑞葉; 庄野雄介; 杉田純一; 武田紫; 重松明男; 藤本勝也; 西尾充史; 近藤健; 橋野聡; 田中淳司; 佐藤典宏; 小池隆夫; 浅香正博; 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 225, 2011
Japanese - HAART開始後のHIV‐RNA早期抑制の臨床的意義に関する検討
遠藤知之; 後藤秀樹; 白鳥聡一; 渡部恵子; 杉田純一; 重松明男; 小原雅人; 藤本勝也; 西尾充史; 近藤健; 橋野聡; 田中淳司; 今村雅寛; 佐藤典宏; 小池隆夫, 日本エイズ学会誌, 12, 4, 374, 374, 20 Nov. 2010
(一社)日本エイズ学会, Japanese - 自然免疫系における核酸認識受容体を介したシグナルの新規調節因子と抗ウイルス作用
亀山武志; 早川清雄; 白鳥聡一; 大和弘明; 北辻千展; 樫木芙美; 後藤翔平; 亀岡章一郎; 藤倉大輔; 水谷龍明; 数馬田美香; 佐藤麻衣子; 今村雅寛; 浅香正博; 大場雄介; 宮崎忠昭; 高岡晃教, 日本ウイルス学会学術集会プログラム・抄録集, 58th, 220, 15 Oct. 2010
Japanese - 自然免疫系の核酸認識受容体を介するシグナルの新規調節因子と抗ウイルス作用
亀山武志; 早川清雄; 白鳥聡一; 大和弘明; 高岡晃教; 高岡晃教, 日本ウイルス学会北海道支部夏季シンポジウム講演抄録, 44th, 2010 - Systemic amyloidosis complicated with peliosis.
Yutaka Tsutsumi; Shinichi Ito; Kazuhiko Ichiki; Yasuyuki Komatsu; Souichi Shiratori; Tkahito Kawamura; Kazuhiro Kudo; Norihiko Shimoyama; Junji Tanaka; Masahiro Asaka; Masahiro Imamura; Nobuo Masauzi, Annals of hematology, 88, 9, 917, 20, Sep. 2009, [International Magazine]
English - EFFICACY OF GRANULOCYTE TRANSFUSION FOR SEVERE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION AFTER HIGH-DOSE CYTARABINE FOR ACUTE MYELOGENOUS LEUKEMIA
SHIRATORI Souichi; KONDO Takeshi; WAKASA Kentaro; IBATA Makoto; SHONO Yusuke; TAKAHATA Mutsumi; SHIGEMATSU Akio; TOUBAI Tomomi; KATO Naoko; OTA Shuichi; KAHATA Kaoru; TAKEDA Yukari; SATO Norihiro; TANAKA Junji; ASAKA Masahiro; IMAMURA Masahiro, Japanese Journal of Transfusion and Cell Therapy, 55, 1, 37, 42, 25 Feb. 2009
A 27-year-old man with acute myelogenous leukemia (AML, M2) who was in complete remission following induction therapy was treated with high-dose cytosine arabinoside (HDAraC). He subsequently developed severe pneumonia, caused by methicillin-resistant Staphylococcus aureus (MRSA), as a result of bone marrow suppression. In spite of treatment with antibiotics, granulocyte colony-stimulating factor (G-CSF) and intravenous immunoglobulin therapy (IVIG), his condition deteriorated into respiratory failure, and he required artificial respiration support. He later relapsed, but achieved complete remission following two courses of re-induction chemotherapy. He was treated with HDAraC again, which once more led to severe MRSA infection. He was then transfused granulocytes from a sibling donor by the apheresis method combined with antibiotics, G-CSF and IVIG, which resulted in a clinical improvement. Antibiotics and IVIG are widely employed in the treatment of severe bacterial infections in patients with hematological malignancies; however the effect of IVIG is not fully obtained in neutropenic conditions, since immunoglobulin requires the co-operation of neutrophils to be effective against bacterial infection. In our case, granulocyte transfusion (GTX) appeared to have prevented the deterioration of MRSA infection, suggesting that combination therapy with antibiotics, IVIG and GTX might be valuable in critically neutropenic patients suffering from severe infection.
, The Japan Society of Transfusion Medicine and Cell Therapy, Japanese - 自然免疫におけるIFN応答の新たな制御メカニズム
早川清雄; 白鳥聡一; 大和弘明; 後藤翔平; 樫木芙美; 亀山武志; 高岡晃教, 日本分子生物学会年会講演要旨集, 32nd, Vol.2, 31, 2009
Japanese - [Loss of CD20 expression following rituximab-combined chemotherapy in CD20-positive and CyclinD1-positive multiple myeloma].
Souichi Shiratori; Takeshi Kondo; Kanako Kubota; Kentarou Wakasa; Makoto Ibata; Yusuke Shono; Mutsumi Takahata; Akio Shigematu; Naoko Kato; Shuichi Ota; Junji Tanaka; Yoshihiro Matsuno; Masahiro Asaka; Masahiro Imamura, [Rinsho ketsueki] The Japanese journal of clinical hematology, 49, 11, 1536, 40, 30 Nov. 2008, [Domestic magazines]
Several studies have confirmed that CD20 is expressed in about 20% of multiple myeloma (MM) cases. This is closely related to a chromosomal translocation between chromosome 11 and chromosome 14, which results in the expression of CyclinD1. The use of rituximab (RIT) in the treatment of CD20-positive MM has been reported, however its effectiveness is still not well established. We encountered a case of CD20-positive/CyclinD1-positive MM; interestingly, CD20 expression could not be detected in MM cells following RIT-combined chemotherapy, while it gradually recovered when RIT therapy was discontinued. This is the first report in which the transition of CD20 expression was accurately analyzed by flow cytometry and immunohistochemical staining before, during and after RIT treatment. Consequently, this case provides insight regarding the mechanism through which CD20 expression is lost following RIT therapy for CD20-positive lymphoid neoplasm, as well as the efficacy of RIT in CD20-positive MM., 「臨床血液」編集部, Japanese - 成人T細胞性白血病/リンパ腫に対する同種造血幹細胞移植の検討‐北海道地域における後方視的解析‐
安本篤史; 安本篤史; 安本篤史; 白鳥聡一; 白鳥聡一; 近藤健; 近藤健; 橋野聡; 橋野聡; 田中淳司; 田中淳司; 小池隆夫; 浅香正博; 笠井正晴; 今村雅寛; 今村雅寛, 臨床血液, 49, 9, 1173, 1173, 30 Sep. 2008
(一社)日本血液学会-東京事務局, Japanese - Infectious complications following allogeneic bone marrow transplantation using reduced-intensity conditioning regimen
SHIGEMATSU AKIO; SUGITA JUNICHI; YAMAMOTO SATOSHI; ONOZAWA MASAHIRO; ENDO TOMOYUKI; KAHATA KAORU; Souichi Shiratori, Shiratori S, S.Shiratori, SHIRATORI SOICHI; WAKASA KENTARO; TAKAHATA MUTSUMI; KONDO TAKESHI; TANAKA JUNJI; NISHIO MITSUFUMI; HASHINO SATOSHI; KOIKE TAKAO; ASAKA MASAHIRO; IMAMURA MASAHIRO, Journal of germfree life and gnotobiology, 38, 1, 27, 32, 01 Sep. 2008
日本無菌生物ノートバイオロジー学会, Japanese - Expansion of CD4+CD25+ regulatory T cells from cord blood CD4+ cells using the common square-chain cytokine IL-15
Junji Tanaka; Junichi Sugita; Souichi Shiratori; Kentaro Wakasa; Akio Shigematu; Mutsumi Takahata; Takeshi Kondo; Masahiro Asaka; Masahiro Imamura, EXPERIMENTAL HEMATOLOGY, 36, 7, S58, S59, Jul. 2008
English, Summary international conference - Hyponatremia after administration of conditioning regimen in myelodysplastic syndrome with empty sella after glandula pituitaria surgery.
Yutaka Tsutsumi; Souichi Shiratori; Asako Nakata; Takahito Kawamura; Shinobu Mashiko; Makoto Ibata; Akio Mori; Junji Tanaka; Masahiro Asaka; Masahiro Imamura; Nobuo Masauzi, Annals of hematology, 86, 11, 843, 4, Nov. 2007, [International Magazine]
English - Analysis of eosinophilia in the patients treated with chemotherapy containing fludarabine
市來 一彦; 堤 豊; 中田 麻子; 白鳥 聡一; 川村 孝仁; 西尾 太郎; 小椋 庸隆; 政氏 伸夫, 函館医学誌 = Hakodate medical journal, 31, 1, 1, 3, Oct. 2007
プリンアナログ由来の抗癌剤であるフルダラビンは慢性リンパ性白血病や,悪性リンパ腫,また骨髄非破壊的移植時の前処置等に広く応用されている1)?5)。フルダラビン使用にあたって種々の合併症の報告がなされているが,好酸球増多症は稀な合併症とされている6)?9)。時に好酸球による重篤な肺の合併症も報告されており,フルダラビン使用時の好酸球増多について注意が必要と考えられる9)。今回我々は少数例であるがフルダラビンを用いた多剤併用化学療法を施行した非ホジキンリンパ腫および急性白血病の8症例について好酸球増多の有無を調べたのでこれを報告する。, 市立函館病院, Japanese - Immediately recurrence was observed after chemotherapy in an intravascular lymphoma patient
中田 麻子; 堤 豊; 白鳥 聡一; 川村 孝仁; 政氏 伸夫, 函館医学誌 = Hakodate medical journal, 31, 1, 24, 26, Oct. 2007
Intravascular large B-cell lymphoma(IVL)はリンパ腫細胞が小血管内に集簇して認められることを特徴とする,Diffuse large B-cell lymphoma の一亜系である。IVL の中には近年,血球貪食症候群により特徴づけられるAsian variant of IVL(AIVL)と皮膚,神経症状により特徴付けられるClassical IVL が存在すると言われている。我々はLDH の異常高値,神経学的症状を呈して来院し,治療には反応したものの,その後に急激な腸炎,腹水の貯留で死亡した1例を経験した。本症例について,若干の文献的考察を加えて報告する。, 市立函館病院, Japanese - 急性リンパ性白血病に対するVP‐16/CY/TBI前処置による同種骨髄移植
重松明男; 田中淳司; 近藤健; 橋野聡; 太田秀一; 高畑むつみ; 若狭健太郎; 白鳥聡一; 杉田純一; 浅香正博; 今村雅寛, 臨床血液, 48, 9, 938, 30 Sep. 2007
Japanese - 異なるサイトカインより誘導されたNK細胞レセプター発現T細胞の細胞障害活性の比較
杉田純一; 田中淳司; 白鳥聡一; 若狭健太郎; 重松明男; 高畑むつみ; 近藤健; 浅香正博; 今村雅寛, 臨床血液, 48, 9, 1080, 30 Sep. 2007
Japanese - 成人急性リンパ性白血病に対するMRD検出法の比較および有用性の検討
白鳥聡一; 田中淳司; 近藤健; 橋野聡; 太田秀一; 福原敬; 笠井正晴; 黒澤光俊; 政氏伸夫; 森岡正信; 岩崎博; 高畑むつみ; 重松明男; 若狭健太郎; 浅香正博; 今村雅寛, 臨床血液, 48, 9, 1110, 30 Sep. 2007
Japanese - Subpopulations of human NK cells after allogeneic stem cell transplantation
J. Tanaka; J. Sugita; A. Shigematu; S. Shiratori; K. Wakasa; M. Takahata; T. Kondo; M. Asaka; M. Imamura, EXPERIMENTAL HEMATOLOGY, 35, 9, 112, 113, Sep. 2007
English, Summary international conference - Syndrome of inappropriate secretion of ADH after administration of intrathecal chemotherapy in acute promyelocytic leukemia with empty sella of pituitary gland.
Yutaka Tsutsumi; Takahito Kawamura; Souichi Shiratori; Shinobu Mashiko; Makoto Ibata; Akio Mori; Junji Tanaka; Masahiro Asaka; Masahiro Imamura; Nobuo Masauzi, Annals of hematology, 86, 2, 149, 50, Feb. 2007, [International Magazine]
English
■ Research Themes
- Innate immune signals in allogeneic hematopoietic stem cell transplantation
Grants-in-Aid for Scientific Research
01 Apr. 2013 - 31 Mar. 2015
SHIRATORI Souichi
Among several innate immune signaling molecules, MyD88 in donor T cells were critical for the maximization of graft versus host disease (GVHD) after murine allogeneic bone marrow transplantation. T cells lack of single upstream molecules of MyD88 caused equivalent GVHD compared to wild type T cells, indicating that an overall blockade of MyD88-dependent signals in T cells are required for GVHD amelioration. MyD88 deficient T cells showed severely impaired Th1 response compared to wild type T cells upon CD3/CD28 stimulation and allogeneic stimulation. MyD88 deficient donor T cells exerted significant graft versus leukemia effects, suggesting that MyD88 inhibitor is a promising therapeutic reagent against GVHD in clinical transplantation.
Japan Society for the Promotion of Science, Grant-in-Aid for Young Scientists (B), Hokkaido University, 25860775
